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IL-8 interleukin-6
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Summary
The  present  study  focuses  on  exploring  the  role  of  placental  syncytiotrophoblast
microparticles  (STBM)  during normal  pregnancy  and  preeclampsia.  In  particular,  the 
qualitative  properties  of  the  STBM  were examined  and  the  effects  of  STBM  and 
placentally  derived  cytokines  were  studied  on  immune  cells.
Three  STBM  methods  were  used  to  generate  qualitatively  different  STBM:
A. Villous  explant  culture  (vSTBM) 
B. Perfusion  of  a  single  placental  cotyledon  (pSTBM) 
These  two  methods  were  used  for  the  first time.  STBM  were  also  prepared  by  third 
well  established  method:
C. Mechanical  dissection  of  the  villous  tissue  (mSTBM)
The  qualitative  assessment  of  the  three  STBM  reveled  that  all  the  three  STBM 
preparations  are  morphologically  similar.  But  biochemically  these  three  STBM
preparations  differ  in  the presence  of  syncytiotrophoblast  protein  PLAP,  nucleic  acids 
(DNA  and  RNA)  and  lipids.  Functionally  the  three  STBM  behaved  differently  on 
endothelial  cell  cultures  in  that  all  the  STBM preparations  inhibited  endothelial  cell
proliferation  in  different  manner.  Only  mSTBM  induced  apoptosis in  the  endothelial 
cells  further  confirming  that  these  three  STBM  preparations  also  differ  biologically. 
Comparative  study  of  the  three  STBM  preparations  and  placentally  derived  cytokines 
on  purified  T  cell  response  in  terms  of  T  cell  activation,  proliferation,  cytokine 
production  and  apoptosis  further  confirmed  that  the  three  STBM  preparations  differ
in  their  qualitative  nature.  These  differences  among  three  STBM  preparations  are 
attributable  to  their  mode  of  preparation.  Placentally  derived  cytokines  and  STBM 
mostly  reduced  T  cell  responses.  These  findings  suggest  that  placental  factors  help 
in  immune  modulation,  which  is  essentially  required  for  successful  pregnancy
completion.
The  effects  of  the  placentally  derived  factors  were  also  examined  on  the  innate 
immune  response.  For  the  first  time  we  were  able  to  show  that  placentally  derived 
factors  IL-8  and  STBM  were  able  to  generate  neutrophil  extracellular  traps  (NETs).
This  is  the  first  indication  where  physiological  signals have  been  shown  to  generate 
NETs.  Furthermore,  massive  presence  of  the  neutrophil  NETs  were  observed  in  the
preeclamptic  placenta,  which  might  make  a  revolutionary  change  in  our
understanding  of  the  pathogenesis  of  this  pregnancy related  disorder. 
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Introduction
1.  Introduction 
Viviparity  is  a  unique  characteristic  of mammals.  An  embryo is  a  mating  product 
of  histo-incompatible  individuals  in  an  outbred  population.  It  can  be  compared
with  a  semi-allogenic  graft  which  has  to  be  tolerated  over  all  the  gestational 
period  [1].  Gestational  outcomes  avoiding  fetal  defects  or  loss,  maternal  infection,
or  morbidity  are  contingent  upon  an intimate  association  between  mother  and 
developing  fetus  that  nurtures  the  fetus  without  provoking maternal  immune 
responses.  The  process  of  nurturing  new individuals  in  this  way  necessitates 
exquisite  integration  and  coordination  of  several  complex  biological  processes, 
including  metabolic,  endocrine,  vascular,  and  immune  functions.  Almost  certainly, 
ancestral  mammals  evolved  fundamental  mechanism(s)  to  allow  successful 
viviparity  [2].
Although  pregnancy  seems  a  happy  symbiosis  between  mother  and  genetically 
different  fetus  but  reality  of  this  symbiosis  is  very  complicated.  Success  of  any 
pregnancy  hinges  on  mother’s  embracing  her  allogenic  fetus  immunologically 
rather  than  attacking  it.  Perturbations  to  the  feto-maternal  symbiosis  can  lead  to
the  miscarriage  early  in  the  pregnancy  or  premature  birth  later.  Premature  birth 
can  also  be  triggered  by  a  condition  called  preeclampsia.
1.1.  Eclampsia  and  Pre-eclampsia:  a  historical  view 
Humans  are  the  only  mammals  to  suffer  frequent  eclampsia  and  preeclampsia  [3, 
4].  Eclampsia  is  an  easily  recognizable  event  and  has  been  described  in  the
medical  literature  as  long  as  4200  years  ago  (Egyptian  Papyrus,  Indian  Atharva 
Veda,  Petric  Papyrus,  Chinese  literature). 2000  years  ago  Celsus  described  seizures
in  pregnant  women,  which  abated  with delivery.  Since  the  condition  seemed  to 
arise  without  warning  it  was  termed eclampsia  from  the  Greek  word  for
“lighting”.  The  etiology  of  eclampsia  typically  consisted  of  the  sudden  onset  of 
convulsions  in  women  nearing  delivery  with  approximately  one-third  ending  in 
maternal  death  or  fetal  death in  utero.  It  is  that  spectacular  complication  which
prompted  the  first  cesarean  sections  on  dying  convulsive  parturients,  at  least  2000 
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years  ago;  to  try  to  save  the  newborns  lives.  In  today's modern  obstetrics,
eclampsia  has  artificially  disappeared.  Obstetricians  either  induce  labor  or  cesarean 
section  in  women  presenting  with  severe  preeclampsia  or  threatening  eclampsia
[5].  Preeclampsia  affects  about  7-10%  of  the  first  pregnancies  and  is  an  important
cause  of  maternal  perinatal  morbidity  or  mortality.  Preeclampsia  is  a  multisystem
disease  of  pregnancy  of  unknown  cause.  It  is  a  maternal  syndrome,  which  is 
characterized  by  increased blood  pressure,  edema,  proteinuria  and  abnormal
clotting,  liver  and  renal  functions  all  of which  may  be  due  to  the  release  of 
placental  toxic  factors  into  the  mother’s circulation.  The  only  effective  therapy  to 
this  complication  is  to  facilitate  the  delivery  (induction,  cesarean  section)  [6-7]. 
1.2.  Clinical  features  of  preeclampsia 
Preeclampsia  is  diagnosed  when  a  woman with  chronic  hypertension  develops  new 
onset  proteinuria  after  20  weeks  of  gestation.  This  usually  occurs  over  several 
days  to  weeks,  but  may  occur  more quickly.  The  following  maternal  signs  or 
symptoms  characterizes  severe  preeclampsia:
x Blood  pressure  greater  than 
160/110
x Severe  headache
x Visual  problems
x Protenuria
x Fluid  in  the  lungs 
x Low  urine  production  (less 
than  500  ml  in  24  h) 
x Low  platelet  count
x Liver  abnormalities
1.3.  Pathogenesis  of  preeclampsia 
It  should  be  emphasized that  the  causes  of  preeclampsia  remain  unknown. 
Therefore,  an  attempt  to  define  pathophysiological  data  in  one  causal  framework
represents  another  one  of  the  many  hypotheses  proposed  to  explain  the 
pathogenesis  of  preeclampsia.  These  theories  can  summarized  in  the  following
flow  chart (Fig:  1).
7
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Figure: 1. Hypothetical  cause and pathogenesis  of preeclampsia.  TGF=transforming  growth
factor. IFN=interferon. VEGF=vascular endothelial growth  factor. PIGF=placental  growth factor.
ANGIO=angiopoietin 2.  Adapted from  Sibai  B  et  al. Lancet 2005.
Preeclampsia  is  caused  by  presence  of  the placenta  or  the  maternal  response  to 
placentation.  However,  it  is now  clear  that  poor  placentation  is  not  the  cause  of 
preeclampsia,  but  rather  a  powerful  predisposing  factor.  Once  poor  placentation  is 
established  it  leads  to  the  maternal  syndrome,  depending  on  the  extent  to  which  it
causes  inflammatory  signals  and  the  nature  of  the  maternal  response  to  those 
signals  [8].  Preeclampsia  is  characterized  by  abnormal  vascular  response  to
placentation  that  is  associated  with  increased  systemic  vascular  resistance,
enhanced  platelet  aggregation,  activation  of  the coagulation  system,  and 
8
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endothelial-cell  dysfunction.  [8,  9].  Several  studies  have  suggested  that  women
who  develop  preeclampsia  are  at  increased  risk  of  cardiovascular  complications
later  in  life.  Indeed,  many  risk  factors  and  pathophysiological  abnormalities  of 
preeclampsia  are  similar  to  those of  coronary-artery  disease  [10-12]. 
The  cause  of  preeclampsia  are  often  described  as  two  opposing  schools  of 
thoughts—the  vascularists,  for  whom  ischaemia-reperfusion  leads  to  oxidative  stress
and  vascular  disease,  and the  immunologists,  who  see preeclampsia  as  a  maternal–
paternal  immune  maladaptation  (ie,  a  maternal  alloimmune  reaction  triggered  by  a
rejection  of  the  fetal  allograft).  Recently  it  has  been  proposed  that  the  difference
between  vascular  and  immune  events  is  no  longer  reasonable  in  view  the
molecules  secreted  within  the  immune  system.  Most,  if  not  all,  cytokines  are 
equipped  with  pleiotropic  effects,  of  which  action  on  the  vascular  endothelium  and
smooth  muscle,  coagulation, and  other  immune  cells are  most  relevant  to 
preeclampsia  [13].  Following theories  have  been  described  to  explain  the
pathogenesis  of  preeclampsia. 
1.3.1.  Placentation  and  the  immune  theory  of  preeclampsia
This  theory  includes  abnormal  placentation,  placental  oxidative  stress  and 
immunological  factors  that  can  be  summarized  as  follows: 
1.3.1.1.  Impaired  trophoblast  invasion  and  differentiation 
In  human  pregnancy  implantation  of  the  embryo  occurs  by  two  physiological 
invasions  of  the  cytotrophoblast  inside  the  uterine  wall.  First,  cytotrophoblast  cells
stream  out  of  the  tips  of  the  anchoring  villi  and penetrate  the  trophoblast  shell
and  overlying  syncytiotrophoblast  to  form  cytotrophoblast  columns  that  develop 
into  the  cytotrophoblast  shell.  Trophoblast cells  continue  to  migrate  into  the
decidua.  After  an  apparent  long  pause  (6–8  weeks)  at  the  end  of  first  trimester
(14–16th  week)  of  gestation,  a  second  very  deep  trophoblast  invasion  colonize  the
placental  bed's  myometrium.  Once  the  cytotrophoblast  shell  makes  contact  with 
spiral-artery  openings,  trophoblast  cells  stream  into  arterial  lumina  to  form
intraluminal  plugs.  Endovascular  trophoblast  cells  replace  the  endothelium  of  spiral 
arteries  and  then  invade  the  media,  resulting  in  destruction  of  the  medial  elastic, 
9
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muscular,  and  neural  tissue.  Trophoblast  cells  become  incorporated  into  the  vessel 
wall,  and  the  endothelial  lining  is  finally  reconstituted.  As  a  result,  these  vessels 
undergo  transformation  from  small  muscular arterioles  to  large  capacitance  vessels 
of  low  resistance  [14,  15]. 
Trophoblast  differentiation  during  spiral  arteries  invasion  involves  alteration  in 
expression  of  the  number  of  different  classes  of  molecules,  including  cytokines, 
adhesion  molecules,  extracellular  matrix molecules,  metalloproteinases,  and  the 
class  Ib  major  histocompatibility  complex  molecule,  HLA-G  [16-19].  During 
normal  differentiation,  invading  trophoblasts  alter  their  adhesion  molecule
expression  from  those  that  are  characteristic  of epithelial  cells  (integrin D6/E1,
Dv/E5,  and  E-cadherin)  to  those  of  endothelial  cells  (integrin D1/E1, Dv/E3,  and 
VE-cadherin),  a  process  referred  to  as  pseudo-vasculogenesis  [16] (Fig:  2).
Figure: 2.  Trophoblast  differentiation and  maintenance  of  early  pregnancy.  The  diagram  shows
an  implanted embryo  (approximately  14 days  after  conception)  and  the  processes  necessary  for  the
maintenance of  an  early  pregnancy. VEGF denotes  vascular  endothelial  growth  factor,  and  hCG
human  chorionic gonadotropin. Adapted from  Norwitz  ER  et.  al.  2001, NEJM.
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The  proper  trophoblast  invasion  and  switching  in  the  adhesion  molecules  allows
increased  blood  flow  (i.e.,  oxygen,  nutrients) to  the  fetus.  It  has  been  proposed 
that  the  trophoblasts  obtained  from  women  with  preeclampsia  do  not  show 
upregulated  adhesion  molecules  expression  or  pseudo-vasculogenesis  [18].  The 
impairment  of  pseudo-vasculogenesis  limits the  cytotrophoblast  infiltration  only  to
the  decidual  portion  of  the  spiral  arteries  and  fails  to  penetrate  the  myometrial
portion  and  inadequate  transformation  of  spiral  arteries  around  14–16th  week  of 
the  gestation,  inducing  poor  vascular  exchanges  between  the  mother  and  the 
placenta  [20-22] (Fig.  3).  The  rise  of  blood  pressure  in  the  human  mother  is  then
probably  a  compensatory  mechanism  to  increase  the  exchanges  and try  to  save  the
fetus  from  poor  supplies.  Whether  this adaptation  is  maternally  driven  or  a 
response  to  fetal  stress signals  is  yet  unknown.
Figure: 3. A  comparison  between uninvaded  arteries  (non-pregnant),  normal  pregnancy  and
pathological  conditions  of pregnancy  such  as  preeclampsia is  shown.  Note  that  the  extent  and
depth  of  trophoblast  invasion  is  less  in  pathological  compared  with  normal  pregnancy, which
results  in  inadequate  transformation  of  the  spiral  arteries  in  the former.  This results  in  reduced
blood  flow  to  the  feto-placental  unit,  which  leads  to  poor  fetal  growth.  Adapted  from  Moffett-King
A,  2002, Nat.  Rev. Immunol.
The  primary  event  that  contributes  to  failed  trophoblast  differentiation  is  unknown 
but  placental  oxidative  stress  and  immunologic  factors  might  play  a  role.
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1.3.1.2.  Placental  oxidative  stress 
The  trigger  for  the placental  oxidative  stress  has  yet  to  be identified.  As  described
above  defective  remodeling  of the  endometrial  spiral  arteries is  the  most  widely
recognized  predisposing  factor  for  preeclampsia  [23].  As  a  result,  perfusion  of  the
intervillous  space  is  impaired compared  with  normal  pregnancies,  leading  to  the 
general  assumption that  the  placental  changes are  induced  by  hypoxia  [24]. 
However, no  direct  measurements  are  available  to  confirm  that  this  is indeed  the
case.  By  contrast,  pregnancy  at  high  altitude  is one  of  the  few  situations  in  which
the  oxygen  tension  in  the maternal  arterial  supply  to  the  placenta  is  known  to  be 
reduced  [25,  26].  Comparison  of  the  placental  histological  changes  seen  in  these
two  situations  indicates  that  many of  the  features  that  characterize the  preeclamptic
placenta,  for  example,  the  increased  incidence of  infarction,  cannot  be  explained 
on  the  basis  of  hypoxia  alone.  It  has been  proposed  that  defective  remodeling
results  in the  retention  of  vasoreactivity in  the  myometrial  segments  of spiral
arteries  and  that  this  leads  to  intermittent  perfusion of  the  intervillous  space  and 
hence  to  fluctuating  oxygen  concentrations within  the  placenta  [27].  Such
fluctuations  in  oxygen  tension  could provide  the  basis  for  an  ischemia-reperfusion
type  insult  [27]. It  has  recently  been  demonstrated  that  oxidative  stress  occurs 
when hypoxic  placental  tissues  are  reoxygenated in-vitro,  which  is consistent  with
an  ischemia-reperfusion  injury  [28].  Collectively,  these  findings  indicate  that 
hypoxia-reoxygenation (H/R)  may  represent  a  suitable  model  system  for
investigating the  generation  of  placental  oxidative  stress  in  preeclampsia.  Indeed,
oxidative  stress  can  cause  apoptosis in  numerous  cell  lines in-vitro [29,  30],  and 
ischemia-reperfusion can  also  induce  apoptosis  in  the  heart  and  brain in-vivo [31].
Therefore,  it  is  speculated  that,  preeclampsia  may  result  from  oxidative  stress  in 
the  preeclamptic  placenta  leading  to  increased  apoptosis  or  even  necrosis  [32]. 
Oxidative  stress  can  lead  to  atherosis (lipid-laden  cells  in  the  wall  of  the 
arteriole),  fibrinoid  necrosis,  thrombosis,  sclerotic  narrowing  of  arterioles,  and 
placental  infarction  [33-36]  although  all  of  these  lesions  are  not  uniformly  found 
in  patients  with  preeclampsia,  there  appears  to  be  a  correlation  between  the
severity  of  the  disease  and  the  extent of  the  lesions  [37,  38].  It  has  been 
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proposed  that  the  placenta,  which  is  in  oxidative  stress  may  elaborate  soluble 
factors  into  the  maternal  bloodstream,  such  as  sFlt-1  (soluble  Fms-like  tyrosine 
kinase  1)  which  might  play  an  important  role  in  regulating  the  maternal 
vasculature  during  pregnancy,  and  proinflammatory  cytokines  that  further  alter 
maternal  vascular  endothelial cell  function  and  lead  to  the  characteristic  signs  and
symptoms  of  preeclampsia  [39].
1.3.1.3.  Immunological  factors
The  focus  on  immunological factors  as  a  possible  cause  of  placental  abnormality
is  based  upon  the  observation that  prior  exposure  to  paternal/fetal  antigens  appears
to  protect  against  preeclampsia.  This is  illustrated  by  the  following  examples:
In  a  report  of  1,011  consecutive  women  who  delivered  on  an  obstetric  unit,  the
incidence  of  pregnancy-induced  hypertension  was  11.9%  among  primigravidae,
4.7%  among  same-paternity  multigravidae,  and  24%  among  new-paternity
multigravidae  [40].
The  length  of  sexual  cohabitation  before  conception  is  inversely  related  to  the  risk
of  preeclampsia,  suggesting  that  prolonged  exposure  to  paternal  sperm  antigens 
may  be  protective  [40-43]. 
The  incidence  of  preeclampsia  is  higher  in  women  using  barrier  contraceptives  and
in  those  conceiving  by  intrauterine  insemination  with  donor  rather  than  partner 
sperm  [44,  45],  although  this  has  not  been  a  consistent  finding  [46].
Growing  reports  on  the  length  of  frequent  sexual  exposure  and  cohabitation  of  the
couples  in  the  reduction  of  preeclampsia  have  now  confirmed  that  the 
preeclampsia  is  a  disease  of  first  pregnancy  and  long  exposure  of the  paternal 
antigens  reduces  the  frequency of  the  preeclampsia  [47-49].  In  summary,  to  reduce
the  risk  of  preeclampsia/eclampsia,  it  is better  for  the  human  female  to  avoid 
conception  soon  after  initiating  sexual  relations  with  a  new  partner,  regardless  of 
her  gravidity.  Biological  explanations  for the  observations  mentioned  above  remain
unclear,  but  the  idea  of  preeclampsia  being a  graft  rejection  of  the  fetal–maternal
allograft  is  a  promising  approach.
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1.3.1.3.1.  Preeclampsia:  graft  rejection  of  the  feto–maternal  allograft 
Since  half  of  the  fetal  genome  is  derived  from  the  father,  the  fetus  synthesizes 
antigens  considered  to  be  foreign  by  the  maternal  immune  system  therefore, 
mother  should  reject  it,  but  this  generally  does  not  occur  [50].  In  his  classic  1953
paper,  Medawar  proposed  the  concept  of the  “fetal  allograft”  to  explain  the
immune  relationship  between  mother  and  fetus  for  successful  pregnancy  out  come.
In  this  model,  three  hypotheses  were  proposed  by  the  authors:  1)  that  the 
conceptus  lacked  immunogenicity;  2)  that there  was  a  significant  lowering  of 
immune  response  during  pregnancy;  3)  and  that  there  is  the  elaboration  of  an 
immune  barrier  by  the  placenta  [51].  Through  the  years,  the  third  hypothesis, 
suggesting  the  existence  of  an  immune  barrier  elaborated  by  the  placenta,  have 
acquired  considerable  attention.  Originally,  this  barrier  was  presumed  to  be  passive 
or  neutral  but  later  the  placenta  was  shown  to  be  a  site  of  active  tolerance.  It  is
presumed  that  fetal  cells  and  molecules are  released  into  the  maternal  blood
during  proliferation  of  trophoblastic  cells  [52],  following  tissue  ruptures  that  occur
at  the  terminal  extremity  of  the  growing  chorionic  villi.  The  whole  immune 
system  comes  into  contact  with  these  potential  fetal  immunogens.  Therefore, 
tolerance  to  the  semi-allogenic  fetus  by  the  maternal  immune  system  seems  mainly
an  active  mechanism  whereby fetal  tissues  are prevented  from  being  recognized  as 
foreign  [53].
Means  of  fetal  tolerance: Human  beings  have  a  particularly  extensive  placental 
invasion,  possibly  because  of  the  long  intrauterine  period  needed  for  fetal  brain 
development  [54].  The  mucosal  lining  of  the  uterus is  transformed  from  the 
endometrium  in  the  non-pregnant  state  to  the  decidua  in  pregnancy.  A  major 
leukocyte  infiltration  is  the  major  cellular  characteristic  of  this  change  [55].  The 
process  begins  in  the  luteal  phase  before  potential  implantation.  During  early
pregnancy,  natural-killer  cells in  the  uterus  (probably  derived  from  those  in  the
blood)  accumulate  as  a  dense  infiltrate  around  the  invading  cytotrophoblast  cells. 
From  mid-gestation  onwards,  these  killer  cells  progressively  disappear,  which 
coincides  with  cytotrophoblast  invasion,  since  human  placentation  is  complete  by 
about  20  weeks’  gestation  [55].  Natural-killer  cells  affect  both  trophoblast  invasion 
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and  vascular  changes  in  the  maternal  placental  bed  [55].  The uterine  natural-killer 
cells  produce  several  cytokines  that  are implicated  in  angiogenesis  and  vascular 
stability,  including  vascular  endothelial  growth  factor  (VEGF),  placental  growth
factor  (PIGF),  and  angiopoietin  2  [56]. Trophoblast-cell  invasion  into  the  decidua 
with  its  massive  leukocyte  infiltration  and  the  subsequent  arterial  transformation
results  in  close  tissue  contact  between  allogeneic  cells.  Then  it  should  be  consider 
that  what  immune  mechanisms  allow  this  deeply  controlled  trophoblast  invasion? 
In  this  regard  many  mechanisms  have  been  proposed  by  large  number  of  studies, 
locally  at  the  placental  level,  many  different  mechanisms  are  involved,  working 
alone  or  in  interaction  with  each  other.  These  mechanisms  are  briefly  summarized 
below:
x In  contrast  to  classical  HLA-A  and  HLA-B,  syncytiotrophoblast  expresses 
HLA-G,  which  is  a  very  particular  set  of  MHC  class  I  molecules  [57]
whereas  HLA-C  seems  weakly  expressed  [58,  59].  Recently,  HLA-G  has  been 
found  to  bind  the  KIRs  (killer-cell immunoglobulin-like  receptors)  of  NK  cells,
as  the  other  HLA  molecules  do.  This  interaction  appears  to  block  the 
cytotoxicity  of  these  cells (Fig:  4A) and  may  contribute  to  the  tolerance  of 
the  conceptus  by  reducing  NK  cell  activity  [60].
x During  implantation,  the  endometrium  secretes  LIF  (leukemia inhibitory  factor) 
whereas  the  blastocyst  expresses  at  its  surface  the  LIF-receptor  (LIF-R)  [61-63]
(Fig:  4B). This  is  absolutely  required  for  blastocyst  implantation.  During 
pregnancy,  LIF  is  synthesized  by  the decidua—the  maternal  part  of  the 
placenta—and  by  Th2  lymphocytes  whereas  the  syncytiotrophoblast  expresses 
LIF-R  [64] (Fig:  4C).  The  exact  function  of  the  LIF/LIF-R  molecules  during
pregnancy  is  still  unknown  but  the  binding  of  LIF  on  its  receptor  might  favor 
trophoblastic  growth  and differentiation  [65].
x Placental  trophoblast  epithelium  express  complement  inhibitory  molecules,  such
as  MCP  (membrane  complement  protein),  DAF  (decay  accelerating  factor)
(Fig:  4D),  or  other  factors  (i.e.  Crry  in rodents)  [66-68].  These  molecules  may
play  an  important  role  in  protecting the  semiallogeneic  human  conceptus  from 
maternal  complement  mediated  attack. 
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x Indoleamine  2,  3  dioxygenase  (IDO)  is  produced  by  the  syncytiotrophoblast 
and  reduces  close-range  immune  cell  reactions.  A  proposed  explanation  for  its 
role  in  tolerance  of  the  fetus  is  that  IDO  could  act  by  catalyzing  tryptophan 
destruction  in  maternal  immune  cells  that  are  localized  in  the  placental  area
(Fig:  4E);  this  tryptophan  deprivation  might  reduce  or  inhibit  some  immune
cell  responses  [69].
x The  Fas/FasL  system  is  in  involved  in  cellular  turnover,  tumor  cell  elimination,
antiviral  responses  or  protection  of  tissues  against  activated  lymphocytes.  It 
might  be  active  in  controlling  trophoblastic  growth  and  elimination  of  cells 
endangering  trophoblastic  cells (Fig:  4F)  [70,  71].  Fas  present  on  trophoblasts 
does  not  seem  to  transduce  apoptotic  signals  in  these  cells but  could  play  a 
role  in  limiting  the proliferation  of  the trophoblast  cells  [72]. 
x Annexins  are  membrane-associated  proteins  that  are  expressed  in  both  normal
and  malignant  cells  and  can  also  be  secreted  by  the  placenta  [73].  Recently,
Aarli  and  Matre  showed  that  annexin  II  can  partially  inhibit 
lymphoproliferation  of,  and  IgG  and  IgM  secretion,  by  maternal  immune  cells
[74] (Fig:  4G). Thus,  this  molecule  might  be involved  in  protection  of  the 
fetus  against  the  maternal  immune  system.
x Syncytiotrophoblast,  cytotrophoblast,  decidual  macrophages  and  both  maternal
and  fetal  endothelial  cells  consistently expressed  IL-4  and  can  also  influence 
cytokine  production  by  the  maternal  cells,  which  can  change  Th1/Th2  balance 
[75,  76].  Trophoblast  cells  generally  direct  Th1/Th2  cytokine  balance  to  a  Th2-
type  response  in  the  endometrium  during  pregnancy  and  reduce  the  production
of  pro-inflammatory  molecules  that  can  endanger  fetus  survival  [77-80].
x Alternatively’  activated  macrophages  that are  able  to  exert  anti-inflammatory
influences  occur  naturally  in  placenta  [81].  Alternative macrophage  molecules
are  induced  by  IL-4  and  inhibited  by  IFNJ,  while  classical  macrophages  are 
induced  by  IFNJ  and  inhibited  by  IL-4.  Alternative  macrophages  produce  little 
to  no  NO  and  free  oxygen  derivatives  but  produce  more  of  the  anti-
inflammatory  molecules  IL-10  and  IL-1-R-antagonist  [82]. These  observations 
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suggest  that  suppressive  macrophages  seems to  be  the  first line  of  defense 
cells  that,  if  they  function  successfully  can  reduce  Th1  immunity  [82].
x Deposition  of  semen  in  the  female  genital  tract  provokes  a  cascade  of  cellular 
and  molecular  events  that  resemble a  classic  inflammatory  response.  The
critical  seminal  factor  seems  to  be seminal-vesicle-derived transforming  growth 
factorE1  (TGFE1)—it  initiates  a  postmating  inflammatory  reaction,  allowing  an 
increased  ability  to  sample  and  process paternal  antigens,  and  a  strong  type-2 
immune  reaction.  By  initiating  a  type-2  immune  response  towards  paternal
antigens,  seminal  TGFE1  may  inhibit  the  induction  of  type-1  responses  against 
the  semi-allogenic  conceptus  that  are  thought  to  be  associated  with  poor
placental  development  and  fetal  growth  [83]. 
x The  diversity  of JG  T  cells  in  maternal  tissue during  pregnancy  contrasts  with 
a  limited  TCR  subtype  diversity  in the  non-pregnant  state  [80,  84].  Many 
other  T,  NK  and  NKT  cells  are  present  in  the  deciduas;  the  identification  of 
their  roles  requires  further  research.
x Production  of  OX-2  by  trophoblast  and  decidua,  a  glycoprotein  which  pushes
Th1/Th2  balance  toward  Th2,  also  inhibits  macrophages  and  decreases  fgl2,  a
pro-thrombinase  able  to  trigger  abortion  by  placental thrombosis  and  activation
of  the  complement,  [85].
In  summary,  maternal  tolerance  of  the  feto-placental  graft  is  the  result  of  the 
integration  of  numerous  mechanisms  of various  origins  and  modes  of  action; 
however  not  all  of  these  mechanisms  may really  be  important  for  the  success  of 
the  pregnancy. 
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Figure: 4. Means  of  fetal  tolerance  during  pregnancy.  (A) HLA-G.  HLA-G  may  inhibit 
cytolytic  activity  of  NK  cells  by  binding  their  KIR  receptors. (B)  LIF  (by  endometrium)  and  its 
receptor  (on blastocyst)  are  essential for  implantation. (C) After  implantation, LIF  could  influence
the growth  and differentiation  of  trophoblasts  . (D) Complement.  Inhibition of complement  (by
destruction  or  binding)  would  reduce  its  availability  to  harm  fetal  tissues. (E)  IDO  is  produced by
the  trophoblast  and  catabolizes  tryptophane  at  short  range  and may  so  inhibit  close  maternal
immune  cells. (F) Syncytiotrophoblastic  CD95-L  (membrane  or soluble form)  can  induce apoptosis
in maternal  immune  cells,  but  not  syncytiotrophoblastic  cells,  expressing  CD95. (G)  The  Annexin
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II secreted  by the  placenta could  inhibit lymphoproliferation  and  secretion of  maternal
immunoglobulins. Adapter  from Thellin  O. et  al., 2000,  Curr.  Opion. Immunol.
Means  of  fetal  rejection:  By  definition,  fetal  rejection  happens  when  critical
tolerance  mechanisms  are  absent  or  severed.  A  most  important  inducible  way  of 
rejection  involves  a  Th1/Th2  imbalance  toward  Th1,  increasing  the  production  of 
Th1  cytokines,  notably  the  pro-inflammatory  IFNJ  ,  TNFD    and  IL-2  [86].  The 
increase  in  the  Th1  cytokines  has  been  shown  to  be  associated  with  preeclampsia
[87].  Th1  cytokines  can  activate  inflammatory  macrophages  and  NK  cells  into 
lectin-activated  killers  (LAK),  which  then  exert  cytolytic  capacities.  Th1  cytokines 
can  also  act  directly  on  trophoblastic  cells,  reducing  OX-2  production  and 
increasing  their  production  of  fgl  2  (pro-thrombinase)  [84].  Fgl  2  can  then  induce 
clotting,  which  blocks  the  circulation of  maternal  blood  in  the  placenta 
(thrombosis),  thus  the  vital  exchanges  between  the  maternal  and  fetal  bloods  [88]. 
This  leads  to  the  death  of  fetal  tissues.  Thrombin-triggered  IL-8-production  in 
endothelial  cells  may  attract  and  activate  neutrophils,  which  attack  feto-placental 
structures.  Th1  cytokines  also  stimulate  the  production  of  immunoglobulins  able  to 
activate  the  complement  cascade.  Failure  to  reduce  complement  capacity
contributes  to  the abortion  process.  TNFD    and  IFNJ,  able  to  act  directly  on 
syncytiotrophoblasts,  appear  to  be  the  effectors  inducing  spontaneous  abortions  in 
stress  situations  leading  to  coagulation,  arrest  of  the  local  maternal  blood  flow, 
and  aggression  of  the  feto-placental  structures  [89].  Hormones  or  inhibitory 
molecules  can  counteract  the  placental hormones  which  sustain  Th2-type  immune 
responses.
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1.3.2.  Placental  debris  hypothesis-syncytiotrophoblast  shedding
It  has  been  known  since  the  end  of  the  19th  century that  fragments  of  trophoblast
break  away  from  the  surface  of  the  placenta  and  enter  the  maternal  circulation
(Fig:  5).
Figure: 5. Schematic  representation of  trophoblast  turnover and trophoblastic  apoptosis at the
villous  surface. Cytotrophoblast  nuclei  surrounded  by  high  concentrations of  ribosomes  are 
transferred  into  syncytiotrophoblast  by  syncytial  fusion.  In  the  course  of  about  three  weeks  the
syncytially incorporated  nuclei  undergo  apoptotic  changes,  accompanied  by  degranulation  of  the
surrounding  cytoplasm.  Finally,  they  are  extruded by apoptotic knotting  and shedding.the  density  of 
point  shading  represents  the  density of  the  ribosomes  (based on Huppertz  et  al., 1998).
It  has  been  proposed  that  this  shedding  occurs  in  normal  pregnancy  and  is 
significantly  increased  in  preeclampsia.  On  the  basis  of  increased  shedding  of 
STBM  during  preeclampsia  the  following  models  has  been  proposed  for  normal
and  preeclamptic  pregnancies  [90] (Fig:  6).
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Figure: 6.  A  proposed  model for the  inflammatory  response  during  normal  and  preeclamptic
pregnancies. (A)  low  burden of  trophoblastic  release  during normal  pregnancy  leads  to mild
inflammatory  response. (B)  Increased  trophoblastic  release  during  preeclampsia  due  to  placental 
abnormalities  leads  to  increased  inflammatory response.
These  "cellular"  trophoblast  fragments  are  readily  detectable  in  uterine  vein  blood
sampled  at  the  time  of  caesarean  section,  both  in  preeclampsia  and  normal
pregnancy,  there  are  very  few  in  peripheral  blood  samples  taken  from  the  same
women  [91],  probably  because  they  become  trapped  in  the  capillaries  of  the  lungs.
Thus,  these  fragments  are  unlikely  to  be  the  cause  of  systemic  leukocyte  and 
endothelial  cell  activation.  The  subcellular  syncytiotrophoblast  microparticles  (which
would  circulate  freely)  are  also  shed  into  the  maternal  circulation.  Using 
trophoblast-specific  antibodies  increased  amount  of  microparticles  released  during 
preeclampsia  have  been  detected  in  the  maternal  plasma  in  comparison  to  the 
plasma  of  normal  pregnant  women  [92]. The  search  for  syncytiotrophoblast  debris, 
have  revealed  that  levels  of  both  cytokeratin  (a  cytoskeletal  protein  of  trophoblast) 
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and  fetal  cell-free  DNA  are also  significantly  increased  in  preeclampsia  compared 
with  normal  pregnancy  [93-95].  Thus,  there  is  a  whole  spectrum  of 
syncytiotrophoblast  debris  in  the  maternal  circulation. 
Syncytiotrophoblast  debris are  the  product  of  syncytiotrophoblast  apoptosis:
The  reason  for  the  shedding  of  this  debris  was  not at  first  apparent.  However,  the
proposal  by  Huppertz  et  al.,  [96]  made  clear  that  apoptosis  plays a  central role  in 
the  formation  of  syncytiotrophoblast  from  the  underlying  villous  cytotrophoblast, 
and  that  it  causes  controlled  cell  fragmentation  in  order  to  allow  continuous 
renewal  of  the  syncytial  surface  of  the  chorionic  villi,  offering  an  explanation  for 
the  shedding  of  subcellular  debris  as  part  of  a  normal  apoptotic  process. 
Furthermore,  it  has  been  shown  that  this process  is  increased  in  preeclampsia  [97, 
98].  To  what  extent  apoptosis  or  necrosis  contribute  in  the  debris  seen  in 
preeclampsia  is  not  certain  but  this  may  have  important  consequences  for  the
effects  it  may  have  on  the  maternal  immune  system.
The  syncytiotrophoblast  microparticles  (STBM)  that  were  detected  in  the  maternal
plasma  were  annexin  V  positive.  This  finding  confirmed  that  STBM  are  product 
of  apoptosis  [99].  These  experiments  have  shown  apoptotic  microparticles  to  be 
present  in  the  plasma  of  normal  pregnancy,  with  significantly  higher  levels  in 
preeclampsia.  However,  it  appears  that  particularly  in  preeclampsia  there  are  more 
apoptotic  microparticles  than  trophoblast  microparticles  [99].  It appears  that  large 
amounts  of  apoptotic  particles  during  preeclampsia  may have  originated  not  only 
from  the  placenta  but  also  from  maternal  leukocytes  and  endothelial  cells  that 
might  also  undergo  apoptosis  as  a  part of  the  systemic  inflammatory  response.
Further  detection  of  annexin  V  positive  STBM  in  uterine  vein  and  peripheral  vein
blood  of  normal  pregnant  and  preeclamptic  women  revealed  that  levels  of  STBM
were  higher  in  the  uterine  vein  than  the  peripheral  vein  samples  [100].  Further 
evidence  for  this  was  obtained  by  looking for  fetal  and  total  cell-free  DNA  in 
similar  samples.  Fetal  DNA  was  found  to  be  higher  in  the  uterine  vein  circulation
whereas  total  DNA  (fetal  plus  maternal) was  the  same  in  uterine  vein  and 
peripheral  vein  samples  [101].
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Why  increased  STBM  shedding?  The  reason  why  levels  of  syncytiotrophoblast 
debris  are  significantly  increased  in  preeclampsia  is  unknown.  It  has  been  believed
since  long  time  that  the  rate of  apoptosis  is  thought  to  be  increased  in 
preeclampsia  as  a result  of  placental  oxidative  stress  [97,  98],  which  is  frequently, 
although not  universally,  increased  in  the  condition. In  2000,  Formigli  et  al 
proposed  a  chimerical  type  of  cell  death  that  is  regarded  as  a  truncated  form  of 
apoptosis  with  an incomplete  execution,  which  is  followed  by  degeneration  via 
necrosis.  This  combination  of  both  forms  has  been  termed  “aponecrosis”  [102]. 
Recently  it  has  been  proposed  that  in  preeclampsia  not  only  apoptosis  is 
increased,  but  it  seems  as  if  the  whole turnover  of  villous  trophoblast  from 
proliferation  via  fusion  to apoptosis  is  enhanced  [103].  This  may  shed  new  light 
on  the  increase  in syncytiotrophoblast  apoptosis.  The higher  rate  of  proliferation 
seems  to  be  linked  to  a  higher  rate  of  fusion,  because  a  multilayered
cytotrophoblast  compartment  is  not  a  feature  of  preeclampsia  [103].  With  a  higher 
rate  of  proliferation,  much more  material  is  introduced  into  the  syncytiotrophoblast 
via  fusion,  and  it  is  hypothesized  that  this  multinucleated layer  has  to  increase  its
apoptotic  release  of  material  to  counterbalance  the  higher  input.  Thus  the  increase 
in  apoptosis  found  in  preeclampsia  may  not  be  a  sign  of  damage but  simply  a
sign  of  a  higher  traffic  or  turnover  of  villous  trophoblast  due  to  an  adaptive 
process.  The  question now  is  whether  the syncytiotrophoblast  is  able  to  adjust  a 
new  physiologic  balance  between  input  and  output.  If  there  is  too  much  input  to 
be  compensated  by  apoptotic  release,  the  apoptotic  machinery  of  the
syncytiotrophoblast  may  be  overwhelmed  and material  may  be  released  from  the
syncytiotrophoblast  in  a  nonapoptotic  manner  [103].  Huppertz  et  al  have  recently 
shown  similar  apoptotic  features  in  preeclampsia  as  observed  by  Formigli  et  al, 
and  have  proposed  villous  trophoblast  in preeclampsia  likely undergoes  aponecrosis
[103].
However,  as  preeclampsia  may  also  occur with  a  perfectly  normal  placenta  as  in 
twin  pregnancy,  in  these  cases,  it  may  just  be  the  larger  placental  mass  which 
contributes  to  the  increased  shedding  of  debris. 
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1.3.2.1.  STBM  and  maternal  inflammatory  response 
As  STBM  cannot  be  readily  retrieved from  maternal  plasma  samples,  the in-vitro
isolation  of  STBM  have  been  performed by  mechanical  dissection  of  the  term 
placenta  [104].  It  has  been  shown  that mechanically  prepared  STBM  from  normal
full  term  placenta  disrupt  the  morphology, inhibit  the  proliferation  of  cultured
endothelial  cell  monolayers in-vitro  [105,  106].  Further  it  has  been  shown  that  the 
STBM  prepared  from  the  preeclamptic  placenta  also  showed  same  levels  of 
inhibition  in  proliferation  of  endothelial  cells  as  shown  by  the  STBM  prepared 
from  normal  placenta  [107]. Furthermore  STBM  perfused  ex-vivo  into  pre-
constricted  small  subcutaneous  fat  arteries  alter  their  relaxation  response  [108].  It
has,  therefore,  been  proposed  that  the  increased  shedding  of  STBM  into  the 
maternal  blood  of  women  with  preeclampsia could  be  responsible  for  the  manifest
dysfunction  of  the  vascular  endothelium  [108].  The  endothelial  dysfunction  caused 
by  STBM  may  induce  release  of  pro-inflammatory  factors  [109].  These 
inflammatory  factors  can  activate  lymphocytes in-vitro [109].
Increased  STBM  in  preeclampsia  could  participate  in  pathogenesis  by  enhancing 
the  inflammatory  stimulus  with  or  without  specific  immune  recognition.  STBM
might  interact  with  the  maternal  innate  immune  system  to  stimulate  the 
inflammatory  response  in  pregnancy.  Monocytes  and  neutrophils  binding  to  STBM 
results  in  raised  production  of  TNFD  and  IL-12,  and superoxide  radicals, 
respectively  [110-112].  Many  other  placental  factors  seen  in  the  maternal
circulation  during  healthy  pregnancy  are increased  in  preeclampsia.  These  include
several  inflammatory  cytokines,  corticotropin-releasing  hormone,  free-radical 
species,  and  activin  A;  all  could  stimulate  the  maternal  inflammatory  response
[113].  More  recently  it has  been  shown  that  monocytes  bind  STBM  both in-vivo
and in-vitro that  can  stimulate  the  production of  the  proinflammatory  cytokines 
TNFD  and  IL-12 in-vitro [114].  In  particular  TNFD,  with  its  ability  to  activate
endothelial  cells,  cause  microvascular  protein  leakage,  and  reduce  acetylcholine-
induced  vasorelaxation,  has  received  a  lot  of  attention  as  a  having  a  potential  key 
role.  Increased  TNFD  amounts  in  the  preeclamptic placenta  are  probably  produced 
by  villous  stromal  cells,  especially  macrophages,  but  sources  other  than  the 
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placenta  seem  to  contribute  to  raised  plasma  TNFD  and  IL-6  concentrations  seen 
in  the  disease  [27,  115].  IL-12  derived  from  monocytes  or  macrophages  is 
important  in  driving  Th1  reactions  in  preeclampsia.  IL-12 is  a  potent  stimulus  of 
IFNJ  release  by  natural-killer  cells  and  naive  T  cells.  Importantly,  IFNJ  efficiently
primes  monocytes  for  further  IL-12  release  that  triggers  a  feed-forward  cycle,
which  could  explain  the  very  rapid  deterioration  in  some  severely  ill  preeclamptic
patients  [110,  111,  116].
It  is  known  since  long  time  that  STBM  can  inhibit  proliferation  of  PHA 
stimulated  lymphocyte in-vitro  [117,  118].  Recent  studies  have  described  the 
methods  of  purification  of STBM  from  the  maternal  serum  and  have  shown  that
shed  STBM  express  FasL  and  have  shown  that  exposure  of  T  lymphocytes  (Jurkat
cells)  to  such  STBM  induced  FasL  mediated  apoptosis  and  down  regulation  of 
CD3-zeta  expression  [119].  These  evidences  suggest  that  during  normal  pregnancy 
T  cell  response  is  impaired  to  suppress Th1  immune  response.  Thus,  it  can  be 
interpreted  that  during  preeclampsia  excessive  shedding  of  STBM  might    stimulate
innate  immune  system  that  will  induce  Th1  response  as  discussed  above.
1.3.3.  Systemic  endothelial  dysfunction  and  inflammation
It  is  still  uncertain  whether  preeclampsia  is  caused  by  the  damaged  ischaemic  or 
reperfused  placenta  or  by  the  inappropriate  or  exaggerated  maternal  inflammatory
response  towards  the  presence  of  the trophoblast,  although  the  endothelium  is 
associated  with  the  pathophysiology  of  disease.  The  inflammatory  response  during 
preeclampsia  is  not  confined  to  the  disease  only  but  is  also  present  in  normal
pregnancy,  albeit  in  a  milder  form.  This  "mild"  inflammatory  response  appears  to 
cause  no  harm  and  may  even  be  beneficial  to  the  pregnancy  [120].  Preeclampsia 
develops  when  the  normal  inflammatory  response in  pregnancy  becomes
exaggerated  in  response  to  excessive  stimuli  and  triggers  the  endothelial 
dysfunction  and  inflammation  leading  to the  maternal  symptoms  [121].
The  feto-placental  unit  initiates  the  pro-inflammatory  stimulus.  However,  a  fetus  is
not  necessary  as  preeclampsia  can  occur in  molar  pregnancies  where  there  is  a 
large  placental  mass  but  no  fetus  [122].  If some  or  all  of  the  placenta  is  left 
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behind,  the  maternal  symptoms  of  preeclampsia  may  persist  after  the  delivery  of 
the  preeclamptic  pregnancy  [123].  The  factor  must  be such  that  it  is  present  in 
the  placenta  in  normal  pregnancy  and  is shed  into  the  maternal  circulation  where
it  can  interact  with  leukocytes  and/or endothelium  to  stimulate  the  inflammatory
response  [124].  This  same  factor  would  then  be  shed  into  the  maternal  circulation 
in  increased  amounts  in  preeclampsia  to  cause  the  exaggerated  inflammatory
response  seen  there.  The  excess  release  of  this  factor  could  be  due  to  either 
oxidative  stress  resulting  from  a  intermittent  placental  blood  supply, as  seen  in  the
placentae  of  some  cases  of  preeclampsia  or  may  be  the  product  of  a  larger 
placental  mass  such  as  in  twin  or  molar  pregnancy  [121,  124].  There  are  many
factors  produced  by  the  placenta  (although  not  necessarily  exclusive  to  the 
placenta),  which  are  found  in  the  maternal  circulation  in  normal  pregnancy,  with
increased  levels  in  preeclampsia.  These  include  STBM,  various  pro-inflammatory
cytokines  [125,  126]  and  activin  A  [127],  all  could  be  potential  stimulators  of  the 
maternal  inflammatory  response. 
All  of  the  clinical  features  of  preeclampsia  can  be  explained  as  maternal  responses
to  generalized  endothelial  dysfunction  [120,  124,].  Endothelial  dysfunction  leads  to 
hypertension,  increased  vascular  permeability  which  results  in  edema  and 
proteinuria.
Laboratory  evidence  supporting  generalized endothelial  dysfunction  in  preeclamptic
women  includes: 
x Increased  concentrations  of  circulating  cellular  fibronectin,  factor  VIII 
antigen,  and  thrombomodulin  [128-130]. 
x Impaired  flow-mediated  vasodilation  [108,  131,  132]  and  impaired 
acetylcholine  mediated  vasorelaxation  [132]. 
x Decreased  production  of  endothelial-derived  vasodilators  such  as  NO  and 
prostacyclin  and  increased  production  of  vasoconstrictors  such  as
endothelins  and  thromboxanes.
x Enhanced  vascular  reactivity  to  angiotensin  II  [133]. 
x Serum  from  preeclamptic  women  causes  endothelial  activation in-vitro
[134].
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x Impaired  endothelial  function  can  be demonstrated  by  brachial  artery  flow-
mediated  dilation  three  years  after  a  preeclamptic pregnancy  [135].  It  is 
unknown  whether  this  is  a  cause  or effect  of  the  preeclamptic  pregnancy. 
These  evidence  suggests  that  endothelial  dysfunction  and  inflammation  is 
associated  with  the  pathogenesis  of  preeclampsia.
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Design  of  the  study 
In  this  study,  we  have  explored  the  role  of  STBM  and  cytokines  in  the  normal
pregnancy  and  preeclampsia.  To  date  all  studies  largely  made  use  of  mechanically
prepared  STBM,  from  normal  full  term  placenta,  which  are  most  likely  to  be
generated  by  a  process  of  necrosis  and  might  not  mimic  physiological  conditions
[105-109].
In  this  study,  we  hypothesized that  not  only  the  quantity  of  the  STBM  as  well  as
their  quality  might  also  play  an  important  role  in  the  pathogenesis  of 
preeclampsia.  It  has  been  proposed  that  STBM  produced  from  normal  or 
preeclamptic  placenta  display  similar  effects  on  endothelial  cell  cultures  [107].
Therefore,  to  have  qualitative  difference  among  the  STBM  we  prepared  STBM 
from  normal  term  placentae  by  three  different  methods:
A)  Placental  villous  tissues  from  freshly  delivered  placentae  were  mechanically
dissected  as  reported  earlier  and  referred  as  mSTBM  [104,  105].
B)  Villous  explants  were  cultured  in conditions,  which  maintain  overall  tissue 
integrity  and  support  the  physiologic  turnover  of  the  syncytiotrophoblast,  including 
apoptotic/aponecrotic  shedding  and  referred  as  vSTBM  [103].
C)  Single  placental  cotyledons  were  perfused  separately  on  both  the  maternal  and
fetal  sides  and  the  maternal  washes  were  collected  and  referred  as  pSTBM  [136, 
137].
Further,  the  morphological,  biochemical, functional  properties  of  the  STBM 
generated  by  the  different methods  were  compared.  After  characterization  of  the 
different  STBM  preparations  their  effects were  analyzed  on  various  cell  types  to 
understand  their  role  during  normal  pregnancy  and  preeclampsia.
The  placentally  derived  soluble  factors  generated  after  villous  explant  culture  were
also  prepared  and  was  analyzed  for  the  presence  of  cytokines  to  study  their 
effects  on  immune  cells. 
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AIM  of  the  study 
The  broad  goal  of  this  work  was  to  understand  the  role  of  placentally  derived  STBM 
and  cytokines  during  normal  pregnancy  and  preeclampsia.  In particular  the  three  STBM 
preparations  were  characterized  qualitatively  to  mimic  most  physiologic  STBM.  Further 
the  effects  of  all  the  three  STBM  preparations  and  placentally  derived  soluble  factors 
were  studied  on  activation,  proliferation,  cytokine  production,  apoptosis  induction  of
different  cell  types  such  as  endothelial,  T  cells  and  neutrophils. 
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2.  Results 
2.1.  Morphological  and  Biochemical  Characterization  of  the 
STBM
In  order  to  understand  the  functional  aspects  of  the  STBM  we  characterized  them
morphologically  and  biochemically.  STBM  were  prepared  by  three  different 
methods:  1)  villous  explant  culture  (vSTBM),  2)  perfusion  of  a  placental 
cotyledon  (pSTBM),  and  3)  mechanically  dissected  STBM  (mSTBM).  The  STBM
depleted  villous  explant  conditioned  medium  (VE-CM)  from  villous  explant
cultures  was  also  collected  considering  it  is  a  rich  source  of  placentally  derived
soluble  factors.  As  mentioned  earlier  that most  of  the  previous  studies  have  made
use  of  mSTBM  therefore,  we  first  characterized  our  two  new  STBM  preparations. 
mSTBM  were  also  used  in  parallel to  the  other  two  STBM  preparations. 
2.1.1.  Origin  and  Morphology  of  the  STBM 
2.1.1.1.  STBM  are  membrane  fragments
To  examine  whether  the  STBM  prepared  by  the  three  methods  are  products  of  the
membrane,  we  carried  out  FACS  analysis  of  the  STBM  after  labeling  with 
membrane  specific  fluorescent  dye  PKH-26,  which  with  its  aliphatic  tails 
incorporates  into  lipid  regions  of  the  cell  membrane.  Our  FACS  analysis  of  all
the  three  STBM  preparations revealed  that  >95%  STBM were  the  products  of  the 
plasma  membrane (Fig:  7).
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Figure: 7. FACS  analysis  of  the  STBM.  STBM  preparations  were  stained  with  PKH-26  dye  and
analyzed  using  FACS  as described  in  materials  and methods.  This  analysis indicated  the  STBM
are  the products  of plasma  membrane. A  single representative  analysis  of  mSTBM  is  shown.
2.1.1.2.  STBM  are  the  product  of  syncytiotrophoblast  layer  of  the 
placenta
To  confirm  that  the  STBM  are  products  of  outermost  layer  of  the  placental 
villous  tree  i.e.  syncytiotrophoblast,  we  examined  these for  the  presence  of  PLAP, 
a  GPI-anchored  enzyme  present  in  syncytiotrophoblast  membrane,  using  an  ELISA 
assay.  STBM  were  captured  with  an  anti-PLAP  antibody  and  the  endogenous 
phosphatase  activity  of  the  immobilized  particles  was  measured.  This  analysis 
indicated  that  membrane  associated  PLAP  was  found  in  all  three  STBM
preparations (Fig:  8),  with  almost  4-fold  higher  concentration  being  present  in  the 
mechanically  prepared  particles. 
Figure: 8. Concentrations  of  PLAP  protein  in  each of  the  STBM  preparations. Equivalent
amounts of  STBM,  as  assessed by  total protein  content,  were  examined  for PLAP  by  ELISA. The
figure  represents  an  examination  of  STBM  preparations  from  3  different  placentae.  RBC 
microparticles  (RBC  ghosts)  were  used  as  a  negative  control  to  confirm that PLAP  is  largely 
associated  with  the STBM only.
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2.1.1.3.  STBM  preparations  are  morphologically  similar 
The  STBM  prepared  by  three  different methods  were  examined  using  scanning 
electron  microscopy.  This  analysis  demonstrated  that  all  three  STBM  preparations 
produced  micro-particles  with  sizes  ranging  from  200-600 nm  in  diameter  and  that 
these  particles  were  morphologically  similar (Fig:  9).  Although  the  SEM  analysis 
was  not  quantitative,  the  data  suggest  that  the  three preparations  vary  in  the
quantity  of  particles produced  relative  to  the  amount  of  starting material,  with  the 
greatest  number  being  produced  by  the  mechanical  method.  Mechanically  prepared 
particles  also  had  a  tendency  to  aggregate  in  clumps (Fig:  9C),  a  feature  not 
observed  with  particles  prepared  by  the  other  two  methods.
   Gupta  et  al.  Placenta,  2005 
Figure: 9.  Scanning  electron  micrographs of  different  STBM  preparations. (A-B)  vSTBM from
explants, (C-D) mSTBM,  (E-F) pSTBM. mSTBM  tend  to  aggregate in  clumps (C).
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2.1.2.  Biochemical  properties  of  the  STBM 
2.1.2.1.  STBM  are  rich  in  RNA  and  DNA 
It  has  been  demonstrated  that  the  amount  of  fetal  nucleic  acids  is  increased  in  the
maternal  circulation  during  preeclampsia  [94,  95,138].  It  is  possible  that  if  fetal 
nucleic  acids  are  associated  with  the  STBM  then  their  increased  release  during
preeclampsia  might  contribute  in  increased  nucleic  acids  concentration  in  the 
maternal  circulation,  therefore,  DNA  and  RNA  concentrations  in  the  STBM
preparations  were  quantified.  The  amount  of  fetal  DNA in  the  different  STBM
preparations,  obtained  from  male  placentae,  was  measured by  a  Taqman®  real-
time  PCR  assay  for  a  Y  chromosome  specific  sequence  (SRY)  [138],  whilst  the
presence  of  fetal  mRNA  was  quantified by  quantitative  RT-PCR  assay  for  CRH 
(corticotropin  releasing  hormone)  gene,  which  is  expressed  in  the placenta  [139]. 
This  analysis  revealed  that  all  STBM  preparations  contain  both  fetal  DNA  and 
mRNA,  although  the  levels  of  each  of  these  fetal  analytes  differ  in  the  three 
preparations  (Table  1).
Gupta  et  al.  Clin. Chem.,  2004. 
Table  1.  Concentration  of  fetal  DNA and  CRH mRNA  in different  preparations. Six  placentae
were  used  for  each  STBM  preparation.  Circulatory  fetal  DNA  (SRY  locus)  and  mRNA  (CRH) 
concentrations  were determined by  real-time  PCR  and real-time  RT-PCR, respectively,  and  are
represented  as  copies/mg  of  STBM.  Values  are given as  median  and range,  in brackets.
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In  this  regard,  highest concentration  of  fetal  DNA was  detected  in  STBM 
prepared  by  vSTBM (Fig:  10A),  whereas  the  highest  concentration  of  fetal  RNA 
was  present  in  pSTBM (Fig:  10B).
Gupta  et  al. Clin. Chem.,  2004
Figure: 10.  Box-plot  illustration  of  circulatory fetal  DNA  and  mRNA  concentrations  in  STBM 
preparations. Fetal DNA  (SRY  locus; A)  and  mRNA (CRH;  B)  concentrations  were  determined
byreal-time  PCR  and  real-time  RT-PCR,  respectively, and  are  represented  as  copies/mg  of  STBM.
Six  placentae  were  used  for  each  STBM  preparation.  Box  plots  indicate  median  value  (line  in
box), 75th  and 25th  percentiles  (limits  of  box). Upper  and  lower horizontal bars  indicate  10th and
90th  percentiles, respectively. Open  circles  indicate outliners.
35
Results
2.1.2.2.  Lipid  analysis  of  the  STBM
Preeclampsia  and  atherosclerosis  share  similar  symptoms  and  lipids  have  been 
shown  to  play  an  important  role  in  the  pathogenesis  of  both  diseases  [140].  As
STBM  are  the  products  of  syncytiotrophoblast  cell  layer  of  the  villous  tree,  they 
should  be  rich  in the  membrane  lipids, and  therefore,  may contribute  in  the 
pathogenesis  of  preeclampsia.  Lipid  content  was  examined  in  all  the  STBM 
preparations  using  Thin layer  chromatography  (TLC)  and    mass  spectrometry.
All  three  preparation  were  applied  to  TLC the  plate  as  mentioned  in  the  materials
and  method.  Around  6  spots  were  observed  on  the  run  front  of  the  TLC  plate. 
All  the  spots  were  identified  by  mass  spectrometry  and  were  products  of 
cholesterol  esters normally  present  in  the  plasma  membrane  [141].  The  spot  at  the 
top  of  the  TLC  plate  was  identified  as  cholesterol.  This  analysis  revealed  that  the 
lipid  concentration  in  the  mSTBM  is  relatively  higher  than  the  other  two  STBM
preparations (Fig:  11A).  This  indicates  the  possibility  of  mSTBM  to  be  richer  in
membrane  materials  at  equal  protein  concentration.  These  cholesterol  lipids  and 
cholesterol  ester  present  in  the  mSTBM  could  be  depleted  in  a  dose  dependent
manner  using  a  known  compound  Methyl-E-cyclodextrin  (MECD)  that  can  deplete 
cellular  membrane  cholesterol  [142] (Fig:  11B).
              A. 
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Figure: 11. Lipid  analysis  in  the  STBM preparations. (A).  Lipids were  extracted  from  all  the
three  STBM preparations  and  TLC  was  carried out. TLC  analysis  revealed  that mSTBM  are  rich 
in  the  lipid content  than the other  two  preparations. (B).  The  lipids from  the  STBM  could  be
depleted  in  a  dose dependent  manner  using  MECD, depleted  lipids  could  be  observed  in  the
supernatant.
2.1.2.3.  Particle  free  nucleic  acids  and  cytokines  produced  by  the 
placenta
Placentally  derived  soluble  factors  might  play  an  important  role  in  the
pathogenesis  of  preeclampsia.  Therefore, STBM  depleted  VE-CM  collected  from 
the  villous  explant cultures.  VE-CM  was  analyzed for  the  presence  of  nucleic 
acids  and  cytokines.  In  comparison  to  fetal  RNA  very  high  levels  of  fetal  DNA 
were  detected  in  the  VE-CM (Fig:  12).  These  levels  of  nucleic  acid  may
correspond  to  the in-vivo  situation  where  majority  of  the  fetal  DNA  is  cell  free 
and  the  fetal  mRNA  species  may  be  largely  associated  with  membrane  particles,
as  reported  previously  [143].  Supernatants  collected  from  other  two  STBM 
preparations  were  also  analyzed  for  the  presence  of  nucleic  acid  and cytokines  but
we  could  not  detect  any  nucleic  acid  and  cytokines  in  these  samples,  which  may
be  depends  upon  the  mode  preparation  of  the  different  STBM. 
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Figure: 12.  Analysis  of  nucleic acids  in  the  culture  supernatant.  DNA  and  RNA  in  the VE-CM
were  analyzed  using  real-time  PCR  assays  as  described  in  materials  and  methods.  This  assay
suggested  that  majority  of  the DNA produced by  the placenta is  cell  and  particle free.
Further,  placentally  derived  cytokines  were  identified  in  the  VE-CM  using  a 
multiplexed  protein  assay  designed  to  enable  the  simultaneous  detection  of  18 
cytokines  within  individual  samples. (Fig:  13).  This  analysis  indicated  that 
placenta  produced  some  inflammatory  cytokines  such  as  IL-1  and  IL-6  and 
chemokines  such  as  IL-8,  RANTES,  MIP1D,  and  MIP1E.  If  released  in  large
quantities  from  the  placenta  into  the maternal  circulation,  these  inflammatory
molecules  and  chemokines  may  activate endothelial  cells  and  innate  immune 
system  as  observed  during  preeclampsia  [144,  145].  Our  cytokine assay  also 
revealed  two  white  spots  in  column  D  row  1  and  2  that  were  TNFD  spots.  The 
intensity  of  the  spots  reveals  that high  levels  of  TNFD  are  present  in the  VE-CM. 
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Figure:  13.   Detection  of  the  cytokines  present  in  the VE-CM. 11  cytokines were  identified  in
VE-CM  using  a multiplexed  protein  assay.  This  analysis  identified  IL-6,  IL-8, Leptin, IL-1D,  IL-
1E,  RANTES,  MIP1D,  MIP1E,  IL-12, IL-17,  in  the VE-CM  which was  collected  after  the villous
explant  culture  further  suggesting  it  is rich source of cytokines. White  spots  corresponds  to  TNFD.
2.1.3.  Conclusion
These  observations  confirmed  that  the  STBM  are  membranous  particles,  which
have  originated  from  the  syncytiotrophoblast.  These  three  preparations  are 
morphologically  similar but  differ  from  each  other  biochemically  in  terms  of  the 
presence  of  STBM  associated,  PLAP,  nucleic  acids,  and  lipids.  Further,  it  can  also
be  concluded  that  the  placentally  derived  VE-CM  is  rich  in  DNA  and  cytokines. 
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2.2.  Functional  characterization  of  the  STBM
2.2.1.  Inhibition  of  HUVEC  proliferation  by  STBM  preparations 
In  order  to  functionally  characterize  the  three  different  STBM preparations,  we
used  HUVEC,  a  well-characterized  endothelial  cell  model.  These  cells  have  been 
previously  used  to  assess the  growth  inhibition  properties  of  mSTBM  [105].  The 
effects  of  equal  amounts  of  STBM,  as  determined  by  protein  content,  were 
compared  on  HUVEC  growth.  Particles  prepared  from  red  blood  cells  (RBC 
ghosts)  were  used  as  a  control.  mSTBM  inhibited  HUVEC  proliferation  up  to 
90%  at  12 Pg  STBM  concentration  while  the  other  two  STBM  preparations  at 
similar  dose  showed  only  a  30-50%  inhibition  of  endothelial  cell  proliferation 
(Fig:  14A).  All  STBM  preparations  inhibited  HUVEC  proliferation  in  a  dose 
dependent  manner (Fig:  14B).  When  the  dose  of  vSTBM  or  pSTBM  was
increased  to  50 Pg/well,  a  further  reduction  in  HUVEC  proliferation  could  be 
observed.  However  the  high  degree  of  inhibition  of  proliferation  achieved  with  the 
mechanically  produced  STBM  could  not  be obtained  with  the  other  preparations.
Gupta  et  al. Placenta,  2005
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Figure: 14.  Inhibition  of  endothelial  cell  proliferation  by  STBM. (A)  Sub-confluent  HUVEC
cells  were  incubated for 40 h with 12 Pg/well  STBM  from  different STBM. Cell  proliferation  is
represented  as  the  percentage  of  cell  proliferation  relative  to  untreated  control  as  100% cell
proliferation. A representative  analysis of  STBM  preparations from  4 placentae  is  illustrated (B) A
representative  experiment  from  one placenta preparation  showing  dose  dependent effect of various
STBM preparations  on  inhibition  of  HUVEC proliferation
2.2.2.  Effects  of  STBM  preparations  on  cell  line  proliferation 
To  investigate  whether  STBM  were  able  to  inhibit  cell  proliferation  of  other  cell 
types  or  whether  this  effect  was  specific  for  HUVEC  proliferation,  the  effects  of 
all  the  STBM  preparations on  adherent  and  non  adherent  cell  types  namely  U937 
(nonadherent)  and  A431,  HELA,  NIH-3T3,  LN-18  (adherent)  was  assessed.  It  was
observed  that  cell  proliferation  was  not  significantly  reduced  by  any  of  the  STBM
preparations  in  any  of  these  cell  lines (Fig:  15A-15C),  unlike  the  effect  that  was 
observed  with  HUVEC.
       Gupta  et  al.  Placenta,  2005
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Figure:  15.  Effects  of  different  STBM  preparations  on  cell  proliferation  comparing  HUVEC
and other  cell  types.  Each  point  is mean  of  three replicates  and  expressed  as  the  percentage  of 
cell  proliferation  relative  to  untreated control  as 100%  cell  proliferation. (A)  Treatment with
mSTBM,  (B) Treatment  with  vSTBM,  (C) pSTBM.  A  representative  experiment  from  one  STBM
of  each preparation  is shown.
2.2.3.  Mechanically  derived  STBM  disrupt  HUVEC  monolayer
When  HUVEC  were  incubated  together  with  the  three  different  STBM
preparations  at  a  dose  of  12 Pg/well,  only  the  mSTBM  caused  disruption  of  the
cell  monolayer,  leading  to  cell  detachment (Fig:  16).  The  kinetics  of  detachment 
was  found  to  be  dose  dependent.  It  was  observed  that  with  a  12 Pg  dose  of 
mSTBM,  the  disruption  of the  HUVEC  monolayer  started after  12h  of  incubation,
and  resulted  in  the  detachment  of  almost  90%  cells  within  the  next  12h.  At  low 
concentrations (3  and  6 Pg),  detachment  started  after  treatment  periods  exceeding
12h  but  eventually  resulted  in  80-90%  HUVEC  detachment  at  24h.  In  contrast, 
the  other  two  STBM  preparations,  even  at  higher  concentration  (50 Pg/well)
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neither  disrupted  the  continuity  of  the  HUVEC  monolayer  nor  caused  any  cell 
detachment.
        Gupta  et  al.  Placenta,  2005
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Figure: 16.  Effects of  different STBM preparations on  HUVEC monolayer  integrity. (A)  Intact
confluent  HUVEC monolayer  incubated  24  h  without  STBM, (B)  with  12 Pg  vSTBM, (C)  with
12 Pg  pSTBM (D)  Disrupted  HUVEC monolayer  following  incubation  with  12 Pg  of mSTBM.
Magnification  is 400x.
2.2.4.  Mechanically  derived  STBM  induce  apoptosis
As  described  above,  all  three  STBM  preparations  inhibited  HUVEC  proliferation, 
albeit  not  to  the  same  extent.  Furthermore  only  mSTBM  caused  detachment  and
disruption  of  the  HUVEC  monolayer.  For  this  reason  HUVEC  apoptosis  was
examined  after  the  treatments  with  STBM preparations.  The  analysis  indicated  that 
mSTBM  caused  approximately  3-5  fold  higher  levels  of  HUVEC  apoptosis  than 
the  untreated  control  cultures (Fig:  17).  No  induction  of  apoptosis  was  evident  in 
the  cultures  treated  with  the  two  other  STBM  preparations,  even  at  high 
concentration  (50Pg/well),  or  RBC  ghost  particles.  HUVEC  treated  with  5 PM
43
Results
staurosporine  (a  well  known  inducer  of  apoptosis)  for  3h  were  used  as  a  positive
control.
       Gupta  et  al.  Placenta,  2005
Figure:  17.  mSTBM induce  HUVEC  apoptosis.  Confluent HUVEC  were  incubated  with various
concentrations  of  the  different  STBM  preparations  and  apoptosis  was measured.  5 PM
staurosporine  was used  as positive  control. Apoptosis  is  expressed  as  percentage  relative  to
staurosporine-induced  apoptosis,  which  was  designated  as  100%.  The  results  of  four  different
STBM  preparations are illustrated.
2.2.5.  Lipid  depletion  from  mSTBM  reduced their  ability  to  inhibit
HUVEC  proliferation 
It  has  been  proposed  that in-vitro  excessive  amount  of  cholesterol  can  induce  cell 
death  by  restricting  cell  processes  [146]. As  we  noticed  above  that  mSTBM  are 
rich  in  cholesterol  and  were  able  to  induce  HUVEC  apoptosis.  We,  therefore, 
hypothesized  that  may  be  this  excessive amount  of  cholesterol  present  in  the
mSTBM  is  responsible  for the  low  HUVEC  proliferation,  therefore,  we  depleted 
lipids  from  mSTBM  by  incubating  them  with  MECD  and  then  HUVEC
proliferation  was  measured.  The  cholesterol  depletion  significantly  but  not 
completely  restored  HUVEC  proliferation suggesting  that  the  high  cholesterol 
levels  present  in  mSTBM  are  partly  responsible  for  the  low  HUVEC  proliferation 
44
Results
(Fig:  18)  further  suggesting  that  high  cholesterol  may  drives  the  cell  towards 
apoptosis.
Figure: 18. Analysis  of  lipid  depletion  on  HUVEC  proliferation. Lipids  were depleted from  the
mSTBM  using  MECD  as described  in materials  and  methods  and  then HUVEC  proliferation  was 
measured.  HUVEC  proliferation  was  significantly  but not  completely  restored  after  lipid  depletion
in  the  mSTBM.
2.2.6.  Conclusion
This  functional  characterization  of  the  three  STBM  preparations  suggests  that  the 
three  STBM  preparations  are  biologically  different  from  each  other  and  differ  in
their  effects  of  HUVEC  cultures.  In  particular  the  effects  observed  by  vSTBM
and  pSTBM  are  quite  similar  in  contrast  to  mSTBM,  which  induced  HUVEC
apoptosis.  These  observations  suggest  that  the  mode  of preparation  greatly  affects
their  functional  properties. 
2.3.  Effects  of  placentally derived  factors  (STBM  and 
soluble  factors)  on  the  T  cells 
It  has  been  reported  that  mechanically  derived  STBM  and  placental  homogenates
can  inhibit  proliferation  of  PHA  stimulated  lymphocyte in-vitro  [117,  118].  It  has 
also  been  shown  that  maternal  serum derived  STBM  can  induce  Jurkat  T  cell 
apoptosis in-vitro  [119].  Therefore,  in this  study  we  examined  the  effects  of  three 
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biologically  different  STBM  preparations and  VE-CM  on  purified  T  cells,  which 
is  in  contrast  to  the  previous  studies  that  have  used  a  mixed  lymphocyte  culture 
and  crude  homogenates  prepared  from  the  placenta. 
2.3.1.  Effects  of  STBM  on  T  cells 
2.3.1.1.  STBM  did not  activate  T  cells
T  cells  enriched  from  peripheral  blood  samples  were  cultured  with  the  3  different 
STBM  preparations  for  24h  to  examine  whether  they  activated  these  cells.  The 
FACS  analysis  of  early  activation  marker  CD69  expression  indicated  that  none  of 
the  STBM  preparations  upregulated CD69  expression  after  the  treatments (Fig:
19).  We  also  observed  that  STBM  treatment  did  not  affect  the  viability  of  T 
cells,  as  >90%  cells  were  viable  after  treatments  as  measured  by  tryptan  blue  dye
exclusion  test. This  analysis  indicates  that  STBM  preparations  were  not  able  to 
activate  T  cells. 
Figure: 19. Analysis of T  cell  activation after  incubation  with  different  STBM  preparations.
Enriched T  cells  were  incubated  separately with  each  STBM  preparations  (300Pg/ml  each)  alone 
for 24h.  FACS  analysis was  carried  out  to  check  the  expression  of  the  early  T  cell  activation
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marker  CD69.  Non-treated  T  cells (A), T  cells  treated  with  pSTBM (B), vSTBM (C),  mSTBM
(D),  and  RBC  ghosts (E)  showed  basal  level  of  CD69  expression.  T  cells  stimulated  with  PMA
and  ionomycin  for  a  3h period  of  time  showed  significant  increase  in  the  CD69  expression  on  T
cells (F).
2.3.1.2.  STBM  preparations  affect  T  cell  proliferation  differently 
In  order  to  see  the  effects  of  the  three  STBM  preparations  on  purified  T  cells  we
used  PMA  and  ionomycin  in  a  combination to  synergistically  activate  T  cells  in  a
receptor  and  APC-independent  manner  [147].
This  analysis  revealed  that  vSTBM  and  mSTBM  significantly  inhibited  T  cell 
proliferation (Fig:  20).  On  the  other  hand,  pSTBM  significantly  enhanced  T  cell 
proliferation (Fig:  20).  This  observation  suggests  that  the  three  STBM  preparations
affect  the  proliferative  response  of  activated  T  cells  differently.
Figure:  20.  Analysis of  T  cell  proliferation after  incubation with different  STBM
preparations. 1x105  T  cells  were  stimulated  with  PMA  and  ionomycin  in  the  presence of  each
STBM  preparations (300Pg/ml  each) for 72 h.  T  cell proliferation was measured using  a
commercial  ELISA. pSTBM  significantly  induced  T cell  proliferation  while vSTBM  and  mSTBM
reduced  T  cell  proliferation  in  a  significant manner  (**  P  value  =  0.005).  Cell  proliferation  is 
represented  as  the  percentage of  cell proliferation relative  to  PMA  and  ionomycin  induced  T  cell 
proliferation  (referred  as  100%  proliferation).  An  analysis  of  STBM  preparations  from  6  placentae
is  illustrated  as  mean r S.D.
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2.3.1.3.  STBM  preparations  affect  IL-2  and  IFNJ  production  differently
Three  STBM  preparations  showed  different  effects  on  T  cell  proliferation; 
therefore,  the  effects  of  STBM  treatments  were  observed  on cytokines  production. 
It  was  found  that  mSTBM  and  vSTBM  significantly  reduced  the  IL-2  production 
at  both  mRNA  and  protein  levels,  while  the  IL-2  production  in  the  presence  of 
pSTBM  preparations was  not  affected (Table  2).  In  a  similar  manner,  mSTBM 
and  vSTBM  significantly  reduced  the  IFNJ  production  at  both  mRNA  and  protein 
levels,  while  this  appeared  to  be  moderately  enhanced  by  pSTBM (Table  2).  In 
all  experiments  we  used  RBC  ghosts)  as  a  negative  control.  These  did  not  affect
any  of  the  parameters  we  examined  including  cytokine  production (Table  2)  or  T 
cell  proliferation (Fig  20).  This  suggests  that  the  observed  change  in  cytokine 
production  with  the  different  STBM  preparations  is  specific  to  syncytiotrophoblast 
micro-particles.
Table:2.  Cytokine  production  by  the  activated  T cells  after  the  STBM  treatment. 1x106  T
cells  were stimulated  with  PMA  and ionomycin  in  the presence of  each STBM  preparations
(300Pg/ml  each)  for  72 h.  After  incubation  cells were  collected  for  total  RNA  isolation  and
culture  supernatant  was  saved for  cytokine  analysis  using  ELISA.  Total  RNA was  reverse
transcribed  and relative  IL-2  and  IFNJ mRNA  expression  was  measured  using ''CT  method  as
described  in the materials  and  method.  Cytokines  production  described  here  is  relative  to the
cytokines  levels  produced by  PMA  and  ionomycin  stimulated  T  cells,  which was  considered  as 
100%  cytokine  production  for  both mRNA  and  protein  measurement.  An  analysis  of  STBM
preparations from  6 placentae  is  illustrated  as  mean r  S.D.  P value  represented here  are  same  for
the  RNA  and  protein production.  NS; Non  significant.
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2.3.1.4.  STBM  reduced  CD69  expression
To  investigate  whether  the  reduced  levels  of  IL-2  and  IFNJ  expression  may  be 
due  to  the  reduced  activation  of  T  cells  following co-incubation  with  STBM,  T 
cells  were  activated  in  the  presence  of  the  three  STBM  preparations  and  then
CD69  expression  was  examined.  Data  indicated  that  all  three  STBM  preparations 
reduced  T  cell  activation  mediated  by  PMA  and  ionomycin,  albeit  to  different 
degree,  in  that  CD69  expression  was  reduced  after  the  STBM  treatments (Fig:
21). The  reduction  in  CD69  expression  due  to  treatment  with  pSTBM  was  not  as
great  as  that  caused  by  treatment with  mSTBM  or  vSTBM  preparations (Fig:  21)..
These  results  suggest  that  the  reduction  in  T  cell  activation,  caused  by  mSTBM
and  vSTBM  may  be  responsible  for  the  reduced  IL-2  and  IFNJ  expression  and
low  T  cell  proliferation  under  these  conditions.
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Figure:  21.    Analysis  of  CD69  expression  on  activated  T  cell after  incubation  with  different
STBM  preparations. Enriched T  cells  (1x106)  were stimulated  with  PMA  and ionomycin  in  the
presence of  each  STBM  preparations  (300Pg/ml  each)  for  24  h.  FACS analysis  was  carried out  to
check CD69  expression  on activated  T  cells  after  STBM  co-incubation.  20,000 gated  events were
acquired.  PMA  and  ionomycin  activated  T  cells  showed  significant  increase  of  CD69  expression on
T  cells (A), whereas  all  the  STBM  preparations, namely  pSTBM (B), vSTBM (C),  and  mSTBM
(D)  reduced  CD69  expression on PMA and  ionomycin  activated  T  cells. 
2.3.1.5.  STBM  do  not  cause  T  cell  apoptosis 
It  has  been  reported  that  maternal  serum  derived  STBM  caused  FasL  mediated
apoptosis  of  the  Jurkat  T  cell  lymphoma  cell  line  [119].  In order  to  examine
whether  reduced  cytokine  production  and  impaired  proliferation  of  T  cells  is 
associated  with  T  cell  apoptosis.  T  cell  apoptosis  was  assessed  using  the  annexin 
V  assay,  which  recognizes  phosphatidylserine  on  the  outer leaflet  of  apoptotic  cell 
membranes  [148].  Interestingly,  this  analysis  showed that  none  of  the  three 
different  STBM  preparations  induced  apoptosis  in  T  cells (Fig:  22).  The  vSTBM
and  mSTBM  preparations  reduced  apoptosis  of  the  activated  T  cells  to  a  small
extent (Fig:  22),  which  may  be  a  consequence  of  impaired  T  cell  activation  under
these  conditions.
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Figure: 22.  Measurement  of  T  cell  apoptosis  by annexin  V  binding  assay  after  incubation 
with  different  STBM  preparations.   All  three STBM preparations (300Pg/ml  each) were
incubated  with  PMA  and  ionomycin  stimulated  T  cells  for  48h.  Annexin  V  binding  assay  in
combination with  propidium  iodide  was  performed  to  assess  T  cell  apoptosis.  The  analysis
indicated  that  none  of  the  STBM  preparation  induced  significant  T  cell  apoptosis. After  48h
incubation  a basal  level  of  apoptosis  was  observed  in  the  non-treated  T  cells (A).  Upon  activation
with  PMA  and  ionomycin this  basal  level  of  apoptosis  increased  3  fold (B).  Further  activated  T
cells incubated  with  different  STBM  preparations  showed  reduced  apoptosis.  pSTBM (C),  vSTBM
(D),  and  mSTBM (E). When  activated  T  cells  were  incubated with  5PM  staurosporine for  period
of  3h  it induced  massive  apoptosis  of  T  cells (F).  Cells  in  the  lower  right  corner  represent
apoptotic cells  and  the  cells  in  upper  right  corner  are either  late  apoptotic  or  necrotic  cells. 
2.3.2.  Effects  of  placentally-derived  soluble  factors  on  T  cells 
Our  cytokine  analysis,  described  above, detected  10  cytokines  in  placentally 
derived  particles  free  VE-CM.  Therefore,  we  examined  the  effects  of  placentally 
derived  soluble  factors  on  T  cell  response.
2.3.2.1.VE-CM  did  not  activate  T  cells 
To  examine  whether  VE-CM can  activate  T  cells  we cultured  T  cells  with  VE-
CM  for  24h.  Data,  obtained  by  FACS  analysis  of  early  activation  marker  CD69 
expression  indicated  that  VE-CM  did  not  cause  T  cell  activation (Fig:  23). VE-
CM  treatment  did  not  affect  the  viability  of  T  cells,  as  >90%  cells  were  viable
after  treatment  as  measured  by  tryptan  blue  dye  exclusion  test. 
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Figure: 23. Analysis of T  cell  activation after  incubation  with  VE-CM. Enriched  T  cells  were
incubated  with  varying  concentration  of  VE-CM  alone  for  24h.  FACS  analysis was  carried  out  to
check  the  expression  of  the  early  T  cell activation  marker  CD69.  Non-treated T cells (A),  T cells
treated  with  20% (B),  40% (C),  60% (D),  and  100%  VE-CM  (E)  showed  negligible  levels  of
CD69  expression. T  cells  stimulated  with  PMA and ionomycin  for  a  3h period  of  time  showed
significant  increase  in  the CD69 expression  on  T  cells (F).
2.3.2.2.  VE-CM  inhibited  T  cell  proliferation
When  PMA  and  ionomycin  activated  T  cells  were  incubated  with  varying
concentrations  of  VE-CM,  T  cell  proliferation  was  significantly  inhibited  in  a  dose
dependant  manner (Fig:  24).  At  high  doses  of  the VE-CM  T  cell  proliferation
was  completely  inhibited.  In  this  retrospect  we  examined  whether  the  culture
supernatant  influenced  cytokine production  in  a  similar  manner.
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Figure: 24.  Analysis  of  T  cell  proliferation  after  incubation  with  VE-CM. 1x105  T  cells  were
stimulated  with  PMA  and  ionomycin  in  the  presence  of  varying  concentration  of VE-CM  for  72  h.
T  cell  proliferation  was  measured  using a  commercial  ELISA.  VE-CM  reduced  T  cell  proliferation
significantly  in  a  dose  dependent  manner.  Cell proliferation  is  represented  as  the  percentage of  cell
proliferation  relative  to  PMA  and  ionomycin  induced  T  cell  proliferation (referred  as 100%
proliferation). An  analysis  of 8  placentae preparations  is  illustrated  as  mean r S.D.
2.3.2.3  Reduced  T  cell  proliferation  by  VE-CM  is  specific  to
placentally  derived  factors 
In  order  to  examine  that  the  reduced T  cell  proliferation  caused  by  VE-CM  is 
specific  to  placentally  derived  factors  and  is  not  due  to  the  low  nutrient
concentrations  or  high  salt  concentration  (MgSO4),  used  in  the  villous  explant 
cultures.  We  examined  various  controls and  then  measured  T  cell  proliferation. 
None  of  the  control  revealed  low  T  cell  proliferation (Fig:  25).  This  observation 
suggests  that  low  T  cell  proliferation  by the  VE-CM  is  specific  to  placentally 
derived  factors.
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Figure:  25. Analysis of  T  cell  proliferation after  incubation  with  various  control  groups. 1x105
T  cells  were stimulated  with  PMA  and  ionomycin  (PI)  in  the presence of various  control groups
for 72 h.  T  cell  proliferation was  measured using  a  commercial  ELISA. None  of the  control  group
reduced  T  Cell  proliferation.  Cell  proliferation  is  represented  as  the  percentage  of  cell  proliferation
relative  to  PI  induced  T  cell  proliferation  (referred as  100%  proliferation).  An  analysis  of    4 
control  preparations  is  illustrated  as  mean r  S.D.
2.3.2.4  VE-CM  reduced  IL-2  and  IFNJ  production  by  activated  T  cells
T  cells  were  stimulated  by  PMA  and  ionomycin  in  the  presence  of  VE-CM  for
72h,  after  which  the  supernatant  was  collected  and  the levels  of  IL-2  and  IFNJ
protein  were  measured  using  ELISA. It  was  observed  that  the  VE-CM
significantly  reduced  the  IL-2  production  as  well  as  IFNJ  production  in  a  dose 
dependent  manner  after  the  treatments (Fig:  26A,  26B),  which  suggests  that  the 
placentally  derived  soluble  factors  are immunosuppressive  in  nature  and  reduce 
Th1  type  immunity.  Cytokines  production  was  also  measured  in  the  various
control  groups  mentioned  above.  None  of  the  control  group  reduced  cytokines 
production  by  T  cells. 
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Figure: 26. Analysis  of  cytokines  production by  T  cells  after  incubation  with VE-CM. 1x106
T  cells  were stimulated  with  PMA  and  ionomycin in  the  presence  of varying  concentration  of VE-
CM  for 72 h.  Supernatant  was  collected after  the incubation  and IL-2  and IFNJ levels  were 
measured using  ELISA.  VE-CM  reduced IL-2 (A)  and IFNJ (B)  production.  Cytokine production  is
represented  as  the  percentage  of  cytokine  production  relative to PMA  and  ionomycin mediated
cytokine production (referred  as  100%  production). An  analysis  of 8  placentae  preparation  is
illustrated  as mean r  S.D.
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2.3.2.5.  VE-CM  reduced  CD69  expression
To  investigate  whether  the  reduced  levels  of  IL-2  and  IFNJ  expression  may  be 
due  to  the  reduced  activation  of  T  cells  following  co-incubation  with  VE-CM,  we
stimulated  T  cells  in  the  presence  of  VE-CM  and  then  CD69  expression  was
examined.  Note  that  the  VE-CM  reduced  T  cell  activation  by  PMA  and 
ionomycin  in  dose  dependent  manner (Fig:  27).  It  is  likely  that  the  reduction  in 
the  CD69  expression,  and  hence,  reduction  in  T  cell activation,  caused  by  VE-CM
may  directly  be  correlated  with  the  reduction  of  IL-2  and  IFNJ  expression  under 
these  conditions. 
Figure: 27. Analysis  of CD69  expression  on activated  T  cell after  incubation  with  VE-CM.
1x106  enriched  T  cells  were  stimulated with  PMA  and  ionomycin in  the  presence  of  VE-CM  for
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24  h.  FACS analysis  was  carried out  to  examine  CD69  expression  on  activated  T  cells,  20,000
gated  events were  acquired.  PMA  and  ionomycin activated  T  cells  showed  significant  increase  of 
CD69  expression on  T  cells (A),  whereas  increasing  concentration  of VE-CM, namely  20% (B),
40% (C), 60% (D), and  100%  VE-CM (E) significantly reduced CD69  expression  on  PMA  and 
ionomycin  activated T  cells.
2.3.2.6.  VE-CM    did  not  induce  T  cell  apoptosis 
We  examined  whether  reduced  cytokine production  and  low  proliferation  of  T 
cells  upon  treatment  with  VE-CM  is  associated  with  T  cell  apoptosis.  T  cell 
apoptosis  was  examined  using  the  annexin  V  assay.  FACS  analysis  showed  that 
VE-CM  did  not  induce  apoptosis  in  T  cells  (Fig:  28).
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Figure: 28.  Measurement  of  T  cell  apoptosis  by annexin  V  binding  assay  after  incubation 
with  VE-CM. T  cells  were  activated  and  incubated for 24h  in  the  presence  of VE-CM.  Annexin
V binding  assay  in  combination of propidium  iodide  was  performed  to  assess T  cell  apoptosis
using FACS.  The  analysis  indicated  that  VE-CM  did not  induce  T  cell  apoptosis. After  24h
incubation  a basal  level  of  apoptosis  was  observed  in  the  non-treated  T  cells (A).  Upon  activation
with  PMA  and  ionomycin  this  basal  level  of  apoptosis  increased 2.5  fold  (B).  Further  activated  T
cells  incubated  with 20% (C),  40% (D), 60% (E), 100% VE-CM (F),  showed  either  lower or
similar levels  of  apoptosis as  observed  in  the  PMA  and  ionomycin  activated  T  cells.  When  5PM
of  staurosporine  was  added  to  activated  T  cell  cultures  for  period  of  3h,  it  induced  massive
apoptosis  of  T  cells (G). Cells  in  the  lower  right  corner  represent  apoptotic  cells  and  the  cells  in 
upper right  corner  are  either  late  apoptotic  or  necrotic cells.
2.3.2.7.  IDO  is  not  responsible  for  low  T cell  proliferation 
It  has  previously  been  proposed  that  IDO  mediated  depletion of  the  L-tryptophan 
at  the  feto-maternal  interface  is  responsible  for  the  reduced  T  cell  proliferation
[69].  To  examine  whether  IDO  is  responsible  for  the  low  T  cell  proliferation 
mediated  by  VE-CM,  we  added  L-tryptophan  and  the  inhibitor  of  IDO  1-methyl-
DL-tryptophan  (1-MT)  to  the  T  cell  cultures  and  measured  T  cell  proliferation.
The  addition  of  L-tryptophan  and  1-MT  did  not  significantly  alter  the  T  cell 
proliferation (Fig:  29).  This  observation suggest  that  under these  conditions,  the 
inhibition  of  T  cell  proliferation  is  not  mediated  by  IDO,  but  is  rather  due  to
some  unknown  factors. 
Figure:  29. Effects  of  L-trp  and  1-MT  on  T  cell  proliferation. 1x105  T  cells  were  stimulated
with  PMA  and  ionomycin in  the presence  of varying  concentration  of VE-CM for 72  h  with or
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without 25PM  L-tryptophan  or 2mM  1-MT. T  cell  proliferation was measured using a  commercial.
Addition  of  L-trp  or  inhibitor of  IDO, 1-MT,  could not  reverse  low  T  cell  proliferation  mediated
by  VE-CM. Cell  proliferation  is  represented  as  the percentage of  cell  proliferation relative  to PMA
and  ionomycin  mediated  T  cell  proliferation  (referred  as  100%  proliferation).  Data  represent  mean
r  S.D. of 5  separate  experiments  with  triplicate  assay. 
2.3.3.  Conclusion 
These  observations  suggest  that  the  placentally  derived  factors  can  modulate  T  cell
response in-vitro.  Different  STBM,  which  differ  in  their  mode  of  preparations  and
biological  properties,  can  modulate  T  cell  response  in  terms  of  their  proliferation, 
and  activation.  Overall  these  observations  suggest  that  the  placentally  derived
factors  are  inhibitory  in  nature  and  can  reduce T  cell  response. 
2.4.  Effects  of  placentally-derived  STBM  and  soluble  factors 
on  neutrophils
Activation  of  neutrophils  by  the  placental  factors  has  been  shown  during  normal
pregnancy  and  preeclampsia [144,  145].  It  has  recently  been  shown  that  upon 
activation  by  inflammatory  signals  such  as  that  mediated  by  IL-8  (a  member  of
the  chemokine  superfamily  of  proinflammatory  cytokines),  neutrophils  generate 
extracellular  DNA  containing  fibrous  lattices,  termed  NETs  (neutrophil  extracellular 
traps),  which  are  used  by  these  cells  to ensnare  and  kill  bacteria  [149,  150].  Also 
it  has  previously  been  observed  that  maternal  cell-free  DNA  levels  are 
significantly  increased  in  the  circulation  of  pregnant  women  with  preeclampsia  [94,
95,  138].  Intrigued  by  the  observation  that  neutrophils  can  release  DNA  in  an 
extracellular  form,  we  examined  whether  placentally  derived  inflammatory  factors 
can  similarly  activate  neutrophils  to  generate  NETs,  and  whether  the  presence  of 
such  NETs  was  increased  in  preeclampsia.
2.4.1.  STBM  and  placental IL-8  activated  neutrophils
In  order  to  examine  the activation  of  neutrophils  by  placentally  derived  factors in-
vitro,  we  assessed  CD11b  up-regulation  on  neutrophils  after  treatments  with  VE-
CM  and  STBM.  CD11b  expression  was  significantly  increased  in  isolated 
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neutrophils  activated  with  PMA (Fig:  30A),  or  rIL-8 (Fig:  30B).  Similarly,
treatment  with  VE-CM  lead  to  a  significant  increase in  CD11b  expression (Fig:
30C) on  neutrophils.  vSTBM (Fig:  30D)  and  mSTBM (Fig:  30E) also  induced 
CD11b  expression. 
As  our  cytokine  analysis,  mentioned  above,  detected  IL-8  (a  known  activator  of 
neutrophils)  in  VE-CM.  Therefore,  we quantified  IL-8  levels  in  the  STBM
preparations  and  VE-CM.  Results  from  ELISA  indicated  that  IL-8  was  detectable
in  VE-CM,  as  well  as  in  highly  purified  vSTBM  preparations.  Negligible  levels  of
IL-8  were  detected  in  mSTBM (Table:  3).
Further  to  determine  whether  the  activation  of  neutrophils  by  these  placentally 
derived  factors  is  mediated by  IL-8,  we  used  an  anti  IL-8  blocking  antibody.  This
antibody  significantly,  but  not  completely  blocked  CD11b  expression  induced  by 
the  VE-CM (Fig:  30F),  suggesting  that  IL-8  is  largely  responsible  for  the 
neutrophil  activation  under  these  conditions.  On  the other  hand,  the  induction  of 
CD11b  expression  by  the  two  different  STBM  preparations  occurred  in  an  IL-8
independent  manner,  as  this  effect  was  not  hindered  by  co-incubation  with  the  IL-
8  blocking  antibody (Fig.:  30G).  To  summarize,  these  observations  clearly 
demonstrate  that  placentally  derived  factors  (IL-8  and  STBM)  can  individually 
activate  neutrophils.
60
Results
Figure: 30. FACS  analysis  of  CD11b  up-regulation on  activated neutrophils. (A). Neutrophils
activated with 25nM  PMA for 30  min  showed  significant up-regulation of CD11b. Similarly
CD11b  expression  is  up-regulated when  neutrophils were  activated  with  10ng/ml  rIL-8  (B),  with
20%  VE-CM (C), 150 Pg/ml  vSTBM (D) and  mSTBM (E). Neutralizing  IL-8  with 2.5ug/ml  IL-8
neutralizing  antibody  in  VE-CM  could significantly  reverse  the  effect  of  soluble  IL-8 on  CD11b
up-regulation (F), while  neutralizing IL-8  in  vSTBM did not  affect CD11b  expression (G).
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Table:3.  Quantification  of  IL-8  present  in the VE-CM  and  STBM.  IL-8  was quantified using  a
commercial  ELISA  kit.  Significant  levels  of  IL-8  are  present  in  the  vSTBM  as well  as  in  the  VE-
CM,  while  the  mSTBM  contain  traces  of IL-8.  Data  in  the  table  is  expressed  in  median  and
range  and  was  calculated from  6  samples  of  each preparation.
2.4.2.  Preeclamptic  plasma  moderately  activated  neutrophils 
ELISA  revealed  that  the  IL-8  concentrations  were  also  elevated  in  the  plasma  of 
preeclamptic  pregnant  women  when  compared  to  those  with  uncomplicated
pregnancies (Fig:  31A) When  neutrophils  were  incubated  with  normal  and 
preeclamptic  plasma,  only  preeclamptic  plasma  samples  slightly  increased  CD11b 
expression (Fig.  31B)  than  that  attained  by  the  normal  plasma  samples (Fig.
31C).  Neutrophils  with  the normal  plasma  samples  did  not  show any  CD11b 
upregulation.  The  degree  of  neutrophils activation  attained  by  the  preeclamptic
plasma  samples  is  very  low  in  comparison  to  those  obtained  by  STBM  and  VE-
CM.  This  low  activation  of  neutrophil  activation  by  the  preeclamptic  plasma
samples  is  may  be  due  to  very  low  concentration  of  IL-8  and  STBM  present  in
these  samples.
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Figure: 31.  IL-8  quantification  in  the  maternal  plasma  samples.  12  plasma  samples  of  each 
normal  pregnancy,  and  preeclampsia  were  analyzed  for  presence  of  IL-8  using  a  commercial
ELISA  kit.  The  higher  levels  of  soluble  IL-8 were present  in  the preeclampsia  samples (A). FACS
Analysis of CD11b  up-regulation on  neutrophils  treated  with  plasma  samples.  1x106  Neutrophils
were  resuspended  in  RPMI  1640  culture medium  supplemented  with  10%  heat-inactivated  FCS,
2mM  L-glutamine,  100 U/ml  penicillin,  100Pg/ml  streptomycin  and  incubated with 60% plasma
either  normal  or  preeclamptic  for  3  h.  CD11b up-regulation  was  measured by  FACS. Very little
up-regulation of  CD11b  was observed when neutrophils were  activated with  preeclamptic  plasma
(B)  and  normal  plasma (C).
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2.4.3.  Placentally-derived  IL-8  induced  DNA  rich neutrophil  NETs
formation  by  activated  neutrophils
We  investigated  whether  placentally  derived  stimuli  can  also  trigger  NETs 
formation.  Our  observations, using  scanning  electron  microscopy  and  fluorescence 
microscopy  clearly  indicated  that  these  placentally  derived  factors  induced  NETs
formation (Fig:  32).  Non-stimulated  neutrophils  remained  round (Fig:  32A,  32J),
while  neutrophils  incubated  with  preeclamptic  plasma, (Fig:  32B,  32K),  VE-CM
(Fig:  32C,  32L),  mSTBM (Fig:  32D,  32M),  and  vSTBM (Fig:  32E,  32N)
generated  NETs.  The  NETs  produced  by either  the  VE-CM  or  STBM  were
comparable  to  those  observed  using  known  inducers  of  NETs,  PMA (Fig:  32F, 
32O)  or  rIL-8 (Fig:  32G,  32P),  and  were  morphologically  similar  to  those 
described  by  Brinkmann  et  al  [149],  consisting  of  smooth  fibers  with  a  15-17nm
diameter  and  globular  domains  of  25-28nm  diameter (white  arrows  Fig.  32H, 
and  32Q).  Although,  NETs  formation  by  VE-CM could  be  inhibited  by  the  IL-8 
neutralizing  antibody (Fig:  32I  and  32R),  this  antibody  did  not  reduce  NETs
formation  by  either  of  the  two  STBM  preparations.  Therefore,  these  data  suggest
that  the  formation  of  NETs  can  occur  in  IL-8  dependent  and  independent  manners
and  that  the  generation  of  NETs  may be  a  general  phenomenon  associated  with 
neutrophil  activation. Furthermore,  the  major  structural  component  of  the  NETs 
was  DNA  as  they  could  be  stained  using  the  DNA binding  dye,  sytox  green, 
(Fig:  32J-  32R), and  a  brief  treatment  with  DNase  I  resulted  in  disintegration  of 
the  NETs. 
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Figure:  32. Analysis of  activated  neutrophils using  electron  and  fluorescent microscopy. Non-
treated  and  treated  cell  were  fixed  and  stained with  sytox green  DNA  binding  dye  for  fluorescence
microscopy. Nonactivated  neutrophils  are  round  and devoid of NETs (A and  J).  Upon  activation
with  60%  preeclamptic  plasma (B  and  K)  60%  VE-CM (C  and  L), mSTBM  (D  and  M)  ,
vSTBM  (  E and N), 25nM  PMA (F and  O),  and  with  10ng/ml  rIL-8 (G and P), neutrophils
generated NETs within  30  min  of  incubation.  High  resolution SEM  revealed  that  NETs  consist  of 
smooth  fiber and  globular domains (white arrow,  H). NETs formation was reduced  significantly
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when  soluble  IL-8  present  in  the  VE-CM  was  neutralized  with  2.5Pg/ml  IL-8  neutralizing  antibody
(I and R). NETs  were rich  in  DNA (J-R).  Bars  in the  figures A-G, H, I  and J-R  and  are 5Pm,
300nm,  5Pm  and 50Pm,  respectively.
2.4.4.  Neutrophil  NETs  trap  STBM 
Our  studies  revealed  that  STBM  contain  fetal  RNA and  DNA,  and  that  these 
small  particles  (200nm-600nm)  have  a  tendency  to  make  clusters  (shown  above
[151,  152]).  Here  we  observed  that  NETs  entrapped  clusters  of  both  mSTBM
(Fig:  33A,  33B  white  arrows)  and  vSTBM (Fig:  33C  33D,  white  arrows)  as 
revealed  by  scanning  electron  microscopy. This  observation  suggests  that  NETs
not  only  capture  large  microorganisms  such  as  bacteria  (>2 Pm),  [149]  but  also 
ensnare  very  small  (<200nm)  inflammatory  particles  such  as  STBM (Fig:  33D).
Figure: 33.  Entrapment  of  the  STBM  by  neutrophil  NETs.  150Pg/ml  vSTBM  or mSTBM  were 
incubated  with  neutrophils  for  30 min.  Cells  were  then  fixed  for  SEM  analysis.  SEM  analysis
show  that both  mechanical (white  arrows, A,  B)  and  villous explant STBM (white  arrows,  C  D)
clusters  are  trapped  in  the neutrophil  NETs.  Bars  in  the  figures A-C,  and D,  and  are  5Pm,  1Pm,
respectively.
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2.4.5.  Generation  of  the  neutrophil  NETs  is  dose  and  time
dependent
Fluorometric  quantification  of  NETs  induction  by  PMA (Fig:  34A),  STBM
(mSTBM  or  vSTBM) (Fig:  34B),  and  VE-CM (Fig:  34C) using  a  DNA  binding 
dye  (sytox  green)  [149],  indicated  dose  dependent  increases  in  NETs  formation  by 
these  treatments.  This  analysis  also  indicated  that  though  NETs  were  generated 
within  5  min  of  incubation  with  high  doses  of  PMA  or  VE-CM,  but  only  formed
within  30  min  of incubation  with  STBM  (Fig:  34D).  This  implies  that  the 
kinetics  for  NETs  induction  may  differ  between  the  IL-8  dependent  and 
independent  pathways. 
Figure:  34. Quantification  of  NETs formation by  activated neutrophils. NETs  formation  by
neutrophils  activated  with  PMA (A),  STBM  (B), and  VE-CM (C)  induced  DNA  release  in  dose
and  time  dependent (D) manner. The values represented  for  the STBM  response were obtained
after  subtracting  the values  obtained  for  the DNA present  in  the STBM  alone. The  error  bars  in
the figures  represent r  standard  deviation  of  the  means.
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2.4.6.  Increased  presence  of  neutrophil  NETs  in  preeclamptic 
placenta
Because  STBM,  and  possibly  placentally  derived  IL-8,  are  released  directly  by  the 
syncytiotrophoblast  into  the  maternal  circulation  in the  intervillous space  of  the 
placentae,  we  examined  for  the  presence of  neutrophil  NETs  in  cryosections  of 
placental  villous  tissue.  The  presence  of  NETs,  as  detected  by  combined  staining
for  DNA  and  neutrophil-derived  elastase  indicated  that  their  number  was  quite 
small  in  normal  placental  tissue (Fig:  35A-35C).  This  is  to  be  expected,  as 
STBM  are  released  during  normal  pregnancy,  especially  at  term.  It  furthermore,
appears  that  these  NETs  also  confined  in  close  contact  with  the
syncytiotrophoblast,  possibly  at  the  site  of  immediate  release  of  STBM,  as  this 
shedding  may  involve  a  budding-off  process  [96]. 
In  preeclamptic  placentae,  the  number  of  NETs  was  found  to  be  increased  and 
they  appear  to  fill  the  entire  intervillous  space  areas.  This  is  evident  from  a  haze 
over  the  entire  inter-villous  area  when  stained  with  the  neutrophil  elastase  and 
DNA  binding  dye  (DAPI) (Fig:  35D-35F).
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Figure: 35. Analysis of  placental tissue  sections of  normal  (A  to  C) and  preeclamptic  placenta
(D  to  F). (A)  Immunofluorescence  staining of  the  neutrophil  elastase  reveals  localization  of 
neutrophil  elastase  within  the  villi  or  adjacent  to  the  syncytiotrophoblast  in  the  normal  placenta.
(B) Elastase staining  largely  overlaps with  staining  for DNA. (C) The  overlay  indicates  that the
DNA  is  closely  associated with  the  neutrophil  elastase. (D) Staining  for neutrophil  elastase, DNA
(E), revealing  a  haze  over  large  portions  of  the  intervillous  space  and  their  overlay (F)  in  the
preeclamptic  placenta  reveals  that  the NETs  are  largely  localized within  the  intervillous space.  Bar
in  the figures  is 50Pm.
It  has  been  shown  that  histone  proteins  are  the  major  component  of  the  NETs
[149];  therefore,  NETs within  the  placenta  were  also  examined  for  the  presence  of
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histones.  The  NETs  observed  within  the  intervillous  space  were  also  shown  to  be 
rich  in  histones,  which  largely  overlapped  with  DNA  staining  (Fig:  36).  These
observations  indicate  that  NETs  are  rich  in  DNA,  histones,  and  neutrophil  elastase 
and  are  similar  to  those  described  previously  [149]. 
Figure:  36.  Analysis  of  tissue sections from preeclamptic  placenta. (A) Immunofluorescence
staining  of  the  histones  reveals  that  the  NETs  are rich  in histones. (B) Histones  staining  largely
overlaps  with  the  DNA  staining. (C) The  overlay  indicates  that  the  histones  are  associated  with 
the  DNA  and  the  NETs  are  largely localized  within  the  intervillous  space  and  are  rich  in  DNA 
and histones. Bar  in  the figures  is  50Pm.
2.4.7.  The  NETs  formation  ends  with  the  death  of  neutrophil
Activated  neutrophils  were  stained  with  the  non-cell-permeant  DNA  binding  dye, 
sytox  green,  and  directly  observed  under  the  fluorescence  microscope  without 
fixing.  This  dye  stained  the  whole  cell  surface,  which was  releasing  extracellular 
DNA  containing  NETs.  This  observation  suggests  that  the  NETs  are  coming  out 
from  the  whole  cell  surface  and  cell  still  is alive.  When  the  NETs  producing  cell 
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was  observed  continuously  for  3-4  min,  slowly  the  NETs  were  disappeared.  Later
sytox  green  dye  entered  in  the  cells  and  stained  nucleus  concomitantly  suggesting 
that  the  cell  is  no  more  viable (Fig:  37A-37L).  This  interesting  observation 
suggests  that  this  NETs formation  is  a  general  neutrophils  activation  phenomenon, 
which  ends  with  the  death  of  the  activated  neutrophil.  It  is  not  clear  that  how  the
NETs  generated  by  neutrophils  are  disintegrated  but  it  is  evident  by  these
observations  that  the  NETs  formation  occurs  much  more  quickly  than  apoptosis, 
and  that  stimuli  (IL-8  and  PMA)  known  to  prolong life  of  neutrophils  in  fact 
induce  NETs  formation  [149].
Figure: 37.  Fluorescent  microscopical  analysis  of NETs  formation after  DNA  staining.
Neutrophils  were  incubated  with  60%  VE-CM  for 30  min  and  stained  with 10PM  sytox green
DNA binding  dye  for 5  min  and  observed  under the microscope. NETs were released  from  the
entire  cell  surface  and  spread  in  all  direction  as  dye could  stain  DNA  in  the  NETs (A-H). The
NETs were  then dismantled  in  3-4  min  and  later nuclear  staining  revealed  that  the  cell  is  dead 
now (I-L).  The  bar  in  the  figures  is 50Pm.
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2.4.8.  Conclusion 
These  data  suggest  that  the  placentally  derived  STBM  and  IL-8  can  individually 
activate  neutrophil  and  can  induce  them  to  generate  NETs,  which  are  rich  in 
DNA,  histones  and  neutrophil  elastases.  Furthermore,  massive  numbers  of 
neutrophil  NETs  are  present in  the  preeclamptic  placenta  further  suggesting  that 
these  NETs  may  play  a  role  in  the  pathogenesis  of  preeclampsia.
72
Discussion
Discussion........
73
Discussion
3.  Discussion 
This  study  was  designed  to  study  the  role  of  placentally  derived  factors  (STBM
and  cytokines)  during  normal  pregnancy  and  preeclampsia.  It  has  been  reported 
earlier  that  the  STBM  produced  either  from  normal  or  preeclamptic  placenta 
showed  similar  effects  on  the  endothelial  cells  cultures [107].  Therefore,  in  this 
study  STBM  and  cytokines  were  prepared  from  normal  term  placentae.  It  has  also 
been  proposed  that  the  excessive  shedding  of  STBM  in  maternal  circulation  leads
to  endothelial  dysfunction  during  preeclampsia,  which  suggests  that  quantity  of  the 
shed  STBM  is  responsible  for  this  maternal  syndrome    [105-109].  In  contrast  to 
previous  studies  in  this  study,  we,  therefore,  hypothesized  that  STBM  produced 
during  normal  pregnancy  and  preeclampsia  may  differ  in  their  quality,  which 
might  help  us  to  explain  the  pathogenesis  of  preeclampsia.  To  prepare 
qualitatively  different  STBM,  we  prepared  STBM  by three  different  preparatory 
methods:
A. mSTBM  were  prepared  by  mechanical   dissection  of  villous  tissues,  these 
STBM  are  known  since  long  time  [105-109].  Based  on  the  mode  of 
preparation  we  assumed  that  this  method  should  produce  STBM  that  are  rich 
in  necrotic  particles.
In  addition  to  the  above-mentioned  STBM  for  the  first  time  we  prepared  STBM
by  two  new  methods:
B. vSTBM  were  prepared  by  villous  explant  culture  based  on  methods  described
by  Huppertz  et  al.  [103],  which  will  produce  STBM  of  aponecrotic  nature. 
C. pSTBM  were  prepared  from  the  placental  cotyledon  perfusion  as  described 
earlier  [136,  137]  assuming  that  most  of  the  STBM  produced  by  this 
procedure  should  be  apoptotic. 
We  hypothesized  that  these  STBM  may  mimic  physiologic  STBM  that  are 
released  by  the  placenta  into  the  maternal  circulation  during  normal  pregnancy  and
preeclampsia.  Therefore,  in  this  study  we  have  biochemically  and  functionally 
characterized  STBM  preparations  and  have  examined  their  effects  on  immune 
cells.  In  addition  to  the  STBM,  the  effects  of  placentally  derived  cytokines  were 
also  examined  on  immune  cells. 
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3.1.  Characterization  of  the  STBM  preparations 
Characterization  of  these  preparations  revealed  that  all  three  STBM  preparations
(including  mechanical  one) contained  the  syncytiotrophoblast  specific  membrane
protein  PLAP (Fig:  8),  thereby  confirming their  origin  as bona  fide  STBM.  Their
morphological  examination  also  confirmed  that  STBM  prepared  by  three  different 
methods  are  of  similar  sizes (Fig:  9).  The  finding  that  the  concentration  of  PLAP 
is  about  4-5  fold  higher  in  the  mSTBM  compared  to  the  other  two  STBM 
preparations  suggests  that  mSTBM  contains  a  higher  amount  of 
syncytiotrophoblast-derived  material.  One  important  observation  made  in  this  study 
is  that  all  STBM  preparations  contain  both  fetal  DNA  and  mRNA,  although  the 
levels  of  each  of  these  fetal  analytes  differ  in  the  three  preparations.  In  this
regard,  the  highest  concentration  of  fetal  DNA  was  detected  in  vSTBM,  whereas
the  highest  concentration  of  fetal  RNA  was  present  in  pSTBM (Fig:  10  and 
Table:  1).  Although  we  have  taken  great  care to  harvest  as  many  of  the  STBM
as  possible  by  the  use  of  high-speed  ultra-centrifugation,  we  were  still  able  to
detect  considerable  amounts  of  fetal  DNA  in  VE-CM (Fig:  12).  The  high  levels 
of  particle  free  fetal  DNA  in  VE-CM  may  be  extrapolated  to  the  release  of  fetal 
DNA  into  maternal  plasma  [138],  then  it  is  possible  that  the  major  proportion  of 
circulatory  fetal  DNA  may  exist  in  a  completely  particle  free  form.  On  the  other 
hand,  very  little  fetal  RNA  was  detected  in  VE-CM.  Again,  provided  that  the 
observations  we  have  made  with in-vitro  generated  STBM  correspond  to  the in-
vivo  situation,  then  it  is  possible  that  fetal  mRNA  species  may  be  largely 
associated  with  membrane  particles,  as  has  been  previously  reported  [143].  It  is 
also  likely,  that  these few  mRNA  species  present  in  the  cleared  VE-CM  are 
associated  with  very  small  micro-particles,  which  are  not  effectively  harvested  by 
high-speed  ultra-centrifugation.  The  difference  observed  in  fetal  DNA  and  mRNA
content  in  the  three  STBM  preparations  may  be  due  to  the  manner  in  which  these
particles  are  generated,  in  that those  obtained  by  perfusion  or in-vitro  villous 
explant  culture  are  generated  predominantly  by  apoptotic  cell turn-over  [96,  103], 
in  contrast  to  STBM  isolated  by  mechanical  disruption  where  STBM  may  involve 
release  by  necrotic  pathways.
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In  this  context  it  is  worth  noting  that  the  release  of  STBM  differs  in  normal
pregnancy  to  that  occurs  in  preeclampsia  [96,  103,  153].  In normal  pregnancy,  the
shedding  of  placental particles  occurs  continuously  as  part  of the  self-renewal  of 
the  syncytiotrophoblast  monolayer,  a  process that  involves  apoptosis  of  the  aged 
nuclei  and  fusion  of  cytotrophoblast  cells  [96,  103].  In preeclampsia,  this  process 
is  altered  in  that  syncytiotrophoblast  apoptosis  rates are  significantly  increased, 
which  has  been  suggested  to  contribute  to  the  elevated  release  of  STBM,  possibly 
by  apo-necrotic  pathways  [98,  103,  153]. As  our  data  suggests  that  the  vSTBM 
are  rich  in  DNA  concentration  than  the  other  two  STBM  preparations  this  suggest
that  shedding  of  such  STBM  by  apo-necrosis  might  contribute  in  the  increased
DNA  concentrations  during  preeclampsia. 
Based  on  these  observations  it  can  also  be  hypothesized  that  pSTBM  may  be 
regarded  as  being  the  closest  representatives  of  those  generated  under  normal
physiological  conditions,  in  that  STBM  are collected  directly  from  the  intervillous 
space,  the  site  where  they  would  normally  enter  the  maternal  circulation.  The
presence  of  fetal  DNA  and  mRNA  species  in  all  three  STBM  preparations,
especially  in  those  obtained  by  perfusion  of  the  maternal  compartment  of  the 
placenta  near  to  physiological  conditions  implies  that  cell-free  fetal  nucleic  acids 
may  similarly  be  STBM-associated in-vivo.    This  facet,  however,  needs  to  be 
confirmed  by  the  analysis of  STBM  isolated  from  maternal  blood  samples,
currently  a  technically  demanding  undertaking.  Furthermore,  provided  that
circulatory  fetal  nucleic  acids  are  indeed  associated  with  STBM in-vivo,  then  it  is
possible  that  the  analysis  of  the  fetal  DNA  and  RNA  content  of  STBM  in  the
maternal  circulation  in  normal  and  pathological  pregnancies  may  yield  new  insight 
into  the  underlying  mechanisms  leading  to  their  release  by the  syncytiotrophoblast. 
It  may  also  provide  a  new  strategy  for  the  enrichment  of  these  fetal  analytes
from  maternal  blood  samples.
Functional  characterization  of  the  three  STBM  preparations  indicated  that  all 
preparations  altered  HUVEC  proliferation  in  a  dose  dependant  manner,  with  the 
mSTBM  showing  the  greatest degree  of  growth  inhibition.  While  it  has  previously 
been  reported  that  mSTBM  can  inhibit  HUVEC  proliferation [92,  105,  106],  this 
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is  the  first  study  that  has  examined  the  potential  effects  of two  other  forms  of in-
vitro  generated  STBM  on  endothelial  cell  growth (Fig:  14A,  14B).    The  inhibition
of  cell  proliferation  by  all  three  STBM preparations  was  specific  to  HUVEC  only 
(Fig:  15A-C).  Although  a  slight  effect  on  the  proliferation  of  some  of  the  cell 
lines  was  observed  upon  treatments  with  the  STBM  preparations,  these  results 
were  similar  to  the  observations  made  previously  by  Samarson  et  al  [105]. 
Differential  HUVEC  cell  proliferation  upon  treatment  with  the  STBM  preparations 
suggest  that  the  three  STBM  populations  differ  in  their  biological  properties. 
Whereas  vSTBM  and  pSTBM  reduce  cell growth  without  causing  a  loss  of 
endothelial  cell  integrity,  mSTBM  massively  disrupted  the  HUVEC  monolayer
(Fig:  16)  and  triggered  endothelial  cell  death (Fig:  17).  From  these  observations  it
is  however  unclear  whether  the  onset  of  apoptosis  preceded  detachment  of  the 
endothelial  cells  from  the  culture  dish  or  occurred  once  the  monolayer  had 
become  disrupted.  Since  a  previous  study has  reported  that the  anti-proliferative
activity  of  mechanically  derived  STBM  might  be  due  to  the  interaction  of 
adhesion  molecules  on  STBM  with  endothelial  cells  [154],  it  is  tempting  to 
propose  that  apoptosis  follows  cell  detachment  induced  by  competitive  binding  to 
the  gelatin-bound  ligands.  Nevertheless  the  observation  that  increased  amounts  of 
STBM  (up  to  50 Pg/well)  from  the  two  new  preparations  do  not  achieve  the  high
degree  of  growth  inhibition  triggered  by mSTBM  strongly  suggests  that  the  quality
of  the  STBM  produced  rather  than  their  quantity  is  determining  for  altering 
HUVEC  proliferation  and  induction  of  cell  death. 
These  observations,  therefore,  indicates  that  the  three  STBM  preparations  differ
functionally  with  regard  to  their  effect  on  HUVEC  cultures  that  raise  the  issue  of 
which  of  the  different  STBM  preparations  is  closest  to  normal  physiology.  STBM
prepared  either  from  villous  explant  cultures  or  by  placental perfusion  may  more 
closely  mimic  the  physiological  status  of  apoptotic  release,  as  the  micro-particles
released  by  these  methods  are  more  likely  to  result  from  normal
syncytiotrophoblast  turnover  than  the  STBM  isolated  by  physical  disruption  of 
villous  integrity like  the  mechanical  preparation  [153],  which  may  lead  to  necrotic 
particle  release.  A  remarkable  feature  of  vSTBM  and pSTBM  is  that  they  do
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inhibit  HUVEC  proliferation  in  a  dose  dependent  manner without  the induction  of
endothelial  cell  apoptosis;  this  suggests  that  these  STBM  might  alter  endothelial 
cell  function  rather  than cell  integrity.  This  is  in  good  agreement  with  the in-vivo
findings,  where  evidence  of endothelial  cell  activation  in  preeclampsia  is  observed 
from  increased  plasma  levels  of  von  Willebrand  factor,  fibronectin,  sVCAM-1  and 
sE-selectin  [155,  156].  Furthermore,  in  preeclampsia  endothelial  function  is  altered 
as  myometrial  arteries  from  women  suffering  with  the  disorder  exhibit  an
attenuated  endothelium-dependent  vasodilatory  response  [157].  As  none  of  these 
observations  suggest  an  increased  endothelial  cell  turnover  and/or  massive
endothelial  cell  apoptosis,  the  possible  physiological  role  of  particles  having 
similar  properties  to  those  exhibited  by  mSTBM  will  have  to  be  further  addressed.
Therefore  we  conclude  that  investigations  studying in-vitro  effect  of  placental 
STBM  on  endothelial  cells  will  have  to  consider  the  mode  in  which  these  micro-
particles  are  prepared. 
In  an  effort  to  understand  the  qualitative  difference  of  the  three  STBM
preparations,  lipid  analysis  of  STBM  preparations  was  carried  out.  This  analysis
revealed  that  in  comparison  to  the  two  new  STBM  preparations,  mSTBM  are  rich
in  lipids  such  as  cholesterol  esters (Fig:  11A).  It  has  been  proposed  that  the 
excessive  amount  of  the  cholesterol  can  induce  inflammatory  reaction  [146.  158]. 
Therefore,  depletion  of cholesterol  in  mSTBM  was  carried  out  using  MECD (Fig:
11B), and  HUVEC  proliferation  was  measured  after  co-incubation  with  lipid-
depleted  mSTBM. This  cholesterol  depletion  in  mSTBM  resulted  into  the 
significant  restoration  of  HUVE  proliferation,  which  suggests  that  presence  of  high 
cholesterol content  in mSTBM  is  partially  responsible  for  the  reduced  HUVEC
proliferation (Fig:  18).
These  observations  summarizes  that  the  three  STBM  preparations  differ
biologically  and  these  differences  are  attributable  to their  mode  of  preparation. 
3.2.  Placentally  derived  factors  and  T  cell  response 
In-vitro  generated  STBM  have  been  shown  to  modulate  lymphocyte  activities,  in 
that  STBM  can  inhibit  lymphocytes  proliferation  and  can  induce  apoptosis  in 
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Jurkat  T  cell  line  [109, 118,119].  These  studies  largely  made  use  of  STBM
prepared  by  mechanical  dissection  of  villous  tissue  or  STBM  prepared  form
maternal  serum.  In  contrast  to  these  studies,  in  this  study  the  effect  of  three 
qualitatively  different  STBM  preparations,  characterized  above,  and  VE-CM  was
examined  on  purified  T  cells.
This  comparative  study  revealed  that  the  three  different  STBM  preparations  and 
VE-CM  are  not  able  to  activate  T  cells  on  their  own in-vitro (Fig:  19,  23).  This 
observation  suggests  that  in  the  presence  of  antigen  presenting  cells  (APCs),
STBM  might  have  antigenic  potential.  It  might  also  be  possible  that  the  effects  of
STBM  on  T  cells  is  mediated  via  an  intermediate  step,  such  as  STBM  mediated
activation  of  endothelial  cells,  which  then leads  to  the  production  of  inflammatory
molecules  which  subsequently  act  on  the T  cells.  Evidence  for  such  a  mechanism
is  partially  obtained  from  previous  studies,  which  indicated  that  supernatants  from
endothelial  cells  treated  with  STBM  activate  PBLs in-vitro  [109,  159].  As  these 
studies  have  made  use  of  PBLs  it  is  most  likely  that  observed  effects  are  specific
to  leukocytes  (neutrophils)  not  to  T  cells.
This  study,  however,  do  indicate  that mSTBM  and  vSTBM  can  influence  the 
response  of  PMA  and  ionomycin  activated  T  cells,  in  that  these  two  STBM 
preparations  significantly  reduced  T  cell  proliferation (Fig:  20),  as  well  as  IL-2
and  IFNJ  production (Table:  2).  This  phenomenon  was  associated  with  reduced 
CD69  expression  in  these  T  cells (Fig:  21).  On  the  other  hand,  pSTBM  enhanced 
T  cell  proliferation  and  lead  to  a  moderate  increase  in  the  cytokine  production 
(Fig:  20,  Table:  2).
One  common  facet  observed  with  all  the  three  STBM  preparations  is  that  none  of
the  STBM  preparations  induced  apoptosis  in  activated  T  cells (Fig:  22).  It  is  in
contrast  to  the  data  where  maternal  serum  STBM  have  been  shown  to  cause  FasL
mediated  apoptosis  of  Jurkat  T  cells,  which  might  be  explained  by  the  fact  that 
this  transformed  T  cell  line  is  highly  receptive  to  pro-apoptotic  signals  [119],  or 
these  particles  differ  qualitatively  than  the  placentally  derived  STBM  and  may  be
contaminated  with  the  particles  that  are  of  maternal  origin.  Differential  T  cell
proliferation  and  cytokine  production  (IL-2  and  IFNJ)  that  was  observed,  however 
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do  emphasize  that  the  three  STBM  preparations  are  functionally  and  qualitatively 
different.  The  effects  examined  with  pSTBM  are  intriguing  as  they  behave  largely 
opposite  to  the  other  two  STBM  preparations.  In  this  context,  it  should  be  noted 
that  it  is  similar  to  that  observed  with  HUVEC  cultures  where  these  STBM  also 
exhibited  different  activities.  These  differences  exhibited  by  three  STBM
preparations  on  T  cells  may  reflect upon  the  mode  whereby  these  different
particles  are  generated  as  described  above  where  the  mSTBM may  be  produced 
by  the  necrosis  and  other  two  new  STBM  preparations  are rich  in  apoptotic/apo-
necrotic  particles. 
To  examine  the  effects  of placentally  derived  factors  on  purified  T  cells,  activated 
T  cells  were  cultured  in  the  presence  of  VE-CM.  VE-CM  reduced  proliferation  of 
the  activated  T  cells (Fig:  24)  and  decreased  IL-2  and  IFNJ  production (Fig:  26)
in  a  dose  dependent  manner.  It  was  also  observed  that  T  cell  activation  was 
reduced  upon  treatment  with  VE-CM (Fig:  27)  and  this  treatment  did  not  induce 
any  T  cell  apoptosis (Fig:  28).  These  observations  suggest  that  low  T  cell 
proliferation  and  reduced  cytokines  production  observed  with  VE-CM  treatments
might  be  associated  with  the  reduced  T  cell  activation.
An  important  mechanism  for  the  low  T  cell  proliferation in-vitro  is  via  the  IDO
system,  which  suppresses  T-cell  responses  by  limiting  the  availability  of 
tryptophan  in  local  tissue microenvironments  [160].  However,  in  context  of  our 
study,  it  has  been  shown  that  IDO  expression  by  tumor  cells  did  not  interfere 
with  their  ability  to  stimulate  naive  T  cells  to  enter  cell  cycle  and  to  express
early  activation markers  such  as  CD69  [161]. In-vitro  studies  have  shown  that 
addition  of  IFNJ  to  placental  villous  explant  cultures  can  induce  IDO  expression 
in  the  villous  tissue.  The  villous  explant  homogenates  obtained  form  such  cultures
can  inhibit  the  proliferation  of  PHA  stimulated  PBMC in-vitro [162].  In  contrast 
to  these  studies  we  did  not  induce  IDO  expression  in  villous  explant  culture  with
IFNJ  and  did  not  use  villous  explant  homogenate  to  study  T  cell  response.  Rather
we  used  placental  micro-particles  free  conditioned  medium  still,  we  observed
significant  inhibition  of  the  T  cell  proliferation.  Further  to  rule  out  the  role  of 
IDO  in  the  low  T  cell  response  in  our  conditions,  we  added  L-tryptophan  or 
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inhibitor  of  IDO,  1-MT,  to  the  T  cell  cultures  that  could  not  recover  reduced  T 
cell  proliferation (Fig:  29).  These  observations  strongly suggest  that  the  inhibition 
of  T  cell  proliferation  is  not  mediated  by  the  IDO.  Therefore,  it  can  be
hypothesized  that  IDO  is  a  cytoplasmic  enzyme [163],  present  in  the 
syncytiotrophoblast  [164,  165],  acts  locally  by  deletion  of  activated  T  cells  at  the 
site  of  feto-maternal  interface  but  not  distally.  Furthermore,  CD69  expression  was 
not  affected  by  the  IDO [162],  this  suggests  that  the  reduction  in  CD69 
expression  on  activated  T  with  VE-CM involves  some  unknown  factors  produced 
by  the  placenta.  As  we  could  observe  a  significant  reduction  in  the  IL-2  and 
IFNJ  production  by  the  activated  T  cells after  the  treatment  with  VE-CM  this 
suggest  that  placentally  derived  soluble factors  are  immuno-modulatory  in  nature. 
In  summary  this  data  suggests  that  the  placentally  derived  STBM  and  soluble
factors  are  immunosuppressive  in  nature.  The  effects  of  STBM on  T  cells  largely 
depend  upon  the  quality  of  the  STBM.  These  features  should,  therefore,  be  taken
into  consideration  when  using in-vitro prepared  STBM  as  a  model  to  study  their 
potential  role  in  normal  pregnancy  and  preeclampsia.  We  could  observe  a 
significant  reduction  in T  cell  proliferation in-vitro  by  an  IDO  independent 
mechanism  and  reduced  Th1  cytokine  production  by  the  activated T  cells  after  the
treatment  with  placentally  derived  factors.  These  observations  further  confirm  that 
the  normal  pregnancy  is  associated  with  the  reduced  Th1  immunity  as  proposed 
earlier  [86,  166,  167].  Therefore,  these  data strengthen  the  fact  that  T  cell 
response  during  pregnancy  is  tightly  regulated  to  achieve  successful  pregnancy.
3.3.  Placentally  derived  factors  and  innate  immune  response 
It  has  been  proposed  that  the  maternal innate  immune  system  is  activated  during 
pregnancy  [110].  It  has  been  speculated  that  monocytes  are  the  likely  target  of 
the  innate  immune  system  that  are  activated  by  placentally  derived  soluble  factors,
cytokine,  enzymes,  lipids  and  free  radicals  [110].  In  this  study  we  have  focused 
upon  the  polymorphonuclear  cells  i.e.  neutrophils.  Evidence  suggests  that  STBM 
can  activate  neutrophils in-vitro [112].  Recent  observations  suggested  that  activated
neutrophils  generate  extracellular  DNA  containing  networks  (NETs),  which  trap 
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and  kill  bacteria  [149].  In  this  study  for  the  first  time  we  have  demonstrated  that 
these  NETs  can  be  induced  by  physiological  factors,  such  as  STBM  and  placental 
cytokine,  IL-8.  This  is  the  first  evidence,  which  suggests  that  NETs  induction  is 
not  solely  mediated  by  foreign  objects,  such  as  bacteria.  In  this  regard,  we
observed  that  the  placentally  derived  cytokine  IL-8  and  STBM  efficiently  activated
neutrophils  individually (Fig:  30). Here,  We  show  that  upon  activation  with 
different  STBM  and  VE-CM,  neutrophil  NETs  were  generated (Fig:  32).  These 
observations  also  provides  the  first  evidence  implicating  neutrophil  NETs  in
preeclampsia  in  that  NETs  were  induced  by  plasma  samples  from  cases  with 
preeclampsia (Fig:  32B,  32K). NETs  formation  with  the VE-CM  could  be  blocked
by  the  IL-8  neutralizing  antibody,  which  suggests  the  placentally derived  IL-8  is 
responsible  for  the  NETs  formation (Fig:  32I  and  32R).  These  NETs  were  able
to  entrap  STBM (Fig:  33).  This  NETs  formation  occurred  in  time  and  dose
dependent  manner (Fig:  34).  These  observations  suggest  that  placentally  derived 
factors  can  induce  NETs  formation  in  an  IL-8  dependent  and  independent  manner.
Furthermore,  DNA,  histones  and  elastase  rich  NETs  were  found  to  occur  with 
high  frequency  directly  in  the  intervillous  space  of  preeclamptic  placentae (Fig:
35,  36).  This  latter  observation  may  be  of  considerable  importance  regarding  the 
etiology  of  this  disorder,  which  is  widely  accepted to  involve  inadequate  perfusion
of  the  placenta  [168],  in  that  it  provides  new  evidence  that  the  underlying
hypoxic  lesion  can  occur  directly  at  the  feto-maternal  interface,  and  need  not  be
distally  located  to  the  placental  villi,  such  as  the  maternal  spiral  arteries.
By  their  ability  to  trap  and  immobilize  large  bacteria  such  as  S. aurens [149],  it 
is  very  likely  that  the  presence  of  these  neutrophil  NETs,  especially  when  present 
in  such  large  numbers  as  we  have  observed  in  preeclampsia (Fig:  35,  36),  will 
severely  disrupt  maternal  blood  through  the  intervillous  space.  This  reduction  in 
perfusion  will  therefore  lead to  a  condition  of  oxidative  stress  directly  at  this 
critical  site  of  feto-maternal  exchange.
Previous  studies  have  suggested  that  the  oxidative  stress  resulting  from  placental 
hypoxia  is  instrumental  in  mediating  the downstream  events  that  lead  to  the 
maternal  syndrome  of  preeclampsia  [23],  including  an  imbalance  in  the  VEGF-R1 
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system  and  ensuing  endothelial  cell  damage  [169,  170].  In  this  context,  it  should 
be  noted  that  placental  hypoxia  per  se may  not  be  the  main  contributor  to 
oxidative  stress,  but  rather,  that  this  may  result  from  periods  of  hypoxia  and  re-
oxygenation  [28].  The  phenomenon  we  have  described  here  would  be  very 
amenable  to  such  a  proposed  model,  in  that  the  fluctuation  in  blood  flow  through 
the  intervillous  space  would  be  mediated by  the  rapid  generation  and  clearance  of 
NETs,  leading  to  a  sudden  influx  of  oxygen  rich  maternal  blood  into  these 
hypoxic  tissues  and  ensuing  oxidative  stress. 
Furthermore,  as  enhanced  interactions  between  vascular  tissue  and  neutrophils  have
been  demonstrated  in  ischemic  tissues  [171,  172],  it  is  possible  that  such  a
mechanism  may  operate  in  preeclampsia  [173],  contributing  to  the  generation  of
the  NETs  that  we  have  described  here.  Therefore,  it  is  possible  that  these 
conditions  may  lead  to  the  formation  of  a  cascade  with  endless  loop  character, 
whereby  the  initial hypoxic  condition  and associated  oxidative  stress  brought  about 
by  inadequate  modification  of  the  spiral  arteries,  will  lead  to  neutrophil  activation
and  NETs  formation,  which  will  then  lead  to  further  hypoxia  /  re-oxygenation  or 
oxidative  stress  conditions.  Although  enticing,  these  speculations  need  to  be
confirmed,  by  further  studies,  perhaps,  using in-vitro  placental  villous  culture 
systems  [174]. 
With  regard  to  the previous  observations  concerning  cell-free  DNA  in
preeclampsia  [94,  95],  these  data  are  also  of considerable  interest,  as  the  major
component  of  NETs  is  extracellular  DNA.  Therefore,  the  generation  of  these 
NETs  in  preeclampsia  may  contribute  to  the  increased  levels  of  maternal
circulatory  cell-free  DNA detected  in  this  disorder  [94,  95].  Furthermore,  as  the
levels  of  circulatory  cell-free  DNA  correlated  very  well  with  the  severity  of  the 
disorder,  this  could  be  indicative  of  increased  NETs  formation,  which  would 
support  our  proposal  that  these  novel  extracellular  entities  generated  by  neutrophils 
may  play  an  important  role  in  the  underlying  etiology  of  preeclampsia.
Based  on  the  above  data  where  placentally  derived  factors  activated  neutrophils
and  induced  NETs  formation  following model  can  be  proposed  for  the 
pathogenesis  of  preeclampsia. 
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Figure:  38. A  proposed model  for the  pathogenesis  of  preeclampsia.  A.  Aberrant  trophoblast
differentiation  reduces  invasion  of  the  trophoblast  cells  into  the myometrial  spiral  arteries,  which
results  in  the  poor vascular  exchange  and  reduced  blood  supply  to placenta. B.  Reduced blood
supply  leads  to  oxidative  stress  in placenta. C. Oxidative  stress results  into  the  increased  apoptosis
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and  increased  shedding  of STBM,  which  will  then  enter  into  the maternal  circulation  and  will  lead
to  endothelial  dysfunction. More  neutrophil  infiltration  will occur  due  to  increased IL-8 production
by  hypoxic  tissue. D. Activated  neutrophils  will  then  generate  NETs  within  the  placenta  which 
will  further induce oxidative  stress by  blocking  blood  flow  in  the  intervillous  space,  some
activated neutrophils  might  escape from  the  placenta and will  enter  into  the  maternal circulation
and  may  cause  endothelial  dysfunction. E.  Quick  disappearance  of  the  NETs  will  reperfuse
placenta,  which will  then  lead  to  hyperoxia within  the placenta.  This  reperfusion will  further 
recruit  more neutrophils, which  will  then  again  form  NETs. In  this  manner  an  endless  loop  of  the
hyperoxia  and  hypoxia will  continue. F.  Endothelial  dysfunction  caused by  STBM  and  activated
neutrophils.
Finally  to conclude,  these  all  data  summarized  here  provides  an  insight  that  not 
only  the  quantity  of  the  STBM  but  also  their  quality  play  an  important  role  in
the  pathogenesis  of  preeclampsia.  Furthermore,  it  can  be  interpreted  by  these  data 
that  placentally  derived   factors  are  immuno-modulatory  in  nature.  In  regard  to
maternal  innate  immune  response,  our data  do  provide  some  evidences  that 
placentally  derived  factors  are  able  to  activate  innate  immune  system,  therefore,  it 
can  be  proposed  that  excessive  activation  of  maternal  innate  immune  system  leads
to  preeclampsia.  Though  not  studied  here, but  it  can  hypothesized  by  these  data 
that  the  Th1  immune  response  observed  during  preeclampsia  is  secondary  to 
activation  of  maternal  innate  immune  system.  Lastly,  our  novel  and  important
observations  regarding  the  generation  of  neutrophil  NETs  within  the  preeclamptic
placenta  provides  better  understanding  of the  pathogenesis  of  this  pregnancy
related  disorder. 
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4. Methods 
4.1. Collection of Samples 
This  study  was  approved  by  the  Cantonal Institutional  Review Board  of  Basel,
Switzerland.  Written  informed  consent  was  requested  in  all  instances. Placentae  and
umbilical  cords  were  obtained  after  normal  term  delivery  or  elective  cesarean
section  from  uncomplicated  pregnancies  and  processed  within  30-90  min  of 
collection.
For  T  cells  and  neutrophils  isolation  blood  samples  were  obtained  from  healthy 
donors  at  the  blood  donation  center,  Swiss  Red  Cross,  Basel. 
Maternal  blood  samples  were  collected from  pregnant  women  with  manifest
preeclampsia.  Preeclampsia  was  defined  by blood  pressure  of  at  least  140/90  mm 
Hg  in  two  determinations  4  h  apart  or  by  a  diastolic  blood  pressure  of  more  than
110  mm  Hg  and  an  associated  proteinuria  of  at  least  300  mg  in  24 h  after  20 
weeks  of  gestation.  Control  maternal  blood  samples  drawn  from  normotensive
pregnant  women  at  term  who  all  delivered  healthy  babies. 
4.2. Preparation  of  syncytiotrophoblast  micro-particles 
4.2.1. Villous  explant  culture
Villous  tissue  was  isolated  by  dissection of  the  placentae  and  removal  of  the 
decidua.  Following  a  wash  in  sterile  phosphate  buffered  saline  (PBS),  the  villous
tissue  was  cut  into  pieces  of  1-2  mm. Explants  were  cultured  in  100  mm  culture 
dishes  (Corning  NY,  USA)  in  Dulbecco Modified  Eagle’s  Medium  (DMEM)  :  F-
12  Nutrient  Mixture  (1:1)  (GIBCO  Invitrogen  Life  Technologies,  Grand  Island, 
NY,  USA)  supplemented  with  1%  antimycotic/antibiotics  (GIBCO  Invitrogen  Life 
Technologies,  Grand  Island,  NY,  USA),  10%  fetal  calf  serum  (FCS),  25  U/ml
heparin  (Roche  Diagnostics,  Germany),  50  U/ml  aprotinine  (Fluka  Chemicals  AG, 
Buchs,  Switzerland)  and  2  mM  MgSO4  for  72  h  at  37°C  in  5%  CO2.  After 
incubation  the  culture  medium  was  collected  and  stored  at  -70°C.
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Figure: 39. A  schematic  representation  of preparation and  isolation of vSTBM.  From  all  the
preparations  after  initial  procedures  the  supernatant  was  subjected  to  three  centrifugation  steps.  The
isolated STBM  and  culture  supernatant  stored  aliquoted  at  -70°C.
4.2.2.  Mechanical  dissection
STBM  were  prepared  by  a  slight  modification  of  methods  described  previously 
[99,  120].  We  used  a  smaller  volume  of  0.15M  NaCl  and  a  higher  speed 
centrifugation  step  to  ensure  greatest  yield.  Briefly,  villous  tissue  was  washed 
three  times  in  PBS  containing  100  mM  CaCl2  then  chopped  with  scissors  and 
rinsed  in  100  ml  0.15 M  NaCl  supplemented  with  1%  antimycotic/antibiotics 
overnight  at  4°C.  After  rinsing,  tissues  were  discarded  and  the  supernatant  was
collected.
4.2.3. Placental  perfusion
STBM  were  prepared  using  a  well-described  perfusion  system [132,  133].  Briefly, 
the  intervillous  space  ( maternal  compartment)  and  the villous  vasculature  (fetal
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compartment)  of  an  isolated  placental  cotyledon  were  perfused  separately  in  open 
systems i.e.  without  recirculation  at  flow  rates  of  about  12  and  6  ml/min,
respectively.  Perfusion  medium  was  composed  of  NCTC-135  tissue  culture  medium
diluted  with  Earle`s  buffer (1:1)  with  the  addition  of  glucose  (1.33 g/l),  dextran  40 
(10 g/l),  4%  BSA,  heparin  (2500  IU/l) and  clamoxyl  (250 mg/l).  After  30  min  of 
initiation  of  the  perfusion,  the  perfusate  from  the  maternal  side  was  collected  and 
stored  at  -70°C.
4.2.4. Isolation  of  STBM
To  isolate  STBM,  supernatants  from  all  the  three  preparations  were  subjected  to  a 
three-step  centrifugation  at  4°C:  1000  x  g  for  10  min,  10000  x  g  for  10  min  and 
70000  x  g  for  90  min.  The  final  pellet was  collected,  washed  with  PBS  and 
resuspended  in  1  ml  sterile  PBS  containing  5%  sucrose and  stored  at  –20°C  until 
use.  Red  blood  cell  micro-vesicles    (RBC  ghosts)  were  prepared  as  described 
previously  by  Khalfoun  et  al.  [175]  and  used  as  a  negative  control  in  all
experiments.
4.3. Protein  and  PLAP  (placental  alkaline  phosphatase) 
quantification  of  STBM  preparations
The  protein  content  in  each  STBM  preparation  was  quantified  with  the  advanced
protein  assay  reagent  (Cytoskeleton  Inc.  Denver,  CO,  USA)  according  to 
manufacturer’s  instructions.  The  amount  of  PLAP  protein  was  determined  using  an 
ELISA.  In  brief,  a  96  well  microtiter  EIA  plate  (Nunc,  Denmark)  was  coated
with  anti  PLAP  antibody  (mouse  monoclonal  Ab-5,  Neomarkers  Inc.  Fremont,  CA,
USA)  for  2  h  at  RT.  After  washing  with      PBS/0.05%  Tween  20,  the  STBM
samples  were  added  and  incubated  for  2 h  at  RT.  After  4  consecutive  washes 
alkaline  phosphatase  yellow substrate  (pNPP,  Sigma  chemicals,  St.  Louis,  MO, 
USA)  was  added  and  incubated  for  1  h  in  the  dark. Subsequently  the  plate  was
read  at  405  nm  in  an ELISA  reader    (Molecular  Devices,  Sunnyvale,  CA,  USA) 
and  the  data  was  analyzed  using  Soft Max  Pro  Software.  A dilution  series  of 
purified  PLAP  (Sigma  Chemicals,  St.  Louis,  MO,  USA)  was  used  as  a  standard. 
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4.4. Scanning  electron  microscopy  (SEM)  of  STBM
For  SEM  examination  3 Pg  STBM  of  each  preparation  were  diluted  in  25 Pl
PBS,  then  transferred    onto  0.2 Pm  polycarbonate  membrane  (Whatman,  New 
Jersey,  USA)  under  the  application  of  vacuum  and  dehydrated with  an  acetone
series  (30%,  50%,  70%,  100%,  and  100%  acetone  for  10, 10,  10,  10  and  15  min,
respectively).  Then  specimens  were  coated  with  2nm platinum  and  analyzed  using 
a  Philips  XL-30  ESEM  scanning  electron  microscope  (ZMB,  University  of  Basel). 
4.5. FACS analysis of the STBM
To  confirm  that  the  STBM  were  the  products  of  the  syncytiotrophoblast 
membrane,  PKH-26  GL  membrane  dye  (Sigma  Chemicals,  USA)  were  used  and
FACS  were  used  to  detect  the  STBM.  50 Pg  of  the  STBM  were  diluted  in  1ml
of  Diluent  C,  which  was  provided  with  the  dye.  Dilute  dye  in  the  diluent  C  at 
20 PM  and  add  it  to  the  diluted  STBM  at  10PM  concentration  (1:1  STBM:  Dye
both  in  diluent  C).    Incubate  for  5  min  and  then  add  equal  volumes  (2ml)  of 
heat  inactivated  FCS,  incubate  two  more minutes  then  add  equal  volumes  of  PBS 
(4ml).  Pellet  downs  the  particles  at 2000g.  Wash  three  times  using  5ml  PBS. 
Finally  resuspend  the  labeled  particles in  1ml  PBS  and  carryout  FACS.  As
particles  are  very  small,  therefore,  change  FSC  and  SSC  scale  to  log  scale. 
4.6. DNA and RNA detection in the STBM
For  the  quantitation of  the  placentally  derived  DNA  and  RNA  in  the  STBM  SRY 
and  CRH  mRNA  were  amplified  using  real-time  PCR.  DNA  was  extracted  from
STBM  using  High  Pure  PCR  template  preparation  kit  (Roche  Diagnostic).  Total 
RNA  was  isolated  using  High  Pure  RNA  isolation  kit  (Roche  Diagnostic)  and 
eluted  in  50  µL  of  elution  buffer. cDNA  was  reverse  transcribed  from  500ng  of
total  RNA  using  a  commercial  reverse transcription  system  (Promega). Real-time
quantitative  PCR  and  real-time  quantitative  RT-PCR  were  used  for  all  DNA  and 
mRNA  quantifications  as  described  earlier  [138,  176,  177].  The  real-time  PCR  and
real-time  RT-PCR  reactions were  set  up  according to  the  manufacturer’s
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instructions  (Applied  Biosystems)  in  a  reaction  volume  of  25  µL.  Each  sample
was  analyzed  in  duplicate,  and  the  corresponding  calibration  curve  was  run in
parallel  with  each  analysis.  Absolute  concentrations of CRH  mRNA  and  SRY 
DNA  were  expressed  as  copies/mg  of  STBM.
PCR  primers  and  probes sequences  were: 
Forward  Primer  SRY:  TCC  TCA  AAA  GAA  ACC  GTG  CAT
Reverse  primer  SRY:  AGA  TTA  ATG  GTT  GCT  AAG  GAC  TGG  AT 
Probe  SRY:  TCC  CCA  CAA  CCT CTT 
Forward  Primer  CRH:  5'-GCC  TCC  CAT  CTC  CCT  GGA  T-3'
Reverse  primer  CRH:  5'-TGT  GAG  CTT  GCT  GTG  CTA  ACT  G-3'
Probe  CRH:  5'-(FAM)  TCC  TCC  GGG AAG  TCT  TGG  AAA  TGG  C
(TAMRA)-3'
Oligo  CRH:  5`-GGA  GCC  TCC  CAT  CTC CCT  GGA  TCT  CAC  CTT  CCA
CCT  CCT  CCG  GGA  AGT  CTT  GGA  AAT  GGC  CAG  GGC  CGA  GCA  GTT
AGC  ACA  GCA  AGC  TCA  CAG  CA-3` 
4.7.  Lipid  analysis  of  the  STBM 
Lipids  in  the  STBM  were  identified  using  thin  layer  chromatography  and  Mass 
spectrometry.
4.7.1.  Thin  layer  chromatography  of  the  STBM
100  µg  of  the  each  STBM  preparation was  extracted  with  chloroform.  After 
centrifugation  for  1  min  the  lipid containing lower organic  layer  was  collected  and 
applied  to  the  pre-coated  TLC  plate.  TLC  was  carried  out  in  the  pre-saturated
chamber.  The  running  buffer  consisted  of  chloroform:  Methanol:  water:
Ammonium  hydroxide-  65:30:3:2 (v/v/v/v).  The  TLC  run  was  monitored  until  the 
top  of  the  plate.  The  separated  lipids were  visualized  staining  in  mosatin  stain
[4%  ammonium  molybdate  tetrahydrate  (w/v)  +  0.08%  cesium  sulfate  tetrahydrate 
(w/v)  +  30%  H2SO4 (10%, v/v)]  and  charring  at  200°C. 
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4.7.2.  Mass  spectrometry  of  the  STBM 
A  large  TLC  was  run  for  the  mass spectroscopy  analysis and  8  spots  were 
scrapped  out  from  the  plate  after  the  TLC  run is over.  The  lipids  from  the  Silica
gel  were  extracted  using  methanol  and then  stored  for  the  mass  spectrometry
analysis at  Biozentrum,  University  of  Basel. 
4.8.  HUVEC and Cell lines  proliferation  assay 
HUVEC  were  isolated  from  normal  term  human  umbilical  cord  by  the  method 
described  by  Jaffe  et  al.  [178]  and  stored  in  liquid  nitrogen  until  use.  Cells  from
passage  2  to  passage  7 were  used.  To  assess  HUVEC  proliferation  the  cell 
proliferation  kit  (Roche  Diagnostics,  Basel,  Switzerland)  was  used,  which  measures
BrdU  incorporation  during  DNA  synthesis. In  brief 1.5x104  cells  were  plated  onto
1%  gelatin  coated  96  well  microtiter  plates  (Nunc,  Denmark)  in  E-SFM
(endothelial  serum  free  medium)  medium  supplemented  with  20  ng/ml  human
recombinant  bFGF  (basic  fibrobalst growth factor)  and  10  ng/ml  human
recombinant  EGF  (epidermal  growth  factor,  GIBCO  Invitrogen  Life  Technologies, 
Grand  Island,  NY,  USA).  After  6  h,  the  culture  medium  was  replaced  with 
STBM  or  RBC  ghost  particles  diluted  in  DMEM:F-12  medium  supplemented  with 
1  %  antimycotic/antibiotics,  10%  FCS,  50  U/ml  aprotinin,  25  U/ml  heparin 
(DMEM:F12  complete  medium).  The  cells  were  then  incubated  for  22  h,  followed 
by  an  additional  incubation  with  10 PM  of  BrdU  for  a  further  18  h.  The  amount 
of  incorporated  BrdU  was  detected  using  an  ELISA  according  to  the 
manufacturer’s  instructions. 
U-937  (human  histiocytic  monocyte  like  lymphoma  [179]  was  used  as  nonadherent 
control  cell  line.  A431  (human  epidermal  squamous  carcinoma  [180], HELA 
(human  epithelial  cervix  carcinoma  [181],  NIH-3T3  (Swiss  mouse  embryo
fibroblasts  [182],  and  LN-18  (human  brain  malignant  glioma  cell  [183]  were used 
as  adherent  control cell  lines.   U-937,  NIH-3T3,  HELA,  A431,  and  LN-18  cells  ( 
each  1.5x104  cells/well)   were grown  in  RPMI  1640  (GIBCO  Invitrogen  Life
Technologies,  Grand  Island,  NY,  USA)   supplemented  with  Glutamax,  10%  FCS, 
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and   100  U/ml  penicillin,  100 Pg/ml  streptomycin.   With all  adherent  cells  RPMI 
1640  medium  was  replaced  with  STBM  diluted  in  DMEM:F-12  complete  medium
6  h  after  seeding.   For  the  nonadherent  cells,  the  STBM  preparations  were  added 
directly  to  the RPMI 1640 medium  6h  after  the  plating.  All  cells  were  incubated 
for  the  same  amount  of  time  and  cell proliferation  was  measured  as  described 
above.
4.9. HUVEC  apoptosis 
Apoptosis  was  measured  using  a  commercial  cellular  DNA fragmentation  ELISA 
kit  (Roche  Diagnostics,  Germany).  This assay  measures  the  release  of  BrdU 
labeled  DNA  fragments  into  the  cytoplasm  during  apoptosis.  In  brief,  2x104
HUVEC  were  plated  in  96 well  microtiter  plates  (Nunc,  Denmark)  in  E-SFM
culture  medium  supplemented  with  20  ng/ml  bFGF  and  10  ng/ml  EGF.  After  6  h 
10 PM  BrdU  was  added  and  incubated  for  a  further  18  h.  Following  BrdU 
labeling,  the  cell  monolayer  was  washed  with  sterile  PBS,  and  STBM  containing 
DMEM:F12  complete  medium  was  added  for  24  h.  In  positive  control  wells,
apoptosis  was  induced  with  5 PM  staurosporine  (Sigma  Chemicals,  St.  Louis,  MO,
USA),  a  potent  inducer  of apoptosis,  for  3  h.  The detection  of  BrdU  labeled 
apoptotic  DNA  fragments  was  performed  according  to  the  manufacturer’s
instructions.
4.10. Isolation  and  enrichment  of  T  lymphocytes 
PBLs  were  isolated  from  whole  blood  by centrifugation  over  a  ficoll  paque  plus 
gradient  (Amersham  Biosciences,  Uppsala,  Sweden)  for  20  min  at  RT.  CD4+  and 
CD8+  T  cells  were  enriched  together  with  specific  magnetic  microbeads  (Miltenyi
Biotech,  Gladbach,  Germany)  using  MACS  mini  columns  (Miltenyi  Biotech, 
Gladbach,  Germany)  according  to  the  manufacturer's  instructions. The  purity  of  the
enriched  T  lymphocytes  routinely  reached  >90%,  as  confirmed  by  flow  cytometry.
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4.11. T  cell  proliferation  assay 
Cell  proliferation  was  assessed  using  the  “Cell Proliferation  Kit”  (Roche
Diagnostics,  Basel,  Switzerland),  which  measures  BrdU  incorporation  during  DNA 
synthesis.  T  cells  (1x105)  were  cultured  in  triplicates  in  96  well  plate  (Nunc,
Denmark)  for  72  h  at  37  °C  in  5%  CO2  in  the  presence  or  absence  of  STBM  or
RBC  ghost  particles  as  indicated  in  the figure  legends.  The  culture  medium  used
was  RPMI  1640  medium  (GIBCO  Invitrogen  Life  Technologies,  Grand  Island, 
NY,  USA)  supplemented  with  10%  FCS,  2mM  L-glutamine  (GIBCO  Invitrogen 
Life  Technologies,  Grand  Island,  NY,  USA),  100  U/ml  penicillin,  100 Pg/ml
streptomycin  (GIBCO  Invitrogen  Life  Technologies,  Grand  Island,  NY,  USA).  50 
ng/ml  PMA  (Sigma  Chemicals, St.  Louis,  MO,  USA)  and  1PM  ionomycin  (Sigma
Chemicals,  St.  Louis,  MO,  USA)  were  used  as  stimuli.  In  the  last  18  h  of  culture
10 PM  of  BrdU  was  added  to  the  cells.
4.12. Total  RNA  isolation  and  Real  Time  PCR 
Total  RNA  was  isolated  from  T  lymphocytes  using  High  Pure  RNA  isolation  kit 
(Roche  Diagnostics,  Mannheim,  Germany). cDNA  was  reverse transcribed  from
500  ng  of  total  RNA  using a  reverse  transcription  system  (Promega,  Madison,  WI,
USA)  according  to  the  manufacturer’s  instructions.  For  the  RT-PCR  analysis,  25 
Pl  reaction  mixture  consisted  of  2 Pl  of  cDNA,  1x  Taqman®  universal  master  mix
(Applied  Biosystems,  Foster  City,  CA,  USA)  and  1x  pre-developed  Taqman®  assay
reagents  (PDAR,  Applied  Biosystems,  Foster  city,  CA,  USA),  containing  gene 
specific  probes  and  primers  for  IL-2  or  IL-4  or  IFNJ  or  18s  RNA.  For  these
experiments  the  ABI  Prism  7000  system  (Applied  Biosystems,  Foster  city,  CA, 
USA)  was  used.  18s  RNA  was  used  as  an  internal  control  to  correct  for  any 
unequal  sample  loading.  It  has  previously been  shown  that  the  amount  of  18sRNA
per  cell  does  not vary  significantly  with  cell  activation  [184].  Thermal  cycler
conditions  comprised  of  2  min  at  50°C,  10  minutes  at  95°C  followed  by  45 
cycles  of  15  seconds  at  95°C  and  1  min  at  60°C.
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The  change  in  cytokine  mRNA  expression  was  assayed  by  normalization  to  the
18sRNA  internal  control.  In  order  to  obtain  the  fold  difference  the  data  was 
analyzed  using  the ''CT  method  described  previously  by  [185],  where ''CT  =
(cytokine  CT  -  18sRNA  CT) stimulated  -  (cytokine  CT  -  18sRNA  CT)  unstimulated.
4.13. IFNJ  and  IL-2  ELISA 
IFNJ  and  IL-2  levels  produced  by  T  cells  after  incubation  with culture  upernatant
or  STBM  were  measured using  commercial  human  IFNJ  and  IL-2  ELISA  kits
(Ebioscience  Inc,  San  Diego,  CA,  USA)  according  to  the  manufacturer's
instructions.  The  ELISA  plate  was  read at  450  nm  in  an  ELISA  reader
(Molecular  Devices,  Sunnyvale,  CA,  USA)  and  the  data  was  analyzed  using  Soft
Max  Pro  Software. 
4.14. FACS  analysis of  for  T cell  activation 
FACS  analysis  was  performed  to  examine  CD69  expression  and  apoptosis  of  T 
cells  following  co-incubation  with  ulture  upernatant  nd  different  STBM
preparations.  Analysis  of CD69  expression  was  performed  using  directly  labeled 
monoclonal  antibodies  to  CD3  and  CD69  (BD  Biosciences,  Basel,  Switzerland).  In 
brief,  1x106  T  cells  were  harvested,  washed  and  incubated  with  the  antibodies  for 
30  min  at  4°C,  following  which  they  were  washed  again  prior to  two  color  flow
cytometry  using  a  Becton  Dickinson  FACScan  flow  cytometer    (BD  Biosciences,
Basel,  Switzerland).  20,000  gated  events  were  acquired  and  data  was  analyzed 
using  Cell  Quest  Pro  ®  software  (BD Biosciences,  Basel,  Switzerland).  Apoptosis 
of  T  cells  after  STBM  treatment  was measured  using  the Annexin-V-FLUOS  kit 
(Roche,  Diagnostics,  GmbH,  Mannheim,  Germany)  according  to  the  manufacturer’s
instructions.
4.15.  Isolation  of  neutrophils 
Human  neutrophils  were  isolated  using  a dextran-ficoll  method  [186].  In  brief,  the 
mononuclear  cells  were  depleted  from  whole  blood  by  centrifugation  over  a  ficoll 
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paque  plus  gradient  (Amersham    Biosciences).  Neutrophils  containing  RBC  layer 
was  resuspended  in  HBSS  medium  (GIBCO) and  6%  Dextran  T-500  was  added  to
1%  final  concentration.  RBCs  were  allowed  to  settle,  neutrophils  containing  upper 
layer  was  collected,  remaining  RBCs  were  lysed  the  pure  neutrophil  population 
was  obtained  after  washing  with  HBSS. 
4.16.  IL-8  ELISA 
IL-8  levels  were  measured  in  the  samples  using  a  commercial  human  IL-8  ELISA
kit    (R&D  systems,  Minneapolis,  USA,),  detection  sensitivity  1.5-7.5pg/ml,
according  to  the  manufacturer’s  instructions.   ELISA  plate  was  read  at  450  nm 
with  wavelength  correction  of  562nm  in  an  ELISA  reader    (Molecular  Devices,
Sunnyvale,  CA,  USA)  and  the  data  was analyzed  using  Soft  Max  Pro  Software. 
4.17.  FACS  analysis for  neutrophils  activation 
1x106  neutrophils  were  resuspended  in RPMI  1640  medium  supplemented  with 
10%  FCS,  2mM  L-glutamine    (GIBCO  Invitrogen  Life Technologies,  Grand
Island,  NY,  USA),  100  U/ml  penicillin,  100Pg/ml  streptomycin  (GIBCO  Invitrogen 
Life  Technologies,  Grand  Island,  NY,  USA)  and  incubated  with  PMA,  rIL-8,  pre-
eclamptic  plasma,  STBM  (mechanical  or  villous  explant)  or  culture  supernatant  for
60  min  except  the  pre-eclamptic  plasma  where  the  cells  were  incubated  for  3h. 
After  incubation  cells  were collected  washed  and  stained  with  directly  conjugated 
mAb  against  CD15  (FITC)  and  CD11b  (PE)  for  20  min  at  4°C.  Appropriate 
isotype  match  control  were  also  used.  Later  cells  were  washed  and  analyzed  using
a  Becton  Dickinson  FACScan  flow  cytometer    (BD  Biosciences,  Basel,
Switzerland).    A  minimum of  20,000-gated  events  were  acquired  and  analyzed 
with  the  Cell  Quest  Pro  software    (BD  Biosciences,  Basel,  Switzerland).
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4.18.  Quantification  of  DNA  release  from  activated
neutrophils
Freshly  isolated  neutrophils  were  seeded  into  96-well  plates  and  stimulated  either 
with  PMA  at  concentrations  between  0.005  -  10  nM  or  with  50-150Pg/ml  STBM
(mechanical  or  villous  explant)  or  with  20-60%  culture  supernatant  for  30  min.
After  the  incubation,  Sytox  Green  (Molecular  Probes,  USA),  a  non  cell-permeant
DNA  binding  dye,  was  added  to  the  cells  at  a  final  concentration  of  10  µM  to 
detect  extracellular  DNA.  Non-stimulated  neutrophils  were  used  a  control.  The 
plates  were  read  in  a  fluorescence  microplate  reader  SpectraMAX  Gemini
(Molecular  Devices,  Sunnyvale,  CA,  USA)  with  a  filter  setting  of  485 (excitation)/
538(emission)  and  the  data  was  analyzed  using  Soft  Max  Pro  Software. 
4.19.  Immunofluorescence  assays 
Neutrophils  were  seeded  on  glass  coverslips  treated  with  0.001%  polylysine, 
allowed  to  settle  and  either  treated  with rIL-8  (10ng/ml,  R&D  Systems),  PMA  (25
nM),  STBMs  (150 Pg/ml  each  preparation),  culture  supernatant  (60%)  or  left
unstimulated.  Cells  were  fixed  with  4% PFA,  blocked  overnight  (10%  FCS,  1% 
bovine  serum  albumin,  0.05%  Tween  20  in PBS).  For  DNA  detection,  sytox  green
(shown),  DAPI  were  used.  Specimens  were  analyzed  with  a  Zeiss  Axioplan  2 
imaging  fluorescent  microscope.
4.20.  Examination  of  NETs  formation  using  Scanning 
electron  microscopy
Neutrophils  were  seeded  on  12mm  0.001%  polylysine  coated  coverslips  and 
incubated  with  PMA,  rIL-8,  pre-eclamptic  plasma,  STBMs  or culture  supernatant
for  30  min  and  were  fixed  with  2.5%  glutaraldehyde,  postfixed  using  repeated 
incubations  with  1%  osmium  tetroxid  /  1%  tannic  acid,  dehydrated  with  a  graded 
ethanol  series.  After  dehydration  and  critical-point  drying,  the  specimens  were 
coated  with  2  nm  platinum  and  analyzed  in  a  Philips  XL-30  ESEM  scanning
electron  microscope  at  ZMB,  Biozentrum,  University  of  Basel. 
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4.21.  Histology  of  the  placental  tissues 
Placental  villous  tissue  samples  were  embedded  in  Tiise-Tek  ®  OCT  embedding
medium  (Digitana)  and  stored  at  -80°C  prior  to  analysis.  Tissue  sections  were  cut
at  8 Pm,  air-dried  and  post  fixed  with  acetone  for  5  min  and  then  rehydrated 
using  TBS  buffer  (Tris  buffered  saline  +  0.05%  Tween  20  +  0.2%  BSA).  For
immunostainings  rehydrated  samples  were  incubated  with  primary  antibodies 
specific  to  elastase  (Calbiochem)  and  histones  (Chemicon),  for  1h,  which  were 
then  detected  with  secondary  antibody  conjugated  to  Texas  Red  or  FITC.  DNA 
was  stained  with  DAPI. The  antibodies  diluted  according  to the  manufacturer’s
instructions.
4.22.  Statistical  analysis 
Wherever  needed,  Mann-Whitney  test  was  used  to  calculate  the  statistical 
significance  of  the  differences  between  experimental  groups.  Statistical  significance
was  set  at  P0.05.
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Pre-eclampsia is a pregnancy-associated multi-system disorder of unknown etiology, characterized by damage to the maternal
endothelium. The latter facet has been suggested to be mediated in part by elevated shedding of inflammatory placental
syncytiotrophoblast micro-particles (STBM) into the maternal circulation. In this study, we have examined STBM prepared by
three different methods: mechanical dissection, in vitro placental explant culture and perfusion of placental cotyledons. All three
preparations yielded morphologically similar STBM, as confirmed by scanning electron microscopy, and all contained
syncytiotrophoblast-specific proteins as determined by the presence of placental alkaline phosphatase. The functional properties of
the three STBM preparations were examined on human umbilical vein endothelial cells (HUVEC), where the mechanically
prepared particles were found to inhibit proliferation to the greatest extent. Furthermore, only mechanically prepared STBM lead
to the detachment and apoptosis of HUVEC cells. Our study, therefore, suggests that STBM prepared from placental perfusion or
in vitro explant culture are biologically different from mechanically prepared ones, and may provide a better approximation of
physiologically produced placental micro-particles.
Placenta (2005), 26, 59e66  2004 Elsevier Ltd. All rights reserved.
INTRODUCTION
Pre-eclampsia is a multi-system disorder of the second half of
pregnancy unique to humans, which remains a major cause of
maternal and perinatal morbidity worldwide [1]. Its symptoms
include high blood pressure, proteinuria and edema. Recent
research has indicated that these diverse arrays of symptoms
may be the result of an excessive maternal systemic in-
flammatory response to pregnancy, involving activation of the
innate immune system and damage of the maternal endothelial
compartment [2].
Although the origin of the disorder is still unknown, the
central role played by the placenta in its pathogenesis is well
established [3e5]. In particular, it has been suggested that the
generalized maternal endothelial dysfunction that affects pre-
eclamptic women is caused directly or indirectly by circulating
factors of placental origin [6]. In this regard, syncytiotropho-
blast membrane micro-particles (STBM) shed from the
placenta at the feto-maternal interface have drawn considerable
attention. In normal pregnancy, trophoblast cells and STBM
are spontaneously released from the placenta as a sign of
normal placental physiologic turnover [7e9] and this phe-
nomenon has been associated with the mild inflammatory state
accompanying pregnancy [10]. Significantly elevated amounts
of STBM have been found in the circulation of women with
pre-eclampsia [11]. This increased shedding of sub-cellular
material parallels the raise in circulating cell-free fetal DNA
[12,13], demonstrating the increased placental dysfunction
associated with the disorder [14].
Mechanically prepared STBM from normal full term
placenta disrupt the morphology, inhibit the proliferation
and induce cell death of cultured endothelial cell monolayers
in vitro [15]. Furthermore, STBM perfused ex vivo into pre-
constricted small subcutaneous fat arteries alter their re-
laxation response [16]. It has, therefore, been proposed that the
increased shedding of STBM into the maternal blood of
women with pre-eclampsia could be responsible for the
manifest dysfunction of the vascular endothelium [10].
In order to study the effect of STBM in greater detail, we
have prepared micro-particles from normal term placentae by
three different methods.
(A) Placental villous tissues from freshly delivered placentae
were mechanically dissected as reported earlier [15,17].
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(B) Villous explants were cultured in conditions which
maintain overall tissue integrity and support the physiologic
turnover of the syncytiotrophoblast, including apoptotic
shedding [18].
(C) Single placental cotyledons were perfused separately on
both the maternal and fetal sides and the maternal washes were
collected [19,20].
The morphological similarity between the micro-particles
generated by the different methods was confirmed using
scanning electron microscopy. Their functional properties
were compared by characterizing their effects on endothelial
cell proliferation and viability. Our studies demonstrate that
mechanically prepared STBM have very similar activities to
those described previously [15], while the two in vitro and
placental perfusion STBM preparations are functionally
different.
MATERIALS AND METHODS
Preparation of syncytiotrophoblast
micro-particles
This study was approved by the Cantonal Institutional Review
Board of Basel, Switzerland. Written informed consent was
requested in all instances. Placentae and umbilical cords were
obtained after normal term delivery or elective cesarean section
from uncomplicated pregnancies and processed within
30e90 min of collection.
In vitro explant culture. Villous tissue was isolated by dissection
of the placentae and removal of the decidua. Following a wash
in sterile phosphate buffered saline (PBS), the villous tissue
was cut into pieces of 1e2 mm. Explants were cultured in
100 mm culture dishes (Corning NY, USA) in Dulbecco
Modified Eagle’s Medium (DMEM):F12 Nutrient Mixture
(1:1) (GIBCO Invitrogen Life Technologies, Grand Island,
NY, USA) supplemented with 1% antimycotic/antibiotics
(GIBCO Invitrogen Life Technologies, Grand Island, NY,
USA), 10% fetal calf serum (FCS), 25 U/ml heparin (Roche
Diagnostics, Germany), 50 U/ml aprotinin (Fluka Chemicals
AG, Buchs, Switzerland) and 2 mM MgSO4 for 72 h at 37 (C
in 5% CO2. After incubation the culture medium was collected
and stored at 20 (C.
Mechanical dissection. STBM were prepared by a slight
modification of methods described previously [15,17]. We
used a smaller volume of 0.15 M NaCl and a higher speed
centrifugation step to ensure greatest yield. Briefly, villous
tissue was washed three times in PBS containing 100 mM
CaCl2 then chopped with scissors and rinsed in 100 ml 0.15 M
NaCl supplemented with 1% antimycotic/antibiotics over-
night at 4 (C. After rinsing, tissues were discarded and the
supernatant was collected.
Placental perfusion. STBM were prepared using a well-
described perfusion system [19,20]. Briefly, the intervillous
space (maternal compartment) and the villous vasculature
( fetal compartment) of an isolated placental cotyledon were
perfused separately in open systems i.e. without recirculation
at flow rates of about 12 and 6 ml/min, respectively. Perfusion
medium was composed of NCTC-135 tissue culture medium
diluted with Earle’s buffer (1:1) with the addition of glucose
(1.33 g/l), dextran 40 (10 g/l), 4% BSA, heparin (2500 IU/l)
and clamoxyl (250 mg/l). After 30 min of initiation of the
perfusion (n ¼ 4), the perfusate from the maternal side was
collected and stored at 70 (C.
Isolation of STBM
To isolate STBM, supernatants from all the three preparations
were subjected to a three-step centrifugation at 4 (C:
1000! g for 10 min, 10 000! g for 10 min and 70 000! g
for 90 min. The final pellet was collected, washed with PBS
and resuspended in 1 ml sterile PBS containing 5% sucrose
and stored at 20 (C until use. Red blood cell micro-vesicles
(RBC ghosts) were prepared as described previously by
Khalfoun et al. [21] and used as a negative control in all
experiments.
Protein and PLAP (placental alkaline phospha-
tase) quantification of STBM preparations
The protein content in each STBM preparation was quantified
with the advanced protein assay reagent (Cytoskeleton Inc.,
Denver, CO, USA) according to the manufacturer’s instruc-
tions. The amount of PLAP protein was determined using an
ELISA. In brief, a 96-well microtiter EIA plate (Nunc,
Denmark) was coated with anti-PLAP antibody (mouse
monoclonal Ab-5, Neomarkers Inc., Fremont, CA, USA) for
2 h at RT. After washing with PBS/0.05% Tween 20, the
STBM samples were added and incubated for 2 h at RT. After
four consecutive washes, alkaline phosphatase yellow substrate
(pNPP, Sigma chemicals, St. Louis, MO, USA) was added
and incubated for 1 h in the dark. Subsequently, the plate was
read at 405 nm in an ELISA reader (Molecular Devices,
Sunnyvale, CA, USA) and the data were analyzed using Soft
Max Pro Software. A dilution series of purified PLAP (Sigma
Chemicals, St. Louis, MO, USA) was used as a standard.
Scanning electron microscopy (SEM) of STBM
For SEM examination, 3 mg STBM of each preparation was
diluted in 25 ml PBS, then transferred onto 0.2 mm polycar-
bonate membrane (Whatman, New Jersey, USA) under the
application of vacuum and dehydrated with an acetone series
(30%, 50%, 70%, 100%, and 100% acetone for 10, 10, 10, 10
and 15 min, respectively). Then specimens were coated with
platinum and analyzed using a Philips XL-30 ESM scanning
electron microscope (ZMB, University of Basel).
Cell proliferation assay
HUVEC were isolated from normal term human umbilical
cord by the method described by Jaffe et al. [22] and stored
in liquid nitrogen until use. Cells from passage 2 to passage
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7 were used. To assess HUVEC proliferation, the cell
proliferation kit (Roche Diagnostics, Basel, Switzerland) was
used, which measures BrdU incorporation during DNA
synthesis. In brief, 1.5! 104 cells were plated onto 1%
gelatin-coated 96-well microtiter plates (Nunc, Denmark) in
E-SFM (endothelial serum free medium) medium supple-
mented with 20 ng/ml human recombinant bFGF (basic
fibroblast growth factor) and 10 ng/ml human recombinant
EGF (epidermal growth factor, GIBCO Invitrogen Life
Technologies, Grand Island, NY, USA). After 6 h, the culture
medium was replaced with STBM or RBC ghost particles
diluted in DMEM:F12 medium supplemented with 1%
antimycotic/antibiotics, 10% FCS, 50 U/ml aprotinin,
25 U/ml heparin (DMEM:F12 complete medium). The cells
were then incubated for 22 h, followed by an additional
incubation with 10 mM of BrdU for a further 18 h. The
amount of incorporated BrdU was detected using an ELISA
according to the manufacturer’s instructions.
U-937 (human histiocytic monocyte like lymphoma [23])
was used as nonadherent control cell line. A431 (human
epidermal squamous carcinoma [24]), HELA (human epithe-
lial cervix carcinoma [25]), NIH-3T3 (Swiss mouse embryo
fibroblasts [26]), and LN-18 (human brain malignant glioma
cell [27]) were used as adherent control cell lines. U-937, NIH-
3T3, HELA, A431, and LN-18 cells (each 1.5! 104 cells/
well) were grown in RPMI 1640 (GIBCO Invitrogen Life
Technologies, Grand Island, NY, USA) supplemented with
Glutamax, 10% FCS, and 100 U/ml penicillin, 100 mg/ml
streptomycin. With all adherent cells, RPMI 1640 medium
was replaced with STBM diluted in DMEM:F12 complete
medium 6 h after seeding. For the nonadherent cells, the
STBM preparations were added directly to the RPMI 1640
medium 6 h after the plating. All cells were incubated for the
same amount of time and cell proliferation was measured as
described above.
HUVEC apoptosis
Apoptosis was measured using a commercial cellular DNA
fragmentation ELISA kit (Roche Diagnostics, Germany). This
assay measures the release of BrdU-labeled DNA fragments
into the cytoplasm during apoptosis. In brief, 2! 104 HUVEC
were plated in 96-well microtiter plates (Nunc, Denmark) in
E-SFM culture medium supplemented with 20 ng/ml bFGF
and 10 ng/ml EGF. After 6 h, 10 mM BrdU was added and
incubated for a further 18 h. Following BrdU labeling, the cell
monolayer was washed with sterile PBS, and STBM containing
DMEM:F12 complete medium was added for 24 h. In positive
control wells, apoptosis was induced with 5 mM staurosporine
(Sigma Chemicals, St. Louis, MO, USA), a potent inducer of
apoptosis, for 3 h. The detection of BrdU-labeled apoptotic
Figure 1. Scanning electron micrographs of different STBM preparations. (AeB) STBM from explants, (CeD) mechanical STBM, (EeF) STBM derived from
placental perfusion. Mechanically prepared STBM tend to aggregate in clumps (C).
Gupta et al.: Analysis of Placental Micro-particles Preparations 61
DNA fragments was performed according to the manufac-
turer’s instructions.
RESULTS
STBM preparations are morphologically similar
The STBM prepared by three different methods were
examined using scanning electron microscopy. This analysis
demonstrated that all three STBM preparations produced
micro-particles with sizes ranging from 200 to 600 nm in
diameter and that these particles were morphologically similar
(Figure 1). Although the SEM analysis was not quantitative, the
data suggest that the three preparations vary in the quantity of
particles produced relative to the amount of starting material,
with the greatest number being produced by the mechanical
method. Mechanically prepared particles also had a tendency to
aggregate in clumps (Figure 1C), a feature not observed with
particles prepared by the other two methods.
To confirm that syncytiotrophoblast membraneous material
was present in the STBM preparations, we examined these
for the presence of PLAP, a GPI-anchored enzyme present
in syncytiotrophoblast membrane, using an ELISA assay.
STBM were captured with an anti-PLAP antibody and the
endogenous phosphatase activity of the immobilized particles
was measured. This analysis indicated that membrane-
associated PLAP was found in all three STBM preparations
(Figure 2), with the greatest concentration being present in the
mechanically prepared particles.
Figure 2. Concentrations of PLAP protein in each of the STBM
preparations. Equivalent amounts of STBM, as assessed by total protein
content, were examined for PLAP by ELISA. The figure represents an
examination of STBM preparations from three different placentae.
Figure 3. Inhibition of endothelial cell proliferation by STBM. (A) Sub-confluent HUVEC cells were incubated for 40 h with 12 mg/well STBM from different
STBM preparations in DMEM:F12 complete medium. Cell proliferation is represented as the percentage of cell proliferation relative to untreated control as 100%
cell proliferation. A representative analysis of STBM preparations from four placentae is illustrated. (B) Dose-dependent effect of various STBM preparations on
inhibition of HUVEC proliferation. A representative analysis of STBMs prepared from one placenta is shown.
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Inhibition of HUVEC proliferation by
STBM preparations
In order to functionally characterize the three different STBM
preparations, we used HUVEC, a well-characterized endothe-
lial cell model. These cells have been previously used to assess
the growth inhibition properties of mechanically prepared
STBM [15]. The effects of equal amounts of STBM, as
determined by protein content, were compared on HUVEC
growth. Particles prepared from red blood cells were used as
a control. Mechanically derived STBM inhibited HUVEC
proliferation up to 90% at 12 mg STBM per well while the
other two STBM preparations at a similar dose showed only
a 30e50% inhibition of endothelial cell proliferation (Figure
3A). All STBM preparations inhibited HUVEC proliferation
in a dose-dependent manner (Figure 3B). When the dose of
STBM derived from explants or from placental perfusion was
increased to 50 mg/well, a further reduction in HUVEC
proliferation could be observed. However, the high degree of
inhibition of proliferation achieved with the mechanically
produced STBM could not be obtained with the other
preparations. To investigate the specificity of this suppressive
effect on cell proliferation, all three STBM preparations were
tested on U-937 (nonadherent) and A431, HELA, NIH-3T3,
LN-18 (adherent) cell types (Figure 4Ae4C). Our study
showed that cell proliferation was not significantly reduced by
any of the STBM preparations in any of these cell lines, unlike
the effect we had observed with HUVECs.
Mechanically derived STBM disrupt HUVEC
monolayer
When HUVEC cells were incubated together with the three
different STBM preparations at a dose of 12 mg/well, only the
mechanically derived STBM caused disruption of the cell
monolayer, leading to cell detachment (Figure 5). The kinetics
of detachment was dose dependent. With a 12 mg dose of
mechanical STBM, the disruption of the HUVEC monolayer
started after 12 h of incubation, resulting in the detachment of
almost 90% cells within the next 12 h. At low concentrations
(3 and 6 mg), detachment started after treatment periods
exceeding 12 h but eventually resulted in 80e90% HUVEC
detachment at 24 h. In contrast, the other two STBM
preparations, even at higher concentration (50 mg/well)
neither disrupted the continuity of the HUVEC monolayer
nor caused any cell detachment (data not shown). The
detachment caused by the mechanically prepared particles
was similar to that described by Smarason and colleagues [15].
Mechanically derived STBM induce apoptosis
As described above, all three STBM preparations inhibited
HUVEC proliferation, albeit not to the same extent.
Furthermore, only mechanically derived STBM caused
detachment and disruption of the HUVEC monolayer. For
this reason, we next examined whether any of the STBM
preparations triggered HUVEC apoptosis. Apoptosis was
investigated by measuring the release of DNA fragments into
the cytoplasm during cell death using a commercial ELISA kit.
HUVEC treated with 5 mM staurosporine for 3 h were used as
a positive control. The analysis indicated that mechanically
derived STBM caused approximately 3e5-fold higher levels
of HUVEC apoptosis than the untreated control cultures
(Figure 6). No induction of apoptosis was evident in the
cultures treated with the two other STBM preparations, even
at high concentration (50 mg/well), or RBC ghost particles.
DISCUSSION
In this study, we have produced STBM micro-particles from
normal term placentae according to three different preparatory
methods and have investigated their effects on human
umbilical cord endothelial cells proliferation and viability in
Figure 4. Effects of different STBM preparations on cell proliferation
comparing HUVEC and other cell types. Each point is mean of three replicates
and expressed as the percentage of cell proliferation relative to untreated
control as 100% cell proliferation. (A) Treatment with mechanically prepared
STBM, (B) treatment with in vitro STBM, (C) treatment with placental
perfusion STBM. A representative experiment from one placenta preparation
is shown.
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vitro. We show that all three STBM preparations produced
micro-particles of similar sizes, which all contained the
syncytiotrophoblast-specific membrane protein PLAP, thereby
confirming their origin as bona fide STBM.
Our data indicate that all three preparations altered
HUVEC cell proliferation in a dose-dependent manner, with
the mechanically derived STBM showing the greatest degree
of growth inhibition. While it has previously been reported
that mechanically derived STBM can inhibit HUVEC
proliferation [11,15,16], this is the first study to our knowledge
that has examined the potential effects of two other forms of in
vitro generated STBM on endothelial cell growth. The inhi-
bition of cell proliferation by all three STBM preparations was
specific to HUVEC only. Although we had observed a slight
effect on some of the cell lines we had examined, these results
were very similar to the observations made previously by
Smarason et al. [15]. In this regard our findings complement
and extend upon previous reports made by this group [15].
The finding that the concentration of PLAP is about 4e5-
fold higher in the mechanically derived STBM compared to
the other two preparations suggests that the mechanical
preparation contains a higher amount of syncytiotrophoblast-
derived material. Nevertheless, the observation that increased
amounts of STBM (up to 50 mg/well) from the other
preparations do not achieve the high degree of growth
inhibition triggered by mechanical STBM strongly suggests
that the quality of the micro-particles produced rather than
their quantity is determining for altering HUVEC pro-
liferation and induction of cell death.
Although the molecular mechanisms through which HU-
VEC cell proliferation is affected have not been addressed
here, it appears that they differ amongst the three STBM
populations. Whereas STBM prepared either from explant
cultures or by placental perfusion affect cell growth without
causing a loss of endothelial cell integrity, mechanically
prepared STBM massively disrupted the HUVEC cell mono-
layer and triggered endothelial cell death. Although Smarason
and colleagues [15] have previously described that the
mechanically produced STBM do cause cell death of HUVEC
cell cultures, they used a chrome release assay to ensure this.
The problem with the chrome release assay is that it only
Figure 5. Effects of different STBM preparations on HUVEC monolayer integrity. (A) Intact confluent HUVEC monolayer incubated 24 h without STBM, (B)
with 12 mg explant-derived STBM, (C) with 12 mg STBM from placental perfusion. (D) Disrupted HUVEC monolayer following incubation with 12 mg of
mechanically derived STBM. Magnification is 400!.
Figure 6. Mechanically prepared STBM induce HUVEC apoptosis.
Confluent HUVEC were incubated with various concentrations of the
different STBM preparations and apoptosis was measured. The bars in each
preparation represent 0 mg (- - - -), 3 mg (- - - -), 6 mg (- - - -), 12 mg
(- - - -) STBM/well, respectively. 5 mM staurosporine was used as positive
control. Apoptosis is expressed as percentage relative to staurosporine-induced
apoptosis, which was designated as 100%. The results of four different STBM
preparations are illustrated.
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demonstrates loss of membrane integrity, and does not
distinguish between apoptotic or necrotic cell death. Further-
more, it can exhibit very different kinetics to the onset of truly
apoptotic features such as DNA fragmentation [28]. Our data,
therefore, now clearly demonstrate that this event is triggered
by apoptosis. From our study it is however unclear whether
the onset of apoptosis preceded detachment of the endothelial
cells from the culture dish or occurred once the monolayer had
become disrupted. Since a previous study has reported that the
anti-proliferative activity of mechanically derived STBM
might be due to the interaction of adhesion molecules on
STBM with endothelial cells [29], it is tempting to propose
that apoptosis follows cell detachment induced by competitive
binding to the gelatin-bound ligands.
Our comparative analysis, therefore, indicates that the three
STBM preparations differ functionally with regard to their
effect on HUVEC cultures. Consequently, our findings raise
the issue of which of the different STBM preparations is
closest to normal physiology.
In vivo, the shedding of placental particles is a continuous
feature of normal pregnancy, which amplifies with the advance
of pregnancy as the placental size increases. This shedding has
been proposed to be part of the normal renewal of the
syncytiotrophoblast, involving apoptosis of aged nuclei and de
novo cytotrophoblast fusion [8]. In pre-eclampsia, apoptosis
rates are significantly increased in the syncytiotrophoblast [30].
Therefore, it is most probable that the release of STBM in large
amount in pre-eclampsia is the product of increased syncytial
apoptosis [2]. STBM prepared either from explant cultures or
by placental perfusionmaymore closely mimic the physiological
status of apoptotic release, as the micro-particles released by
these methods are more likely to result from normal
syncytiotrophoblast turnover [18] than the STBM isolated by
physical disruption of villous integrity like the mechanical
preparation, which may lead to necrotic particle release.
A remarkable feature of STBM prepared by explant culture
or perfusion is that they do inhibit HUVEC proliferation
without the induction of a significant degree of endothelial cell
apoptosis. As the degree of inhibition occurred in a dose-
dependent manner, this suggests that these STBM might alter
endothelial cell function rather than cell integrity. This is in
good agreement with the in vivo findings, where evidence of
endothelial cell activation in pre-eclampsia is observed from
increased plasma levels of von Willebrand factor, fibronectin,
sVCAM-1 and sE-selectin [31,32]. Furthermore, in pre-
eclampsia, endothelial function is altered as myometrial
arteries from women suffering with the disorder exhibit an
attenuated endothelium-dependent vasodilatory response [33].
As none of these observations suggest an increased endothelial
cell turnover and/or massive endothelial cell apoptosis, the
possible physiological role of particles having properties
similar to those exhibited by mechanically prepared STBM
will have to be further addressed.
Therefore, we conclude that investigations studying in vitro
effect of placental STBM on endothelial cells will have to
consider the mode in which these micro-particles are prepared.
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bind to P. falciparum (15, 16), reduced affinity for LFA-1,
and no apparent affinity for fibrinogen (16 ). Important
insights into the function of ICAM-1 may be obtained
from future investigations of relationships in additional
individuals homozygous and heterozygous for K29M
ICAM-1.
In summary, previous studies exploring sICAM-1 as a
marker for cardiovascular and other diseases may need to
be reevaluated in light of the demonstration that commer-
cial sICAM-1 ELISAs vary markedly in their ability to
recognize this ICAM-1 variant, which is common (20–35%
allele frequency) in African-American populations.
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Fetal DNA and RNA can be readily detected in maternal
plasma samples (1–4). Most of this material appears to be
of placental origin (5 ), and it appears to be in a predom-
inantly cell-free form (2 ), whereas circulatory mRNA is
membrane-encapsulated (6 ).
Pregnancy is associated with the release of micropar-
ticles by the syncytiotrophoblast membrane into the ma-
ternal circulation (7 ). These particles, frequently termed
STBM, are released by turnover of the syncytiotropho-
blast monolayer covering the entire villous tree (8–11).
This process of normal physiologic syncytiotrophoblast
turnover involves the release of apoptotic material into
the maternal circulation by the extrusion of syncytial
knots and the associated release of STBM (8–11). The
amount of material that is released by apoptotic shedding
of syncytial knots (and STBM) is several grams per day
(9 ), and the circulating concentrations are increased sig-
nificantly in preeclampsia (11 ).
STBM particles have been suggested to evoke the mild
maternal inflammatory response accompanying normal
pregnancies (12 ), and increased release has been pro-
posed to play a role in the etiology of preeclampsia by
triggering maternal endothelial cell damage (13, 14).
As these particles are difficult to detect and prepare
from maternal blood samples, use is frequently made of in
vitro-prepared particles to study their physiologic activity
(13 ). In this context, we have recently extensively exam-
ined three different modes of STBM preparation: mechan-
ical dissection of fresh placental villous tissues; in vitro
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cultures of villous explants; and perfusion of single pla-
cental cotyledons (15 ).
All three preparations lead to the production of STBM
as confirmed by the presence of the syncytiotrophoblast-
specific protein placental alkaline phosphatase, physio-
logic activity on human endothelial cell cultures, and their
morphology, as seen by scanning electron microscopy
(15 ).
Intrigued by the seemingly parallel increased release of
STBM and circulatory fetal nucleic acids in preeclampsia
(2, 7, 14, 16, 17) and its potential relationship to the pla-
cental distress associated with the disorder, we examined
whether these two events may be more intimately asso-
ciated. For this reason, we examined whether fetal nucleic
acids are physically associated with STBM.
In our study, after the receipt of informed consent and
Institutional Review Board approval, we prepared, by the
three previously described methods (15 )), STBM from
placentas from normal full-term pregnancies in which
healthy males were delivered. In brief, villous explants
were cultured in a 1:1 mixture of DMEM and Ham’s F-12
medium (Gibco Invitrogen Life Technologies) supple-
mented with 10 g/L antimycotics and antibiotics (Gibco
Invitrogen Life Technologies), 100 mL/L fetal calf serum,
25 kIU/L heparin (Roche Diagnostics), 50 kIU/L aproti-
nin (Fluka Chemicals), and 2 mmol/L MgSO4 for 72 h at
37 °C in 5% CO2, after which the culture supernatant was
collected and stored at 70 °C. Mechanically dissected
STBM were prepared by washing villous tissue three
times in phosphate-buffered saline (PBS) containing 100
mmol/L CaCl2, after which the tissue was manually
dissected and rinsed overnight at 4 °C in 100 mL of 0.15
mol/L NaCl supplemented with 10 g/L antimycotics and
antibiotics. After rinsing, the tissues were discarded, and
the supernatant was collected and stored at 70 °C. For
the collection of STBM from placental perfusion, the
intervillous space (maternal compartment) of a single
cotyledon was perfused with an in vitro system, using a
medium composed of NCTC-135 tissue culture medium
diluted with Earle’s buffer (1:1) with added glucose (1.33
g/L), dextran 40 (10 g/L), 40 g/L bovine serum albumin,
heparin (2.5 kIU/L), and clamoxyl (250 mg/L). The per-
fusates from the intervillous space were collected and
stored at 70 °C.
STBM from these three preparations were harvested by
a three-step centrifugation procedure at 4 °C: 1000g for 10
min, 10 000g for 10 min, and 70 000g for 90 min. The final
pellet, containing the STBM, was washed once with PBS,
resuspended in 1 mL of sterile PBS containing 50 g/L
sucrose, and stored at 70 °C until use.
We examined the presence of fetal DNA and RNA in
these STBM. The amount of fetal DNA was measured by
a TaqMan® real-time PCR assay for a Y-chromosome-
specific sequence (SRY) (17 ), whereas the presence of fetal
mRNA was quantified by a similar quantitative reverse
transcription-PCR (RT-PCR) assay for the corticotropin-
releasing hormone (CRH) gene, which is known to be
expressed in the placenta (18 ).
The protein content in each STBM preparation was
quantified with the advanced protein assay reagent (Cy-
toskeleton). DNA was extracted from STBM by use of the
High Pure PCR Template Preparation Kit (Roche Diag-
nostics). Total RNA was isolated using High Pure RNA
Isolation Kit (Roche Diagnostics) and eluted in 50 L of
elution buffer. cDNA was reverse-transcribed from 500 ng
of total RNA by use of a commercial reverse transcription
system (Promega).
Real-time quantitative PCR and real-time quantitative
RT-PCR were used for all DNA and mRNA quantifica-
tions as described previously (17, 19, 20). The real-time
PCR and real-time RT-PCR reactions were set up accord-
ing to the manufacturer’s instructions (Applied Biosys-
tems) in a reaction volume of 25 L. Each sample was
analyzed in duplicate, and the corresponding calibration
curve was run in parallel with each analysis. Absolute
concentrations of CRH mRNA and SRY DNA were ex-
pressed as copies/mg of STBM.
Our analysis showed that all STBM preparations con-
tained both fetal DNA and mRNA, although the concen-
trations of each of these fetal analytes differed in the three
preparations (Table 1). In this regard, the highest concen-
tration of fetal DNA was detected in STBM prepared by in
vitro villous explant cultures (Fig. 1A), whereas the high-
est concentration of fetal CRH RNA was present in STBM
obtained by perfusion of a placental cotyledon (Fig. 1B).
Although we took great care to harvest as many of the
STBM as possible by the use of high-speed ultracentrifu-
gation, we were still able to detect considerable amounts
of fetal DNA in the STBM-free supernatant of villous
explant preparations. The amounts of fetal DNA in the
supernatants cleared by ultracentrifugation were approx-
imately fourfold higher than those in the matching STBM
preparations. Provided that these results can be extrapo-
lated to the release of fetal DNA into maternal plasma,
then it is possible that the major proportion of circulatory
fetal DNA may exist in a completely particle-free form.
On the other hand, very little CRH mRNA was detected in
the STBM-free villous explant supernatants (10% of that
Table 1. Concentrations of fetal DNA and CRH mRNA in
STBM prepared by villous explant culture, mechanical
dissection, and placental perfusion.a
STBM preparation method
Copies/mg of STBM
DNA (SRY) mRNA (CRH)
Villous explant culture
Median 94 530.5 4986
Range 9444–158 135 1232–10 500
Mechanical dissection
Median 2593 121 144.5
Range 307–7745 17 868–331 607
Placental perfusion
Median 620 222 352.5
Range 268–2975 98 190–275 981
a Six placentas were used for each STBM preparation. Fetal DNA (SRY locus)
and mRNA (CRH) concentrations were determined by real-time PCR and real-time
RT-PCR, respectively.
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present in the STBM preparation). Again, provided that
the observations we have made with in vitro-generated
STBM correspond to the in vivo situation, then it is
possible that fetal mRNA species may be largely associ-
ated with membrane particles, as has been reported
previously (6 ). It is also likely, that these few mRNA
species present in the cleared culture supernatants are
associated with very small microparticles that are not
effectively harvested by high-speed ultracentrifugation.
In our study, STBM prepared by placental perfusion
may be regarded as being the closest representatives of
those generated under normal physiologic conditions in
that here STBM are collected directly from the intervillous
space, the site where they would typically enter the
maternal circulation. The presence of fetal DNA and
mRNA species in all three STBM preparations, particu-
larly in those obtained by perfusion of the maternal
compartment of the placenta under near-physiologic con-
ditions, implies that cell-free fetal nucleic acids may
similarly be associated with STBM in vivo. This facet,
however, needs to be confirmed by the analysis of STBM
isolated from maternal blood samples, currently a techni-
cally demanding undertaking.
The difference we observed in fetal DNA and mRNA
content in the three STBM preparations may be attribut-
able to the manner in which these particles are generated,
in that those obtained by perfusion or in vitro culture are
generated predominantly by apoptotic cell turnover, in
contrast to STBM isolated by mechanical disruption, in
which release of STBM may involve necrotic pathways
(15 ).
In this context it is worth noting that the release of
STBM differs in normal pregnancy compared with pre-
eclampsia (9, 21). In normal pregnancy, the shedding of
placental particles occurs continuously as part of the
self-renewal of the syncytiotrophoblast monolayer, a pro-
cess that involves apoptosis of the aged nuclei and fusion
of cytotrophoblast cells (9 ). In preeclampsia, this process
is altered in that syncytiotrophoblast apoptosis rates are
dramatically increased, which has been suggested to
contribute to the increased release of STBM, possibly by
apo-necrotic pathways (21 ).
Therefore, provided that circulatory fetal nucleic acids
are indeed associated with STBM in vivo, then it is
possible that the analysis of the fetal DNA and RNA
content of STBM in the maternal circulation in normal and
pathologic pregnancies may yield new insights into the
underlying mechanisms leading to their release by the
syncytiotrophoblast. Furthermore, if this proviso concern-
ing the presence of fetal nucleic acids with STBM in vivo
is true, then it may also provide a new strategy for the
enrichment of these fetal analytes from maternal blood
samples.
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High Ischemia-Modified Albumin Concentration Re-
flects Oxidative Stress But Not Myocardial Involvement
in Systemic Sclerosis, Didier Borderie,1†* Yannick All-
anore,2† Christophe Meune,3 Jean Y. Devaux,3 Ohvanesse G.
Ekindjian,1 and Andre´ Kahan2 (Departments of 1 Biochem-
istry A, 2 Rheumatology A, and 3 Nuclear Medicine, Paris
V University, Assistance Publique-Hoˆpitaux de Paris,
Cochin Hospital, Paris, France; † these authors contrib-
uted equally to this work; * address correspondence to
this author at: Service de Biochimie A, 27 rue du faubourg
Saint-Jacques, 75014 Paris, France; fax 33-1-5841-1585,
e-mail didier.borderie@cch.ap-hop-paris.fr)
Systemic sclerosis (SSc) is a connective tissue disease
characterized by widespread vascular lesions and fibrosis
of the skin and internal organs. In SSc, vasospasm causes
frequent episodes of reperfusion injury and free-radical-
mediated endothelial disruption. Primary myocardial in-
volvement is far more common than initially suspected
on clinical grounds (1–5) and affects survival rates be-
cause it is associated with a poor prognosis (6, 7 ). Myo-
cardial fibrosis is thought to occur secondarily to repeated
focal ischemia in the coronary microcirculation as a result
of abnormal vasoreactivity, with or without associated
structural vascular disease (4, 5 ). The early and accurate
identification of cardiac involvement is therefore of para-
mount clinical importance.
The concentration of ischemia-modified albumin
(IMA), as measured by the albumin cobalt binding test
(Ischemia Technologies, Inc.), is a new marker to rule out
transient myocardial ischemia (8, 9 ). This test measures
the binding of exogenous cobalt to the NH2 terminus of
human albumin. In the presence of myocardial ischemia,
structural changes occur in the NH2 terminus of albumin,
rapidly reducing its capacity to bind transition metal ions
after an ischemic event (10 ).
We assessed the accuracy of the albumin cobalt binding
test for detecting ischemia in SSc patients and investi-
gated the roles of myocardial ischemia and peripheral
oxidative stress in this condition. We also considered
carbonyl residues and advanced oxidation protein prod-
ucts (AOPP) as factors indicative of protein oxidation.
We included consecutive patients hospitalized for sys-
tematic follow-up who fulfilled the American Rheuma-
tism Association preliminary criteria for SSc. The exclu-
sion criteria were pregnancy; symptoms of heart failure,
including class III or IV dyspnea (New York Heart Asso-
ciation); venous distension and recent major lower limb
edema; pulmonary arterial hypertension (systolic arterial
pressure 40 mmHg and/or mean artery pressure 25
mmHg, determined by echocardiography); severe pulmo-
nary involvement (forced vital capacity or carbon monox-
ide diffusing capacity 50% of the predicted normal
value); renal involvement (creatinine concentration  106
mol/L); or severe disease complications such as cancer
or gangrene. At the time of the study, none of the patients
was taking medication for cardiac or vascular disease. If
previously treated with vasodilators, patients were asked
to stop taking these drugs 3 days before admission. This
interruption period corresponds to five times the half-life
of calcium channel blockers and angiotensin-converting
enzyme. All patients gave informed consent for all proce-
dures, and the study was approved by the local ethics
committee (Paris, Cochin).
We assessed the following in all patients: blood cell
count, Westergren erythrocyte sedimentation rate, serum
creatinine concentration, and anti-centromere and anti-
topoisomerase I antibody concentrations. The concentra-
tion of high-sensitivity C-reactive protein was measured
by immunoturbidimetry on a Roche modular PP instru-
ment using the CRP latex Tina-quant® assay (Roche
Diagnostics). Pulmonary involvement was assessed by
computed tomography scan, forced vital capacity, and the
ratio of carbon monoxide diffusion capacity to hemoglo-
bin concentration. Pulmonary arterial systolic pressure
was determined by Doppler echocardiography at rest.
The thickness of the skin was quantified on a scale of 0–3,
by use of the modified Rodman skin scoring technique,
for each of 17 body surface areas (11, 12 ).
All patients underwent thallium-201 myocardial single-
photon-emission computerized tomography at rest, using
a gamma camera (Starport 400AT; General Electric) inter-
faced with an ADAC computer (DPS 3300). Myocardial
perfusion was assessed semiquantitatively by two expe-
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Constant IFNg mRNA to protein ratios in cord and adult blood T cells 
suggests regulation of IFNg expression in cord blood T cells occurs 
at the transcriptional level
A. Kumar Gupta, C. Rusterholz, 
W. Holzgreve and S. Hahn
Laboratory for Prenatal Medicine, University 
Women’s Hospital/Department of Research, 
University of Basel, Basel, Switzerland
Summary
Low levels of IFNg produced by umbilical cord blood (UCB) T lymphocytes
upon activation may be due to the need for a high threshold of activation or
to intrinsic blocking transcription/translation. We examined IFNg mRNA
accumulation and protein expression in pharmacologically stimulated human
UCB and adult blood (AB) T cells. Our data indicate that both IFNg mRNA
accumulation and protein synthesis were significantly lower in stimulated
UCB T cells than the AB T cells. Since the RNA dependent kinase PKR, an
inhibitor of translation, can be activated by low levels of IFNg mRNA, we mea-
sured its involvement. Treatment with 2-amino-purine, an inhibitor of PKR,
did not enhance IFNg protein expression in UCB T cells. Furthermore, our
studies indicated that IFNg promoter hypermethylation does not appear to
regulate IFNg expression either, as treatment with the demethylating agent, 5-
aza-2¢-deoxycytidine, did not lead to a significant increase in IFNg mRNA
accumulation in UCB T cells. What is readily evident from our studies is that
the IFNg mRNA to protein ratio was similar in UCB and AB T cells and it was
not altered by any of the treatments used. These results therefore suggests that
IFNg expression in UCB T cells is suppressed at the transcriptional level by an
unknown mechanism(s).
Keywords: T lymphocytes, cytokines, Th1/ Th2, gene regulation, cord blood,
IFNg
Introduction
Neonatal T cells are generally considered to be immature due
to their inability to mount an efficient immune response
against pathogens [1–3]. Many reports have indeed shown
that both cytotoxic and helper neonate T lymphocytes differ
qualitatively and quantitatively from adult T lymphocytes in
their response to produce effector cytokines, for example
IFNg, in vivo and in vitro [4–7]. The basis for this difference,
however, remains unclear.
It has been proposed that the neonatal T cells obtained
from cord blood require a high threshold of activation for
producing mature effector functions. The proliferation of
low cytokine producing neonatal cells can be enhanced with
high concentrations of pharmacological agents PMA and
ionomycin. In this regard, studies have shown that in the
presence of strong adjuvants or costimulatory signals, neo-
natal CD4+ and CD8+ T cells are capable of mature-level
responses [8–11]. It has also been suggested that UCB T lym-
phocytes have an intrinsic defect, the nature of which is
unclear, for producing Th1 specific cytokines, and preferen-
tially favour Th2 responses [12,13]. Previous findings from
our laboratory have described that upon stimulation with
the high concentrations of PMA and ionomycin both CD4+
and CD8+ UCB T lymphocytes expressed mature levels of the
activation marker CD69 but did not produce Th1 cytokine
such as IFNg [14]. Therefore, activation of UCB T cells per se
does not appear to be blocked, but rather production of Th1
cytokines, like IFNg, is hindered.
The pleiotropic cytokine IFNg is known to be principally
produced by NK cells, cytotoxic CD8+ T cells and the Th1
subset of CD4+ T cells. IFNg is essential for both innate and
adaptive immunity, generally amplifying Th1 immune
responses and acting through binding to the IFNg receptors
on the cell surface that trigger Jak-STAT signalling pathway
[15,16]. Neonatal lymphocytes, in comparison to adult
Regulation of IFNg in cord blood T cells
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lymphocytes, produce 10–15 fold less IFNg protein upon
anti-CD3 crosslinking or stimulation with phorbol ester and
calcium ionophore [17–21].
The poor IFNg expression by neonatal T cells might
involve mechanisms regulating gene transcription and/or
translation. In this regard it has been proposed that differ-
ential methylation of the IFNg promoter is closely associated
with low IFNg expression in the UCB T lymphocytes. In
CD4+ UCB T cells IFNg promoter is hypermethylated at CpG
and non CpG sites within and adjacent to the promoter [22–
24], which could reduce IFNg transcription. In addition to
the above reports describing transcriptional regulation of
IFNg expression, Ben Asouli et al. [25] have shown that the
human IFNg mRNA (at low concentration) auto regulates
its own translation through a pseudoknot that activates the
RNA dependent protein kinase PKR. When activated, PKR
blocks translation through the phosphorylation of the eIF2 a
subunit of the RNA polymerase II dependent elongation
complex [26]. In addition to the mechanisms described
above, reduced constitutive NFATc2 (nuclear factor of acti-
vated T cells) expression has been reported in UCB T lym-
phocytes during primary stimulation, which may be one
underlying molecular mechanism for the low IFNg expres-
sion in UCB T lymphocytes [27].
Therefore, in order to further explore the regulation of
IFNg expression in neonatal T cells, we analysed both
umbilical cord blood (UCB) and adult blood (AB) T cells
for IFNg mRNA accumulation, using real time taqman®
PCR, and IFNg protein expression, either by FACS or ELISA.
In order to obtain maximal T cell activation we used two
pharmacological agents: PMA and ionomycin. In this study
we show that the regulation of IFNg expression in neonatal
T cells occurs only at the transcriptional level, and an intrin-
sic program hinders the induction of IFNg expression in
these cells.
Materials and methods
The Cantonal Institutional Review Board of Basel, Switzer-
land approved this study. UCB samples were collected from
healthy term babies at the University Women’s Hospital,
Basel and AB samples were obtained from healthy donors at
the blood donation centre, University Hospital, Basel. Writ-
ten informed consent was obatined in all instances.
Isolation and stimulation of T lymphocytes
PBMC and cord blood mononuclear cells were isolated from
whole blood by centrifugation over a ficoll paque plus
gradient (Amersham Biosciences, Uppsala, Sweden). Then
CD4+ and CD8+ T cells were enriched with CD4+ and CD8+
T cell specific microbeads (Miltenyi Biotech, Gladbach, Ger-
many) either together or separately using MACS mini col-
umns (Miltenyi Biotech, Gladbach, Germany) according to
the manufacturer’s instructions. The purity of the enriched
T lymphocytes routinely reached >90%, as confirmed by
FACS analysis.
0·5 ¥ 106 cells/ml T cells were stimulated in 12 well plates
(Nunc, Denmark) for varying time periods ranging from 3
to 48 h at 37∞C in 5% CO2 in RPMI 1640 medium (Gibco
Invitrogen Life Technologies, Grand Island, NY, USA)
supplemented with 5% FCS, 2 mm l-glutamine (Gibco
Invitrogen Life Technologies), 100 U/ml penicillin, 100 mg/
ml streptomycin (Gibco Invitrogen Life Technologies).
50 ng/ml PMA (Sigma Chemicals, St. Louis, MO, USA) and
1 mm ionomycin (Sigma Chemicals) were used as stimuli. To
analyse intracellular IFNg expression golgistop (BD Bio-
sciences, Basel, Switzerland) was added to the cell culture 3 h
prior to FACS analysis [28]. Further treatments included the
use of 2-amino-purine (2-AP, Sigma Chemicals) and 5-aza-
2¢-deoxycytidine (Sigma Chemicals) as indicated in the fig-
ures or figures legends. Our analysis using the tryptan blue
dye exclusion test indicated that at ≥90% of the T cells were
viable after each drug treatment.
Intracellular cytokine staining and flow cytometry
Following stimulation, cultured T cells were washed twice in
PBS containing 0·5% FCS and incubated with FITC labelled
mAb (BD Biosciences) against CD3, CD4 or CD8 surface
antigens for 15 min at 4∞C. The cells were again washed
twice with PBS containing 0·5% FCS then fixed and perme-
abilized using cytofix/cytoperm plus kit (BD Biosciences)
according to the manufacturer’s instructions. Cells were
then incubated with PE labelled mAb (BD Biosciences)
against IFNg or IL-2 cytokines. Phenotypic analysis of naïve
and mature T cells was performed by two colour flow
cytometry using a Becton Dickinson FACScan flow cytome-
ter (BD Biosciences). A minimum of 10 000 gated events
was acquired and analysed with the Cell Quest Pro software
(BD Biosciences).
IFNg ELISA
IFNg levels were measured using a commercial human IFNg
ELISA kit (Ebioscience Inc, San Diego, CA, USA) according
to the manufacturer’s instructions. ELISA plate was read at
450 nm in an ELISA reader (Molecular Devices, Sunnyvale,
CA, USA) and the data was analysed using Soft Max Pro
Software.
Total RNA isolation and real time RT-PCR
Total RNA was isolated using High Pure RNA isolation
kit (Roche Diagnostics, Mannheim, Germany). cDNA was
reverse transcribed from 1 mg of total RNA using a reverse
transcription system (Promega, Madison, WI, USA) accord-
ing to the manufacturer’s instructions. For the real time
RT-PCR analysis, 25 ml reaction mixture consisted of 1 ml
of cDNA, 1 ¥ taqman universal master mix (Applied
A. Kumar Gupta et al.
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Biosystems, Foster City, CA, USA) and 1 ¥ predeveloped taq-
man assay reagents (PDAR, Applied Biosystems), containing
gene specific probes and primers for IFNg or 18 s RNA. For
these experiments the ABI Prism 7000 system (Applied Bio-
systems) was used. 18 s RNA was used as an internal control
to correct unequal sample loading. It has previously been
shown that the amount of 18sRNA per cell does not vary
with cell activation [29]. Thermal cycler conditions com-
prised of 2 min at 50∞C, 10 min at 95∞C followed by 45 cycles
for 15 s at 95∞C and at 60∞C for 1 min.
The change in IFNg mRNA expression was assayed by
normalization to the 18sRNA internal control. In order to
obtain the fold difference the data was analysed using the
DDCT method described previously by Livak and Schmit-
tgen, where DDCT = (IFNg CT – 18sRNA CT)stimulated – (IFNg
CT – 18sRNA CT)unstimulated [30].
Results
UCB T lymphocyte synthesize very low amount of 
IFNg protein and mRNA
UCB and adult T lymphocytes were stimulated with the
high concentrations of PMA and ionomycin and the fre-
quency of IFNg positive cells was measured by FACS. This
analysis indicated that following 3 h of stimulation the fre-
quencies of IFNg positive UCB T cells were 100 fold less
than the AB T cells (Fig. 1 a,b). In contrast the frequencies of
the IL-2 positive T cells were similar in both UCB and AB
(Fig. 1c,d). Although the frequencies of IFNg positive UCB
T cells further increased about 10 fold (3·39%) and 20 fold
(5·17%) after 24 h and 48 h of stimulation, respectively (Fig.
1e,f), it never reached the equivalent levels attained by AB T
cells.
To examine whether low IFNg expression by UCB T cells
was a consequence of low IFNg gene transcription, IFNg
mRNA accumulation was quantified by real time PCR. The
amount of IFNg mRNA was normalized against the quantity
of 18 sRNA [29]. Following 24 h of stimulation with PMA
and ionomycin, 12-fold less IFNg mRNA was accumulated
by UCB T lymphocytes than the AB T lymphocytes (Table 1).
IFNg mRNA accumulation, measured at 3 h after stimula-
Fig. 1. IFNg and IL-2 production by UCB and AB T cells. Enriched UCB 
and AB T cells were stimulated for 3 h to 48 h with PMA and ionomycin. 
The frequencies of the IFNg and IL-2 positive cells were measured by 
FACS. 10 000 gated events were acquired. The frequencies of (a) the 
IFNg positive UCB T cells were 100 fold less than (b) the IFNg positive 
AB T cells, while the IL-2 positive T cell population was similar in both 
groups (c, d). Frequencies of IFNg positive UCB T cells were increased 
approximately (e) 10-fold and (f) 20-fold upon 24 h and 48 h stimula-
tion, respectively, in comparison to 3 h stimulation.
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Table 1. Real time quantitative PCR analysis of IFNg gene expression using 2–DDCT method. Cord and adult blood T lymphocytes were stimulated for 
24 h using PMA and ionomycin. The fold change in IFNg gene expression was normalized to an internal control (18sRNA gene). 10 samples of each, 
cord and adult blood, were analysed. The fold change in the IFNg gene was calculated using 2–DDCT method as described in the materials and methods. 
Following 24 h stimulation UCB T lymphocytes accumulated 12 fold less IFNg mRNA.
Samples IFNg CT 18 s RNA CT D CT* DD CT** 2–DD CT†
Unstimulated CB T cells 35·47 ± 0·78 15·93 ± 0·41 19·54 ± 0·82 0·0 ± 0·0 1
Stimulated CB T cells 25·98 ± 0·77 15·37 ± 0·34 10·61 ± 0·78 - 8·93 ± 0·15 489·10 ± 0·50
Unstimulated AB T cells 32·80 ± 0·94 15·78 ± 0·32 17·01 ± 0·76 0·0 ± 0·0 1
Stimulated AB T cells 20·00 ± 0·69 15·51 ± 0·40 4·49 ± 0·56 - 12·51 ± 0·80 5865·3 ± 0·57
*D CT (IFNg CT-18 s RNA CT); **DD CT (D CT stimulated – D CT unstimulated); †Normalized IFNg amount relative to unstimulated T cells
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tion, by UCB T cells was 30 fold less than the AB T cells (data
not shown).
IFNg production in UCB T cells is not regulated by PKR
It has been reported earlier that when present in low
amount, IFNg mRNA negatively autoregulates its own trans-
lation by activating the IFNg dependant protein kinase PKR
[25]. Therefore, we hypothesized that this low IFNg protein
produced by UCB T cells could be due to PKR activation. To
check this hypothesis, we stimulated UCB T cells in the pres-
ence of increasing concentrations of the PKR activation
inhibitor, 2-amino-purine (2-AP), and measured frequen-
cies of the IFNg positive cells using FACS. FACS analysis
indicated that 2-AP treatment did not enhance the frequency
of IFNg positive UCB T cells (Fig. 2).
Promoter demethylation is not sufficient to induce IFNg
expression in UCB T lymphocytes
Recent findings have indicated that the hypermethylation of
IFNg promoter might contribute to the mechanisms pre-
venting IFNg gene expression in neonatal vs. adult blood T
cells. We therefore examined whether treatment with 5-aza-
2¢-deoxycytidine (aza); a potent promoter demethylating
agent [22,23,31] would relieve the transcriptional block,
thereby resulting in optimal IFNg mRNA accumulation in
UCB T cell subsets. For this study, UCB CD4+ and CD8+ T
cells were stimulated with PMA and ionomycin for 24 h in
the presence of 5-aza-2¢-deoxycytidine and IFNg mRNA
accumulation was quantified using real time- quantitative
RT-PCR. It has been shown earlier that the treatment with 5-
aza-2¢-deoxycytidine cause demethylation of the IFNg pro-
moter without affecting T cell viability and their prolifera-
tion [22,23,31]. Our results show that neonate CD4+ and
CD8+ T cells accumulated approximately 2 fold more IFNg
mRNA after 5-aza-2¢-deoxycytidine treatment in compari-
son to nontreated controls (see Table 2). This increase in
IFNg mRNA also translated into a corresponding increase in
IFNg secretion (Fig. 3). Thus, demethylation of IFNg gene
Fig. 2. Effect of 2-AP on IFNg expression in UCB T cells. UCB T cells 
were stimulated for 3 h with PMA and ionomycin in the presence of 
varying concentrations of PKR activation inhibitor, 2-AP, which was 
added during the last 30 min of the incubation. Frequencies of IFNg
positive were measured using FACS. 10 000 gated events were acquired. 
The treatment of 2-AP did not show any increase in the frequency of 
IFNg positive UCB T cells in comparison to non treated UCB T cells.
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Table 2. Real time PCR analysis of the IFNg mRNA accumulation UCB T cell after 5-aza-2¢-deoxycytidine (Aza) treatment. Enriched UCB T cell 
subsets were stimulated with PMA and ionomycin in the presence of 5 mm aza for 24 h. The mean fold change in the IFNg gene expression was calculated 
using equation DDCT = (IFNg CT – 18sRNA CT)+Aza – (IFNg CT – 18sRNA CT)-Aza. The fold change was calculated by 2–DDCT. The aza treatment resulted 
in a two fold increase in IFNg mRNA accumulation.
Samples IFNg CT 18 s RNA CT D CT* DD CT** 2–DD CT†
UCB CD4+T cells – Aza 26·35 ± 0·27 12·13 ± 0·11 14·22 ± 0·16 0·0 ± 0·0 1
UCB CD4+T cells + Aza 25·39 ± 0·25 12·23 ± 0·16 13·16 ± 0·09 - 1·06 ± 0·07 2·08 ± 0·18
UCB CD8+T cells – Aza 25·42 ± 0·49 12·58 ± 0·32 12·84 ± 0·17 0·0 ± 0·0 1
UCB CD8+T cells + Aza 24·48 ± 0·53 12·83 ± 0·38 11·65 ± 0·15 - 1·18 ± 0·02 2·26 ± 0·32
*D CT (IFNg CT-18 s RNA CT); **DD CT (D CT +Aza – D CT –Aza); † Normalized IFNg amount relative to untreated T cells
Fig. 3. Effect of 5-aza-2¢-deoxycytidine on IFNg protein production. 
Enriched UCB T cells were stimulated for 24 h in the presence of 5 mm
5-aza-2¢-deoxycytidine (Aza). Following treatment supernatants from 
the cultures were collected and IFNg levels were quantified using an 
commercial ELISA as described in the materials and methods. Each bar 
represent mean ± SD.
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promoter is not sufficient to establish mature-like levels of
IFNg expression. This observation indicates that the tight
regulation of IFNg expression in UCB T cells most likely
involves several mechanisms.
IFNg mRNA to protein ratio is constant in UCB and AB 
T cells
We were able to precisely measure IFNg mRNA and protein
levels in the same samples, by the use of real-time RT-PCR
and sensitive ELISA assays. This feature, enabled us to deter-
mine that the ratio between these two parameters. The IFNg
mRNA to protein ratio was constant in both UCB and AB T
cell subsets (Table 3). Furthermore, we determined that this
ratio was not altered by treatment with 5-aza-2¢-deoxycyti-
dine, which lead to small 2-fold increments in mRNA accu-
mulation (see Table 2), as it was paralleled by a similar
increase in IFNg protein production (Fig. 3). Our results
therefore imply that IFNg expression in UCB T cells is not
regulated at the translational level and that the main regula-
tory modes reside at the transcription level.
Discussion
The complex mechanism regulating IFNg expression in neo-
natal T cells is still a puzzle, and it remains to be resolved
whether this is regulated at the transcription or at transla-
tional level. In order to address this issue in more detail we
have used real-time RT-PCR assays to accurately assess IFNg
mRNA levels, and FACS or ELISA analysis to examine IFNg
protein levels in the same samples. We used high doses of
PMA and ionomycin to synergistically activate T cells in a
receptor and APC-independent manner. PMA activates pro-
tein kinase C (PKC), but does not elevate Ca2+. Ionomycin
elevates Ca2+, but Ca2+ alone does not activate PKC in the
absence of PMA, addition of the Ca2+-mobilizing agent ion-
omycin along with PMA synergistically activates T cell pro-
liferation [32,33]. Our data indicate that the induction of
IFNg mRNA accumulation in neonatal T cells stimulated
with PMA and ionomycin is 30 fold less than similarly stim-
ulated adult T cells. In a similar manner the level of IFNg
protein was found to be much lower in stimulated neonatal
T cells than in adult T cells.
IFNg mRNA has been shown to activate the RNA-depen-
dent protein kinase PKR, a stress kinase that is also activated
by double-stranded RNA. The cis-acting RNA elements
within IFNg transcripts function as sensors of intracellular
PKR levels and regulate IFNg mRNA splicing and translation
[34,35]. Since low levels of IFNg mRNA has been shown to
activate PKR [25] and we could observe very low IFNg
mRNA accumulation by cord blood T cell therefore we
examined the effect of PKR inhibitor drug 2-AP on stimu-
lated UCB T cells. Our data indicate that treatment with 2-
AP did not increase IFNg protein expression in PMA and
ionomycin stimulated UCB T cells, a finding that is in agree-
ment with reports indicating low levels of PKR activation in
T lymphocytes [36].
It is well established that the methylation of DNA is an
epigenetic mechanism for the modulation of gene expression
in mammalian cells [37]. DNA methylation changes chro-
matin structure and may help the recruitment of transcrip-
tion factors to the target genes [38]. Many of the studies have
reported that the differential CpG methylation of IFNg pro-
moter is responsible for the low IFNg expression [22,23,31].
Table 3. IFNg mRNA to protein ratio in the UCB and AB T cell subsets. Enriched UCB and AB T cell subsets were stimulated for 24 h with PMA and
ionomycin. IFNg mRNA accumulation was measured using real-time PCR and calculated according to 2–DDCT method. IFNg protein was measured by 
ELISA and the IFNg mRNA to protein ratio was calculated. The ratio between these two parameters are fairly constant in the T cell subsets obtained
from UCB and AB.
Samples
IFNg
mRNA
IFNg
protein (pg/ml)
mRNA/protein 
ratio
Mean ± SD
(mRNA/protein ratio)
UCB CD4+T cells 576 883 0·652 0·72 ± 0·08
739 982 0·752
3666 4368 0·839
1370 2068 0·662
AB CD4+T cells 31872 47945 0·664 0·68 ± 0·03
99334 150347 0·660
41189 55264 0·745
33456 49264 0·679
UCB CD8+T cells 8135 7066 1·151 1·07 ± 0·08
2721 2384 1·141
8481 8159 1·039
4482 4564 0·982
AB CD8+T cells 49324 40311 1·223 1·08 ± 0·13
187682 94708 0·925
66451 57811 1·149
70728 68811 1.027
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Here, we examined whether IFNg promoter hypermethyla-
tion could be reversed by treatment with a demethylating
agent, 5-aza-2¢-deoxycytidine. Our results show that this
treatment only lead to a 2 fold increase in IFNg mRNA accu-
mulation in PMA and ionomycin stimulated neonatal T
cells. Of interest was that this 2 fold increase in the mRNA
accumulation was paralleled by an equivalent increase in
IFNg protein production.
This finding lead us to assess the IFNg mRNA: protein
ratios in our various study groups. This analysis indicated
that this ratio was fairly constant in all the groups examined,
whether they be activated neonatal or adult T cells. This
analysis strongly suggest that in UCB T cells IFNg expression
is not regulated on a post-transcriptional level but rather on
transcriptional level, at least, partially involves promoter
methylation.
The exact mechanism regulating efficient induction of
IFNg mRNA accumulation is still unclear but may involve
several other mechanisms. The dynamic changes in the his-
tone tail acetylation have been shown to play an important
role in the effector functions of T cells [37,39]. Avni et al.
[39] have suggested that TCR stimulation activates a histone
tail modification mediated change in chromatin structure in
the immature T cells, which allows the binding of TCR-
induced transcription factors to the promoter regions of
IFNg gene. In the absence of polarizing cytokines, both early
histone hyperacetylation and early cytokine gene expression
are reduced to the low basal amounts as observed in UCB T
cells. In UCB T cells certain cytokine genes, such as that for
IFNg, are positioned in such a manner that only limited gene
transcription is possible upon TCR stimulation. The differ-
ence between neonatal and adult T cells is that inactive
cytokine genes in neonatal T cells are located in euchromatin
regions, whereas a large fraction of the silenced genes in
differentiated T cells are repositioned to centromeric
heterochromatin regions due to inhibitory modifications,
previously established by the polarizing cytokines, that
down-regulate the expression of inappropriate genes. It is
likely therefore that in immature T cells, TCR stimulation
initiates permissive chromatin modifications that facilitate
early gene expression. These findings also provide a possible
reason for the delayed response against stimulus that UCB T
cells display before they are able to produce efficient effector
functions upon TCR stimulation, as a period of time is
required for this repositioning of key effector genes in mat-
uration of naïve to memory T cells [40]. Our data provide
some support for this hypothesis, in that longer periods of
PMA and ionomycin stimulation (24 h and 48 h) enhanced
the frequency of IFNg positive cells in the UCB T cell pop-
ulation.
To summarize, we propose here that the regulation of
IFNg in UCB T lymphocytes occurs at the transcriptional
level and not post-transcriptional or translational level, as we
observed fairly constant mRNA to protein ratios in all of the
T cell groups examined. The nature of this transcriptional
block, however, still remains to be resolved or may involve
several factors such as deficient regulatory proteins, RNA or
transcription factors rendering IFNg up-regulation slower
and lower than that of adult T cells.
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